Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Jan. 29, 2016 | Jun. 30, 2015 | |
Document and Entity Information [Abstract] | |||
Entity Registrant Name | BIOGEN INC. | ||
Entity Central Index Key | 875,045 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Large Accelerated Filer | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2015 | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Entity Common Stock, Shares Outstanding | 218,672,717 | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Public Float | $ 94,898,425,323 |
Consolidated Statements of Inco
Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Revenues: | |||
Product, net | $ 9,188.5 | $ 8,203.4 | $ 5,542.3 |
Unconsolidated joint business | 1,339.2 | 1,195.4 | 1,126 |
Other | 236.1 | 304.5 | 263.9 |
Total revenues | 10,763.8 | 9,703.3 | 6,932.2 |
Cost and expenses: | |||
Cost of sales, excluding amortization of acquired intangible assets | 1,240.4 | 1,171 | 857.7 |
Research and development | 2,012.8 | 1,893.4 | 1,444.1 |
Selling, general and administrative | 2,113.1 | 2,232.3 | 1,712.1 |
Amortization of acquired intangible assets | 382.6 | 489.8 | 342.9 |
Restructuring charges | 93.4 | 0 | 0 |
Collaboration profit sharing | 0 | 0 | 85.4 |
(Gain) loss on fair value remeasurement of contingent consideration | 30.5 | (38.9) | (0.5) |
Total cost and expenses | 5,872.8 | 5,747.7 | 4,441.6 |
Gain on sale of rights | 0 | 16.8 | 24.9 |
Income from operations | 4,891 | 3,972.4 | 2,515.5 |
Other income (expense), net | (123.7) | (25.8) | (34.9) |
Income before income tax expense and equity in loss of investee, net of tax | 4,767.3 | 3,946.6 | 2,480.6 |
Income tax expense | 1,161.6 | 989.9 | 601 |
Equity in loss of investee, net of tax | 12.5 | 15.1 | 17.2 |
Net income | 3,593.2 | 2,941.6 | 1,862.3 |
Net income attributable to noncontrolling interests, net of tax | 46.2 | 6.8 | 0 |
Net income attributable to Biogen Inc. | $ 3,547 | $ 2,934.8 | $ 1,862.3 |
Net income per share: | |||
Basic earnings per share attributable to Biogen Inc. | $ 15.38 | $ 12.42 | $ 7.86 |
Diluted earnings per share attributable to Biogen Inc. | $ 15.34 | $ 12.37 | $ 7.81 |
Weighted-average shares used in calculating: | |||
Basic earnings per share attributable to Biogen Inc. | 230.7 | 236.4 | 236.9 |
Diluted earnings per share attributable to Biogen Inc. | 231.2 | 237.2 | 238.3 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Statement of Comprehensive Income [Abstract] | |||
Net income attributable to Biogen Inc. | $ 3,547 | $ 2,934.8 | $ 1,862.3 |
Other comprehensive income: | |||
Unrealized gains (losses) recognized during the period, net of tax | (1.7) | 0.4 | 11.8 |
Less: reclassification adjustment for (gains) losses included in net income, net of tax | 1.3 | (6.4) | (10.4) |
Unrealized gains (losses) on securities available for sale, net of tax | (0.4) | (6) | 1.4 |
Unrealized gains (losses) recognized during the period, net of tax | 110.8 | 101.7 | (26.7) |
Less: reclassification adjustment for (gains) losses included in net income, net of tax | (172.3) | (6.3) | 13.7 |
Unrealized gains (losses) on cash flow hedges, net of tax | (61.5) | 95.4 | (13) |
Unrealized gains (losses) on pension benefit obligation | (6.2) | (12) | 2.1 |
Currency translation adjustment | (96.4) | (109.2) | 37.1 |
Total other comprehensive income (loss), net of tax | (164.5) | (31.8) | 27.6 |
Comprehensive income attributable to Biogen Inc. | 3,382.5 | 2,903 | 1,889.9 |
Comprehensive income attributable to noncontrolling interests, net of tax | 46.2 | 6.8 | 0 |
Comprehensive income | $ 3,428.7 | $ 2,909.8 | $ 1,889.9 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Current assets: | ||
Cash and cash equivalents | $ 1,308 | $ 1,204.9 |
Marketable securities | 2,120.5 | 640.5 |
Accounts receivable, net | 1,227 | 1,292.4 |
Due from unconsolidated joint business, net | 314.5 | 283.4 |
Inventory | 893.4 | 804 |
Other current assets | 836.9 | 309.8 |
Total current assets | 6,700.3 | 4,535 |
Marketable securities | 2,760.4 | 1,470.7 |
Property, plant and equipment, net | 2,187.6 | 1,765.7 |
Intangible assets, net | 4,085.1 | 4,028.5 |
Goodwill | 2,663.8 | 1,760.2 |
Investments and other assets | 1,107.6 | 754.6 |
Total assets | 19,504.8 | 14,314.7 |
Current liabilities: | ||
Current portion of notes payable and other financing arrangements | 4.8 | 3.1 |
Taxes payable | 208.7 | 168.1 |
Accounts payable | 267.4 | 229.2 |
Accrued expenses and other | 2,096.8 | 1,817.7 |
Total current liabilities | 2,577.7 | 2,218.1 |
Notes payable and other financing arrangements | 6,521.5 | 580.3 |
Long-term deferred tax liability | 124.9 | 52.2 |
Other long-term liabilities | 905.8 | 650.1 |
Total liabilities | $ 10,129.9 | $ 3,500.7 |
Commitments and contingencies | ||
Biogen Idec Inc. shareholders' equity | ||
Preferred stock, par value $0.001 per share | $ 0 | $ 0 |
Common stock, par value $0.0005 per share | 0.1 | 0.1 |
Additional paid-in capital | 0 | 4,196.2 |
Accumulated other comprehensive loss | (224) | (59.5) |
Retained earnings | 12,208.4 | 9,283.9 |
Treasury stock, at cost; 22.6 million shares, respectively | (2,611.7) | (2,611.7) |
Total Biogen Inc. shareholders’ equity | 9,372.8 | 10,809 |
Noncontrolling interests | 2.1 | 5 |
Total equity | 9,374.9 | 10,814 |
Total liabilities and equity | $ 19,504.8 | $ 14,314.7 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Common stock, par value | $ 0.0005 | $ 0.0005 |
Treasury stock at cost, shares | 22.6 | 22.6 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Cash flows from operating activities: | |||
Net income | $ 3,593.2 | $ 2,941.6 | $ 1,862.3 |
Adjustments to reconcile net income to net cash flows from operating activities: | |||
Depreciation and amortization | 600.4 | 688.1 | 531.7 |
Share-based compensation | 161.4 | 155.3 | 136.3 |
Deferred income taxes | (145.6) | (308.2) | (245.1) |
Other | 82.2 | (50.3) | (27.6) |
Changes in operating assets and liabilities, net: | |||
Accounts receivable | 29 | (512.4) | (126.7) |
Inventory | (174.4) | (185.9) | (243.9) |
Other assets | (156.6) | (94.5) | (160.2) |
Accrued expenses and other current liabilities | 74.2 | 244.3 | 284.1 |
Current taxes payable | (410.2) | 61 | 156.8 |
Other long-term liabilities and taxes payable | 93.6 | 33.8 | 161.7 |
Due from unconsolidated joint business | (31.1) | (30.7) | 15.7 |
Net cash flows provided by operating activities | 3,716.1 | 2,942.1 | 2,345.1 |
Cash flows from investing activities: | |||
Proceeds from sales and maturities of marketable securities | 4,063 | 2,718.9 | 5,190.1 |
Purchases of marketable securities | (6,864.9) | (3,583.1) | (3,278.1) |
Acquisition of TYSABRI rights | 0 | 0 | (3,262.7) |
Contingent consideration related to Fumapharm AG acquisition | (850) | (375) | (15) |
Acquisitions of businesses | (198.8) | 0 | 0 |
Purchases of property, plant and equipment | (643) | (287.8) | (246.3) |
Other | (59.9) | (16) | 7.3 |
Net cash flows used in investing activities | (4,553.6) | (1,543) | (1,604.7) |
Cash flows from financing activities: | |||
Purchase of treasury stock | (5,000) | (886.8) | (400.3) |
Proceeds from issuance of stock for share-based compensation arrangements | 54.2 | 54.9 | 66.8 |
Excess tax benefit from share-based compensation | 78.2 | 96.4 | 73.5 |
Proceeds from borrowings | 5,930.5 | 0 | 0 |
Repayments of borrowings | (2.1) | (2.7) | (452.4) |
Other | (74.4) | (17.7) | (4.1) |
Net cash flows provided by (used in) financing activities | 986.4 | (755.9) | (716.5) |
Net increase in cash and cash equivalents | 148.9 | 643.2 | 23.9 |
Effect of exchange rate changes on cash and cash equivalents | (45.8) | (40.9) | 8 |
Cash and cash equivalents, beginning of the year | 1,204.9 | 602.6 | 570.7 |
Cash and cash equivalents, end of the year | $ 1,308 | $ 1,204.9 | $ 602.6 |
Consolidated Statements of Equi
Consolidated Statements of Equity - USD ($) $ in Millions | Total | Total Biogen Inc. shareholders' equity | Preferred stock | Common stock | Additional paid-in capital | Accumulated other comprehensive income (loss) | Retained earnings | Treasury stock | Noncontrolling interests |
Beginning Balance at Dec. 31, 2012 | $ (6,963.8) | $ (6,961.5) | $ 0 | $ (0.1) | $ (3,854.5) | $ 55.3 | $ (4,486.8) | $ (1,324.6) | $ (2.3) |
Beginning Balance, shares at Dec. 31, 2012 | 0 | (254,200,000) | (17,700,000) | ||||||
Net income | 1,862.3 | 1,862.3 | 1,862.3 | 0 | |||||
Other comprehensive income, net of tax | 27.6 | 27.6 | 27.6 | 0 | |||||
Deconsolidation of noncontrolling interests | 1.7 | 0 | 1.7 | ||||||
Repurchase of common stock, at cost | (400.3) | (400.3) | $ (400.3) | ||||||
Repurchase of common stock, at cost, shares | (2,000,000) | ||||||||
Issuance of common stock under stock option and stock purchase plans | 66.7 | 66.7 | $ 0 | 66.7 | |||||
Issuance of common stock under stock option and stock purchase plans, shares | 800,000 | ||||||||
Stock Issued During Period, Value, Stock Options Exercised | (89.7) | (89.7) | $ 0 | (89.7) | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 1,000,000 | ||||||||
Compensation expense related to share-based payments | 146.2 | 146.2 | 146.2 | ||||||
Tax benefit from share-based payments | 45.9 | 45.9 | 45.9 | ||||||
Ending Balance at Dec. 31, 2013 | (8,620.8) | (8,620.2) | $ 0 | $ (0.1) | (4,023.6) | (27.7) | (6,349.1) | $ (1,724.9) | (0.6) |
Ending Balance, shares at Dec. 31, 2013 | 0 | (256,000,000) | (19,700,000) | ||||||
Net income | 2,941.6 | 2,934.8 | 2,934.8 | 6.8 | |||||
Other comprehensive income, net of tax | 31.8 | 31.8 | 31.8 | 0 | |||||
Distribution to noncontrolling interests | (9.1) | 0 | (9.1) | ||||||
Acquisition of noncontrolling interests | 6.7 | 0 | 6.7 | ||||||
Repurchase of common stock, at cost | $ (886.8) | (886.8) | $ (886.8) | ||||||
Repurchase of common stock, at cost, shares | (2,900,000) | (2,900,000) | |||||||
Issuance of common stock under stock option and stock purchase plans | $ 54.9 | 54.9 | $ 0 | 54.9 | |||||
Issuance of common stock under stock option and stock purchase plans, shares | 300,000 | ||||||||
Stock Issued During Period, Value, Stock Options Exercised | (140.3) | (140.3) | $ 0 | (140.3) | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 800,000 | ||||||||
Compensation expense related to share-based payments | 165 | 165 | 165 | ||||||
Tax benefit from share-based payments | 93 | 93 | 93 | ||||||
Ending Balance at Dec. 31, 2014 | (10,814) | (10,809) | $ 0 | $ (0.1) | (4,196.2) | (59.5) | (9,283.9) | $ (2,611.7) | (5) |
Ending Balance, shares at Dec. 31, 2014 | 0 | (257,100,000) | (22,600,000) | ||||||
Net income | 3,593.2 | 3,547 | 3,547 | 46.2 | |||||
Other comprehensive income, net of tax | (164.5) | (164.5) | (164.5) | 0 | |||||
Distribution to noncontrolling interests | (60) | 0 | (60) | ||||||
Acquisition of noncontrolling interests | 10.9 | 0 | 10.9 | ||||||
Repurchase of common stock, at cost | $ (5,000) | (5,000) | $ (5,000) | ||||||
Repurchase of common stock, at cost, shares | (16,800,000) | (16,800,000) | |||||||
Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost | $ 0 | 0 | $ 0 | 4,377.5 | 622.5 | $ 5,000 | |||
Retirement of common stock pursuant to the 2015 Share Repurchase Program, at cost, shares | 16,800,000 | 16,800,000 | |||||||
Issuance of common stock under stock option and stock purchase plans | 54.2 | 54.2 | $ 0 | 54.2 | |||||
Issuance of common stock under stock option and stock purchase plans, shares | 300,000 | ||||||||
Stock Issued During Period, Value, Stock Options Exercised | $ (125.1) | (125.1) | $ 0 | (125.1) | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 114,000 | 600,000 | |||||||
Compensation expense related to share-based payments | $ 183.2 | 183.2 | 183.2 | ||||||
Tax benefit from share-based payments | 69 | 69 | 69 | ||||||
Ending Balance at Dec. 31, 2015 | $ (9,374.9) | $ (9,372.8) | $ 0 | $ (0.1) | $ 0 | $ (224) | $ (12,208.4) | $ (2,611.7) | $ (2.1) |
Ending Balance, shares at Dec. 31, 2015 | 0 | (241,200,000) | (22,600,000) |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Business Overview Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies. In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Consolidation Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. Use of Estimates The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. Revenue Recognition We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured. Product Revenues Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances. Reserves for Discounts and Allowances We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns. Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments. Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances. • Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. • Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit. • Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer’s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period. • Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end. • Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare. Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product. In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses. Revenues from Unconsolidated Joint Business Revenues from unconsolidated joint business consists of (i) our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii) reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii) revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note 19, Collaborative and Other Relationships , to these consolidated financial statements. Royalty Revenues We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. Multiple-Element Revenue Arrangements We may enter into transactions that involve the sale of products and related services under multiple element arrangements. In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues. The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management’s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element. Fair Value Measurements We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1 — Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access; • Level 2 — Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and • Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The majority of our financial assets have been classified as Level 2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December 31, 2015 and 2014 , respectively. Other The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities. Cash and Cash Equivalents We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December 31, 2015 and 2014 , cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase. Accounts Receivable The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant. In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country’s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income. The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during 2015 with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled $62.4 million and $90.2 million as of December 31, 2015 and 2014 , respectively, of which $6.1 million and $12.6 million were classified as non-current and included in investments and other assets in our consolidated balance sheets. Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties. Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within 30 to 90 days . We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. As of December 31, 2015 and 2014 , two wholesale distributors individually accounted for approximately 35.4% and 23.1% , and 34.4% and 23.3% , of accounts receivable, net, respectively. Marketable Securities and Other Investments Marketable Debt Securities Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis. Marketable Equity Securities Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security’s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested. Non-Marketable Equity Securities We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet. Evaluating Investments for Other-than-Temporary Impairments We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income. For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss. Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security’s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security’s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss. Equity Method of Accounting In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. Inventory Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign. Capitalization of Inventory Costs We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies. Obsolescence and Unmarketable Inventory We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales. Property, Plant and Equipment Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold. In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from three to five years . We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows: Asset Category Useful Lives Land Not depreciated Buildings 15 to 40 years Leasehold Improvements Lesser of the useful life or the term of the respective lease Furniture and Fixtures 5 to 7 years Machinery and Equipment 5 to 20 years Computer Software and Hardware 3 to 5 years When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income. Intangible Assets Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January 1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable. Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income. Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX. Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Acquired In-process Research and Development (IPR&D) Acquired IPR&D represents the fair value assigned to research and develop |
Acquisitions
Acquisitions | 12 Months Ended |
Dec. 31, 2015 | |
Business Combinations [Abstract] | |
Acquisitions | Acquisitions Convergence Pharmaceuticals On February 12, 2015, we completed our acquisition of all of the outstanding stock of Convergence Pharmaceuticals (Convergence), a clinical-stage biopharmaceutical company with a focus on developing product candidates for neuropathic pain. Convergence’s lead candidate is a Phase 2 clinical candidate Raxatrigine (CNV1014802), which has demonstrated clinical activity in proof-of-concept studies for trigeminal neuralgia (TGN). Additionally, Raxatrigine has potential applicability in several other neuropathic pain states. The purchase price consisted of a $200.1 million cash payment at closing, plus contingent consideration in the form of development and approval milestones up to a maximum of $450.0 million , of which $350.0 million is associated with the development and approval of Raxatrigine for the treatment of TGN. The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business. In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence. In connection with our acquisition of Convergence, we recorded a liability of $274.5 million representing the fair value of the contingent consideration. This amount was estimated through a valuation model that incorporates industry-based probability adjusted assumptions relating to the achievement of these milestones and thus the likelihood of making the contingent payments. This fair value measurement is based upon significant inputs not observable in the market and therefore represents a Level 3 measurement. The purchase price, as adjusted, consisted of the following: (In millions) Cash portion of consideration $ 200.1 Contingent consideration 274.5 Total purchase price $ 474.6 During the second quarter of 2015, we adjusted our preliminary estimate of the fair value of the assets acquired and contingent consideration as of the date of acquisition as a result of finalizing the purchase price accounting. This resulted in an increase in the value of our estimated contingent consideration and goodwill by $36.0 million , respectively. Our revised purchase price allocation is reflected in the chart below. Our purchase price allocation is substantially complete. Subsequent changes in the fair value of the contingent consideration obligation will be recognized as adjustments to contingent consideration and reflected in our consolidated statements of income. For additional information related to the fair value of this obligation, please read Note 7, Fair Value Measurements to these consolidated financial statements. The following table summarizes the estimated fair values of the separately identifiable assets acquired and liabilities assumed as of February 12, 2015, as adjusted: (In millions) In-process research and development $ 424.6 Other intangible assets 7.6 Goodwill 128.3 Deferred tax liability (84.9 ) Other, net (1.0 ) Total purchase price $ 474.6 Our estimate of the fair value of the IPR&D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of 11% . This valuation was primarily driven by the value associated with the lead candidate, Raxatrigine, which is in development for the treatment of TGN and is expected to be completed no earlier than 2020, at a remaining cost of approximately $145.0 million . The fair value associated with Raxatrigine for the treatment of TGN was $200.0 million . We have recorded additional IPR&D assets related to the use of Raxatrigine in two additional neuropathic pain indications, with a total estimated value of $220.0 million . The remaining cost of development for these two indications is approximately $415.0 million , with an expected completion date of no earlier than 2021. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. We have attributed the goodwill recognized to the Convergence workforce's expertise in chronic pain research and clinical development and to establishing a deferred tax liability for the acquired IPR&D intangible assets which have no tax basis. The goodwill is not tax deductible. Pro forma results of operations would not be materially different as a result of the acquisition of Convergence and therefore are not presented. Subsequent to the acquisition date, our results of operations include the results of operations of Convergence. TYSABRI On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, we made an upfront payment of $3.25 billion to Elan, which was funded from our existing cash, and our collaboration agreement with Elan was terminated. We accounted for this transaction as the acquisition of an asset as we did not acquire any employees from Elan nor did we acquire any significant processes that we did not previously perform or manage under the collaboration agreement. Under the collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product's marketing, commercial, regulatory, distribution and ongoing development activities. The collaboration agreement was designed to effect an equal sharing of worldwide profits and losses generated by the activities of the collaboration. For additional information related to this collaboration, please read Note 19, Collaborative and Other Relationships to these consolidated financial statements. The $3.25 billion upfront payment was capitalized in the second quarter of 2013 as an intangible asset in our consolidated balance sheet as TYSABRI had reached technological feasibility. We adjusted the value of this intangible asset by $84.4 million related to deferred revenue from two sales-based milestones previously paid by Elan as well as transaction costs. The net intangible asset capitalized was $3.18 billion . Commencing in the second quarter of 2013, we began amortizing this intangible asset over the estimated useful life using an economic consumption method based on actual and expected revenue generated from the sales of our TYSABRI product. Following the April 2, 2013 closing of the transaction, we began recording 100% of U.S. revenues, cost of sales and operating expenses related to TYSABRI in our consolidated statements of income. Under the terms of the acquisition agreement, we continued to share TYSABRI profits with Elan on an equal basis until April 30, 2013. We recorded the profit split for the month ended April 30, 2013, as cost of sales in our consolidated statements of income as we controlled TYSABRI effective April 2, 2013. Between May 1, 2013 and April 30, 2014, we made contingent payments to Elan of 12% on worldwide net sales of TYSABRI. Commencing May 1, 2014 and thereafter, we will make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion . In 2014, the $2.0 billion threshold was pro-rated for the portion of 2014 remaining after the first 12 months expired. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo. Royalty payments to Perrigo and other third parties are recognized as cost of sales in our consolidated statements of income. |
Restructuring Restructuring
Restructuring Restructuring | 12 Months Ended |
Dec. 31, 2015 | |
Restructuring and Related Activities [Abstract] | |
Restructuring | Restructuring On October 21, 2015, we announced a corporate restructuring, which includes the termination of certain pipeline programs and an 11% reduction in workforce. We anticipate making cash payments totaling approximately $120 million under this program, which includes approximately $15.9 million related to previously 2015 accrued incentive compensation, for a total net expected restructuring charge of $105 million . These amounts will be substantially incurred and paid by the end of 2016. We recognized $93.4 million of these charges during the fourth quarter of 2015, of which $86.2 million was related to our workforce reduction and $7.2 million was related to the pipeline program terminations. Our restructuring reserve is included in accrued expenses and other in our consolidated balance sheets. The following table summarizes the charges and spending related to our restructuring efforts during 2015: (In millions) Workforce Reduction Pipeline Programs Total Restructuring charges incurred during the fourth quarter of 2015 $ 86.2 $ 7.2 $ 93.4 Previously accrued incentive compensation 15.9 — 15.9 Reserves established 102.1 7.2 109.3 Amounts paid through December 31, 2015 (68.4 ) (3.6 ) (72.0 ) Restructuring reserve as of December 31, 2015 $ 33.7 $ 3.6 $ 37.3 |
Revenue Reserves
Revenue Reserves | 12 Months Ended |
Dec. 31, 2015 | |
Reserves for Discounts and Allowances [Abstract] | |
Reserves for Discounts and Allowances | Reserves for Discounts and Allowances As a result of our acquisition of all remaining rights to TYSABRI from Elan, we began recognizing reserves for discounts and allowances for U.S. TYSABRI revenue in the second quarter of 2013. In addition, following our recently launched products, we began recognizing reserves for discounts and allowances related to these products' revenue. An analysis of the change in reserves is summarized as follows: (In millions) Discounts Contractual Adjustments Returns Total 2015 Beginning balance $ 47.6 $ 387.1 $ 49.1 $ 483.8 Current provisions relating to sales in current year 459.7 1,732.1 37.6 2,229.4 Adjustments relating to prior years (1.3 ) (16.3 ) (14.7 ) (32.3 ) Payments/returns relating to sales in current year (405.9 ) (1,258.1 ) (2.6 ) (1,666.6 ) Payments/returns relating to sales in prior years (44.0 ) (296.1 ) (11.5 ) (351.6 ) Ending balance $ 56.1 $ 548.7 $ 57.9 $ 662.7 (In millions) Discounts Contractual Adjustments Returns Total 2014 Beginning balance $ 47.0 $ 345.5 $ 33.7 $ 426.2 Current provisions relating to sales in current year 347.3 1,265.4 39.1 1,651.8 Adjustments relating to prior years (1.0 ) (28.5 ) 13.5 (16.0 ) Payments/returns relating to sales in current year (299.7 ) (933.4 ) (4.1 ) (1,237.2 ) Payments/returns relating to sales in prior years (46.0 ) (261.9 ) (33.1 ) (341.0 ) Ending balance $ 47.6 $ 387.1 $ 49.1 $ 483.8 (In millions) Discounts Contractual Adjustments Returns Total 2013 Beginning balance $ 14.3 $ 196.0 $ 26.8 $ 237.1 Current provisions relating to sales in current year 236.3 861.3 22.9 1,120.5 Adjustments relating to prior years (0.7 ) (16.4 ) 1.1 (16.0 ) Payments/returns relating to sales in current year (189.7 ) (560.4 ) — (750.1 ) Payments/returns relating to sales in prior years (13.2 ) (135.0 ) (17.1 ) (165.3 ) Ending balance $ 47.0 $ 345.5 $ 33.7 $ 426.2 The total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows: As of December 31, (In millions) 2015 2014 Reduction of accounts receivable $ 144.6 $ 124.6 Component of accrued expenses and other 518.1 359.2 Total revenue-related reserves $ 662.7 $ 483.8 |
Inventory
Inventory | 12 Months Ended |
Dec. 31, 2015 | |
Inventory Disclosure [Abstract] | |
Inventory | Inventory The components of inventory are summarized as follows: As of December 31, (In millions) 2015 2014 Raw materials $ 213.0 $ 128.3 Work in process 577.6 511.5 Finished goods 143.0 164.2 Total inventory $ 933.6 $ 804.0 Balance Sheet Classification: Inventory $ 893.4 $ 804.0 Investments and other assets 40.2 — Total inventory $ 933.6 $ 804.0 Inventory included in investments and other assets in our consolidated balance sheets primarily consisted of work in process. As of December 31, 2015 , our inventory included $24.7 million associated with our ZINBRYTA program, $18.4 million associated with our BENEPALI program and $24.2 million associated with our FLIXABI program, which have been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U. As of December 31, 2014 , our inventory included $6.3 million associated with our ZINBRYTA program, which has been capitalized in advance of regulatory approval. For information on our pre-approval inventory policy, please read Note 1, Summary of Significant Accounting Policies to these consolidated financial statements Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled $41.9 million , $50.6 million , and $47.3 million for the years ended December 31, 2015 , 2014 , and 2013 , respectively. |
Intangible Assets and Goodwill
Intangible Assets and Goodwill | 12 Months Ended |
Dec. 31, 2015 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets and Goodwill | Intangible Assets and Goodwill Intangible Assets Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows: As of December 31, 2015 As of December 31, 2014 (In millions) Estimated Life Cost Accumulated Amortization Net Cost Accumulated Amortization Net Out-licensed patents 13-23 years $ 543.3 $ (506.0 ) $ 37.3 $ 543.3 $ (481.7 ) $ 61.6 Developed technology 15-23 years 3,005.3 (2,552.9 ) 452.4 3,005.3 (2,396.8 ) 608.5 In-process research and development Indefinite until commercialization 730.5 — 730.5 314.1 — 314.1 Trademarks and tradenames Indefinite 64.0 — 64.0 64.0 — 64.0 Acquired and in-licensed rights and patents 6-18 years 3,303.2 (502.3 ) 2,800.9 3,280.4 (300.1 ) 2,980.3 Total intangible assets $ 7,646.3 $ (3,561.2 ) $ 4,085.1 $ 7,207.1 $ (3,178.6 ) $ 4,028.5 Amortization of acquired intangible assets totaled $382.6 million , $489.8 million , and $342.9 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Amortization of acquired intangible assets during 2014 included total impairment charges of $34.7 million related to one of our out-licensed patents and $16.2 million related to one of our IPR&D intangible assets. Out-licensed Patents Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During 2014, we recorded a charge of $34.7 million related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product. The charge was included in amortization of acquired intangible assets. The fair value of the intangible asset was based on a discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues. There were no impairment charges related to our out-licensed patents during 2015 . Developed Technology Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of December 31, 2015 , was $443.9 million . IPR&D IPR&D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we determine the estimated useful life. In connection with our acquisition of Convergence in February 2015, we acquired IPR&D programs with an estimated fair value of $424.6 million . This amount has and will be adjusted for foreign exchange rate fluctuations. For a more detailed description of this transaction, please read Note 2, Acquisitions to these consolidated financial statements. An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of 2015. This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates. During the third quarter of 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of $16.2 million in one of our IPR&D assets during 2014. Acquired and In-licensed Rights and Patents Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. The net book value of this asset as of December 31, 2015 was $2,742.9 million . For a more detailed description of this transaction, please read Note 2, Acquisitions to these consolidated financial statements. Estimated Future Amortization of Intangible Assets Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows: (In millions) As of December 31, 2015 2016 $ 346.4 2017 318.6 2018 291.0 2019 275.1 2020 269.1 Total $ 1,500.2 Goodwill The following table provides a roll forward of the changes in our goodwill balance: As of December 31, (In millions) 2015 2014 Goodwill, beginning of year $ 1,760.2 $ 1,232.9 Increase to goodwill 908.1 527.3 Other (4.5 ) — Goodwill, end of year $ 2,663.8 $ 1,760.2 The increase in goodwill during 2015 was related to $900.0 million in contingent milestones achieved (exclusive of $120.2 million in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights and $128.3 million related to our acquisition of Convergence. Other includes changes related to foreign exchange rate fluctuations. The increase in goodwill during 2014 was related to $600.0 million in contingent milestones achieved (exclusive of $72.7 million in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. For additional information related to future contingent payments to the former shareholders of Fumapharm AG, please read Note 21, Commitments and Contingencies to these consolidated financial statements. For additional information related to our acquisition of Convergence, please read Note 2, Acquisitions to these consolidated financial statements. As of December 31, 2015 , we had no accumulated impairment losses related to goodwill. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2015 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: (In millions) As of Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 909.5 $ — $ 909.5 $ — Marketable debt securities: Corporate debt securities 1,510.9 — 1,510.9 — Government securities 2,875.9 — 2,875.9 — Mortgage and other asset backed securities 494.1 — 494.1 — Marketable equity securities 37.5 37.5 — — Derivative contracts 27.2 — 27.2 — Plan assets for deferred compensation 40.1 — 40.1 — Total $ 5,895.2 $ 37.5 $ 5,857.7 $ — Liabilities: Derivative contracts $ 14.7 $ — $ 14.7 $ — Contingent consideration obligations 506.0 — — 506.0 Total $ 520.7 $ — $ 14.7 $ 506.0 (In millions) As of Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 716.3 $ — $ 716.3 $ — Marketable debt securities: Corporate debt securities 1,063.0 — 1,063.0 — Government securities 849.8 — 849.8 — Mortgage and other asset backed securities 198.3 — 198.3 — Marketable equity securities 6.9 6.9 — — Derivative contracts 72.7 — 72.7 — Plan assets for deferred compensation 36.9 — 36.9 — Total $ 2,943.9 $ 6.9 $ 2,937.0 $ — Liabilities: Derivative contracts $ 5.4 $ — $ 5.4 $ — Contingent consideration obligations 215.5 — — 215.5 Total $ 220.9 $ — $ 5.4 $ 215.5 The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, refer to Note 1, Summary of Significant Accounting Policies: Fair Value Measurements , to these consolidated financial statements. Debt Instruments The fair values of our debt instruments, which are Level 2 liabilities, are summarized as follows: As of December 31, (In millions) 2015 2014 Notes payable to Fumedica $ 9.4 $ 12.6 6.875% Senior Notes due March 1, 2018 602.6 634.6 2.900% Senior Notes due September 15, 2020 1,497.5 — 3.625% Senior Notes due September 15, 2022 1,014.2 — 4.050% Senior Notes due September 15, 2025 1,764.6 — 5.200% Senior Notes due September 15, 2045 1,757.6 — Total $ 6,645.9 $ 647.2 The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, Indebtedness to these consolidated financial statements. Contingent Consideration Obligations The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements: As of December 31, (In millions) 2015 2014 Fair value, beginning of year $ 215.5 $ 280.9 Additions 274.5 — Changes in fair value 30.5 (38.9 ) Payments (14.5 ) (26.5 ) Fair value, end of year $ 506.0 $ 215.5 As of December 31, 2015 and 2014 , approximately $301.3 million and $200.0 million , respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. There were no changes in valuation techniques or transfers between fair value measurement levels during the years ended December 31, 2015 and 2014 . During the third quarter 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. We adjusted the value of our contingent consideration liabilities to reflect these changes. The change in probability of success, combined with a delay in one of the projects, resulted in a net gain of $49.4 million during 2014, which was recorded in (gain) loss on fair value remeasurement of contingent consideration and reduced the fair value of our contingent consideration obligations. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information related to the valuation techniques and inputs utilized in valuation of our financial assets and liabilities, please read Note 1, Summary of Significant Accounting Policies to these consolidated financial statements. In connection with our acquisition of Convergence in February 2015, we recorded a liability of $274.5 million , representing the fair value of the contingent consideration. This valuation was based on probability weighted net cash outflow projections of $450.0 million , discounted using a rate of 2% , which was the estimated cost of debt financing for market participants. This liability reflects the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. For a more detailed description of this transaction, please read Note 2, Acquisitions to these consolidated financial statements. As of December 31, 2015 , the fair value of this contingent consideration obligation was $297.5 million , discounted using a rate of 3% , and approximately $197.2 million is reflected as a component of accrued expenses and other in our consolidated balance sheets as we expect to make the payment within a year. In connection with our acquisition of Stromedix in March 2012, we recorded a contingent consideration obligation of $122.2 million . As of December 31, 2015 and 2014 , the fair value of this contingent consideration obligation was $131.5 million and $130.5 million , respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of $419.0 million , discounted using a rate of 2% , which is a measure of the credit risk associated with settling the liability. For 2015 compared to 2014 , the net increase in the fair value of this obligation was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain remaining developmental milestones. Upon completion of our purchase of the noncontrolling interest in our joint venture investments in Biogen Dompé SRL and Biogen Dompé Switzerland GmbH in September 2011, we recorded a contingent consideration obligation of $38.8 million . As of December 31, 2015 and 2014 , the fair value of this contingent consideration obligation was $0.0 million and $15.5 million , respectively. For 2015 compared to 2014 , the net decrease in the fair value of this obligation was primarily due to payments of $14.5 million of sales-based milestones. Our obligations under this agreement were completed as of December 31, 2015 . In connection with our acquisition of Biogen Idec International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG (Panima), in December 2010, we recorded a contingent consideration obligation of $81.2 million . As of December 31, 2015 and 2014 , the fair value of this contingent consideration obligation was $77.0 million and $69.5 million , respectively. Our most recent valuation was determined based upon probability weighted net cash outflow projections of $365.0 million , discounted using a rate of 3% , which is a measure of the credit risk associated with settling the liability. For 2015 compared to 2014 , the net increase in the fair value of this obligation was primarily due to changes in the probability and expected timing related to the achievement of certain remaining developmental milestones and in the discount rate. Acquired IPR&D In connection with our acquisition of Convergence, we also allocated $424.6 million of the total purchase price to acquired IPR&D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. This estimate was also adjusted from our preliminary estimate as of the date of acquisition to reflect revised estimates to our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. These assets will be tested for impairment annually until commercialization, after which time the IPR&D will be amortized over its estimated useful life. For a more detailed description of this transaction, please read Note 2, Acquisitions to these consolidated financial statements. |
Financial Instruments
Financial Instruments | 12 Months Ended |
Dec. 31, 2015 | |
Investments, All Other Investments [Abstract] | |
Financial Instruments | Financial Instruments The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents on the accompanying consolidated balance sheet: As of December 31, (In millions) 2015 2014 Commercial paper $ 21.9 $ 54.2 Overnight reverse repurchase agreements 134.7 305.0 Money market funds 673.8 321.2 Short-term debt securities 79.1 35.9 Total $ 909.5 $ 716.3 The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately 0.7% and 2.1% of total assets as of December 31, 2015 and 2014 , respectively. The following tables summarize our marketable debt and equity securities: As of December 31, 2015 (In millions) Fair Value Gross Unrealized Gains Gross Unrealized Losses Amortized Cost Corporate debt securities Current $ 394.3 $ — $ (0.5 ) $ 394.8 Non-current 1,116.6 0.1 (4.1 ) 1,120.6 Government securities Current 1,723.4 0.1 (1.1 ) 1,724.4 Non-current 1,152.5 — (3.1 ) 1,155.6 Mortgage and other asset backed securities Current 2.8 — — 2.8 Non-current 491.3 0.1 (1.8 ) 493.0 Total marketable debt securities $ 4,880.9 $ 0.3 $ (10.6 ) $ 4,891.2 Marketable equity securities, non-current $ 37.5 $ 9.2 $ — $ 28.3 As of December 31, 2014 (In millions) Fair Value Gross Unrealized Gains Gross Unrealized Losses Amortized Cost Corporate debt securities Current $ 370.4 $ — $ (0.2 ) $ 370.6 Non-current 692.6 0.2 (1.5 ) 693.9 Government securities Current 269.9 — (0.1 ) 270.0 Non-current 579.9 0.3 (0.4 ) 580.0 Mortgage and other asset backed securities Current 0.2 — — 0.2 Non-current 198.1 0.2 (0.2 ) 198.1 Total marketable debt securities $ 2,111.1 $ 0.7 $ (2.4 ) $ 2,112.8 Marketable equity securities, non-current $ 6.9 $ 1.2 $ (0.2 ) $ 5.9 Summary of Contractual Maturities: Available-for-Sale Securities The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows: As of December 31, 2015 As of December 31, 2014 (In millions) Estimated Fair Value Amortized Cost Estimated Fair Value Amortized Cost Due in one year or less $ 2,120.5 $ 2,122.0 $ 640.5 $ 640.8 Due after one year through five years 2,575.9 2,583.9 1,343.7 1,345.2 Due after five years 184.5 185.3 126.9 126.8 Total available-for-sale securities $ 4,880.9 $ 4,891.2 $ 2,111.1 $ 2,112.8 The average maturity of our marketable debt securities available-for-sale as of December 31, 2015 and 2014 , was 16 months and 15 months, respectively. Proceeds from Marketable Debt Securities The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows: For the Years Ended December 31, (In millions) 2015 2014 2013 Proceeds from maturities and sales $ 4,063.0 $ 2,718.9 $ 5,190.1 Realized gains $ 1.5 $ 0.7 $ 6.6 Realized losses $ 3.5 $ 0.5 $ 2.1 Realized losses for the year ended December 31, 2015 , primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended December 31, 2014 , primarily relate to sales of agency mortgage-backed securities and government securities. Realized losses for the year ended December 31, 2013 , primarily relate to sales of agency mortgage-backed securities and corporate securities. Strategic Investments As of December 31, 2015 and 2014 , our strategic investment portfolio was comprised of investments totaling $96.0 million and $47.8 million , respectively, which are included in investments and other assets in our consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. |
Derivative Instruments
Derivative Instruments | 12 Months Ended |
Dec. 31, 2015 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | Derivative Instruments Foreign Currency Forward Contracts - Hedging Instruments Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S. dollar. The value of revenues and operating expenses measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses. Foreign currency forward contracts in effect as of December 31, 2015 and 2014 , had durations of 1 to 18 months and 1 to 15 months , respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter of 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net. The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and expenses is summarized as follows: Notional Amount As of December 31, Foreign Currency: (In millions) 2015 2014 Euro $ 945.5 $ 1,174.6 Swiss francs 80.8 — Canadian dollar 76.7 56.7 British pound sterling — 34.5 Australian dollar — 19.9 Japanese yen — 16.6 Total foreign currency forward contracts $ 1,103.0 $ 1,302.3 The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected gains of $1.8 million and $72.1 million and losses of $23.6 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. We expect all contracts to be settled over the next 18 months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of December 31, 2015 and 2014 , credit risk did not change the fair value of our foreign currency forward contracts. The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted revenues: For the Years Ended December 31, Net Gains/(Losses) Reclassified from AOCI into Net Income (Effective Portion) Net Gains/(Losses) Recognized into Net Income (Ineffective Portion) Location 2015 2014 2013 Location 2015 2014 2013 Revenue $ 173.2 $ 6.8 $ (13.2 ) Other income (expense) $ 4.9 $ (1.5 ) $ (0.2 ) The effect of foreign currency forward contracts designated as hedging instruments on our consolidated statements of income related to our forecasted operating expenses was immaterial for 2015. Interest Rate Contracts - Hedging Instruments We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. Interest Rate Lock Contracts During 2015 , we entered into treasury rate locks, with an aggregated notional amount of $1.1 billion , that were designated as cash flow hedges to hedge against changes in the 10-year and 30-year U.S. treasury interest rates that could have impacted our anticipated debt offering. In connection with the issuance of our 4.05% and 5.20% Senior Notes, as described in Note 11, Indebtedness , we settled the treasury rate locks and realized an $8.5 million gain. As the hedging relationship was effective, the gain was recorded in AOCI and will be recognized in other income (expense), net over the life of the 4.05% and 5.20% Senior Notes. Interest Rate Swap Contracts In connection with the issuance of our 2.90% Senior Notes, as described in Note 11, Indebtedness , we entered into interest rate swaps with an aggregate notional amount of $675.0 million , which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the 2.90% Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the 2.90% Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our consolidated statements of income. Foreign Currency Forward Contracts - Other Derivatives We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions. The aggregate notional amount of these outstanding foreign currency contracts was $721.0 million and $365.2 million as of December 31, 2015 and 2014 , respectively. Net losses of $23.8 million and $15.5 million and net gains of $5.2 million related to these contracts were recognized as a component of other income (expense), net, for the years ended December 31, 2015 , 2014 and 2013 , respectively. Summary of Derivatives While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The following table summarizes the fair value and presentation in our consolidated balance sheets for our outstanding derivatives including those designated as hedging instruments: (In millions) Balance Sheet Location Fair Value Hedging Instruments: Asset derivatives Other current assets $ 16.6 Investments and other assets $ 0.3 Liability derivatives Accrued expenses and other $ 10.2 Other long-term liabilities $ 2.5 Other Derivatives: Asset derivatives Other current assets $ 10.3 Liability derivatives Accrued expenses and other $ 2.0 (In millions) Balance Sheet Location Fair Value Hedging Instruments: Asset derivatives Other current assets $ 69.5 Investments and other assets $ 1.9 Other Derivatives: Asset derivatives Other current assets $ 1.3 Liability derivatives Accrued expenses and other $ 5.4 |
Property, Plant and Equipment
Property, Plant and Equipment | 12 Months Ended |
Dec. 31, 2015 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment | Property, Plant and Equipment Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows: As of December 31, (In millions) 2015 2014 Land $ 74.7 $ 56.9 Buildings 1,035.6 947.7 Leasehold improvements 166.6 155.5 Machinery and equipment 1,079.6 1,011.3 Computer software and hardware 647.1 547.8 Furniture and fixtures 72.9 64.3 Construction in progress 441.2 168.6 Total cost 3,517.7 2,952.1 Less: accumulated depreciation (1,330.1 ) (1,186.4 ) Total property, plant and equipment, net $ 2,187.6 $ 1,765.7 Depreciation expense totaled $217.9 million , $198.4 million and $187.8 million for 2015 , 2014 and 2013 , respectively. For 2015 , 2014 and 2013 , we capitalized interest costs related to construction in progress totaling approximately $10.4 million , $6.4 million and $7.8 million , respectively. Research Triangle Park Facility Purchase On August 24, 2015, we purchased from Eisai, Inc. (Eisai) its drug product manufacturing facility and supporting infrastructure in Research Triangle Park (RTP), North Carolina for $104.8 million . The purchase price consisted of the following: (In millions) Buildings $ 58.6 Machinery and equipment 25.9 Land 20.3 Total purchase price $ 104.8 On August 24, 2015, we also amended our existing 10 year lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As amended, the lease provides for a 3 year term and our agreement to purchase the facility upon expiration of the lease term and Eisai's completion of certain activities. Accordingly, we recorded the assets along with a corresponding financing obligation on our consolidated balance sheet for $20.3 million , the net present value of the future minimum lease payments. The assets were recorded as a component of buildings and machinery and equipment. We expect to complete the purchase of the oral solid products manufacturing facility at the end of the lease term in the third quarter of 2018. Solothurn, Switzerland Facility On December 1, 2015, we purchased land in Solothurn, Switzerland for 64.4 million Swiss Francs (approximately $62.5 million ). We plan to build a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of December 31, 2015 , we have approximately $99.0 million capitalized in construction in progress related to the construction of this facility. Weston Exit Costs As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of $27.2 million in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease for the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement. |
Indebtedness
Indebtedness | 12 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Indebtedness | Indebtedness Our indebtedness is summarized as follows: As of December 31, (In millions) 2015 2014 Current portion: Notes payable to Fumedica $ 3.1 $ 3.1 Financing arrangement for the purchase of the RTP facility 1.7 — Current portion of notes payable and other financing arrangements $ 4.8 $ 3.1 Non-current portion: 2008 Senior Notes 6.875% Senior Notes due March 1, 2018 $ 565.3 $ 571.7 2015 Senior Notes 2.900% Senior Notes due September 15, 2020 1,485.5 — 3.625% Senior Notes due September 15, 2022 992.2 — 4.050% Senior Notes due September 15, 2025 1,733.4 — 5.200% Senior Notes due September 15, 2045 1,721.1 — Notes payable to Fumedica 5.9 8.6 Financing arrangement for the purchase of the RTP facility 18.1 — Non-current portion of notes payable and other financing arrangements $ 6,521.5 $ 580.3 The following is a summary description of our principal indebtedness as of December 31, 2015 : 2015 Senior Notes On September 15, 2015, we issued senior unsecured notes for an aggregate principal amount of $6.0 billion , consisting of the following: • $1.5 billion of 2.90% Senior Notes due September 15, 2020, valued at 99.792% of par; • $1.0 billion of 3.625% Senior Notes due September 15, 2022, valued at 99.920% of par; • $1.75 billion of 4.05% Senior Notes due September 15, 2025, valued at 99.764% of par; and • $1.75 billion of 5.20% Senior Notes due September 15, 2045, valued at 99.294% of par. These notes are senior unsecured obligations and may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The notes also contain a change of control provision that may require us to purchase the notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. The costs associated with this offering of approximately $47.5 million have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the notes is payable March 15 and September 15 of each year. In connection with this offering, we also entered into interest rate swaps. The carrying value of the 2.90% Senior Notes includes approximately $1.8 million related to changes in the fair value of the interest rate swaps. For additional information, please read Note 9, Derivative Instruments, to these consolidated financial statements. 2008 Senior Notes On March 4, 2008, we issued $550.0 million aggregate principal amount of 6.875% Senior Notes due March 1, 2018 that were originally priced at 99.184% of par. The discount is amortized as additional interest expense over the period from issuance through maturity. These notes are senior unsecured obligations. Interest on the notes is payable March 1 and September 1 of each year. The notes may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The notes contain a change of control provision that may require us to purchase the notes under certain circumstances. There is also an interest rate adjustment feature that requires us to pay interest at an increased rate on the notes if the credit rating on the notes declines below investment grade. In accordance with ASU No. 2015-03, during 2015, we reclassified $1.8 million of our debt issuance costs related to our 6.875% Senior Notes from an asset to a reduction to the carrying amount of the 6.875% Senior Notes in our 2014 consolidated balance sheet. Upon the issuance of the 6.875% Senior Notes due in 2018, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these swaps, the carrying amount of the 6.875% Senior Notes due in 2018 was increased by $62.8 million and is being amortized using the effective interest rate method over the remaining life of the Senior Notes and is being recognized as a reduction of interest expense. As of December 31, 2015 , $17.8 million remains to be amortized. Notes Payable to Fumedica In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling 61.4 million Swiss Francs which were payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica had a carrying value of 8.9 million Swiss Francs ( $9.0 million ) and 11.6 million Swiss Francs ( $11.7 million ) as of December 31, 2015 and 2014 , respectively. Credit Facility In August 2015, we entered into a $1.0 billion , 5 -year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of December 31, 2015 , we had no outstanding borrowings and were in compliance with all covenants under this facility. In March 2013, we entered into a $750.0 million 364 -day senior unsecured revolving credit facility. In March 2014, the revolving credit facility expired and was not renewed. Financing Arrangement During 2015 we recorded a financing obligation in relation to the amendment of our lease agreement of Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. As of December 31, 2015 , the financing obligation totaled approximately $19.8 million . For additional information, please read Note 10, Property, Plant and Equipment to these consolidated financial statements. Debt Maturity The total gross payments, excluding our financing arrangement, due under our debt arrangements are as follows: (In millions) As of December 31, 2015 2016 $ 3.2 2017 3.2 2018 553.2 2019 — 2020 1,500.0 2021 and thereafter 4,500.0 Total $ 6,559.6 The fair value of our debt is disclosed in Note 7, Fair Value Measurements to these consolidated financial statements. |
Equity
Equity | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Equity | Equity Preferred Stock We have 8.0 million shares of Preferred Stock authorized, of which 1.75 million shares are authorized as Series A, 1.0 million shares are authorized as Series X junior participating and 5.25 million shares are undesignated. Shares may be issued without a vote or action of stockholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during 2015 , 2014 and 2013 . Common Stock The following table describes the number of shares authorized, issued and outstanding of our common stock as of December 31, 2015 and 2014 : As of December 31, 2015 As of December 31, 2014 (In millions) Authorized Issued Outstanding Authorized Issued Outstanding Common stock 1,000.0 241.2 218.6 1,000.0 257.1 234.6 Share Repurchases In May 2015, our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2015 Share Repurchase Program). As of December 31, 2015 , the 2015 Share Repurchase Program was completed and we repurchased and retired approximately 16.8 million shares of common stock at a cost of $5.0 billion during the year ended December 31, 2015 . In February 2011, our Board of Directors authorized a program to repurchase up to 20.0 million of our common stock (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. The 2011 Share Repurchase Program does not have an expiration date. During 2014 , we purchased approximately 2.9 million shares of common stock at a cost of $886.8 million under our 2011 Share Repurchase Program. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended December 31, 2015 and have approximately 1.3 million shares remaining available for repurchase under this authorization. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Comprehensive Income (Loss) Note | Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component: (In millions) Unrealized Gains (Losses) on Securities Available for Sale Unrealized Gains (Losses) on Cash Flow Hedges Unfunded Status of Postretirement Benefit Plans Translation Adjustments Total Balance, December 31, 2014 $ (0.4 ) $ 71.7 $ (31.6 ) $ (99.2 ) $ (59.5 ) Other comprehensive income (loss) before reclassifications (1.7 ) 110.8 (6.2 ) (96.4 ) 6.5 Amounts reclassified from accumulated other comprehensive income (loss) 1.3 (172.3 ) — — (171.0 ) Net current period other comprehensive income (loss) (0.4 ) (61.5 ) (6.2 ) (96.4 ) (164.5 ) Balance, December 31, 2015 $ (0.8 ) $ 10.2 $ (37.8 ) $ (195.6 ) $ (224.0 ) (In millions) Unrealized Gains (Losses) on Securities Available for Sale Unrealized Gains (Losses) on Cash Flow Hedges Unfunded Status of Postretirement Benefit Plans Translation Adjustments Total Balance, December 31, 2013 $ 5.6 $ (23.7 ) $ (19.6 ) $ 10.0 $ (27.7 ) Other comprehensive income (loss) before reclassifications 0.4 101.7 (12.0 ) (109.2 ) (19.1 ) Amounts reclassified from accumulated other comprehensive income (loss) (6.4 ) (6.3 ) — — (12.7 ) Net current period other comprehensive income (loss) (6.0 ) 95.4 (12.0 ) (109.2 ) (31.8 ) Balance, December 31, 2014 $ (0.4 ) $ 71.7 $ (31.6 ) $ (99.2 ) $ (59.5 ) (In millions) Unrealized Gains (Losses) on Securities Available for Sale Unrealized Gains (Losses) on Cash Flow Hedges Unfunded Status of Postretirement Benefit Plans Translation Adjustments Total Balance, December 31, 2012 $ 4.2 $ (10.7 ) $ (21.7 ) $ (27.1 ) $ (55.3 ) Other comprehensive income (loss) before reclassifications 11.8 (26.7 ) 2.1 37.1 24.3 Amounts reclassified from accumulated other comprehensive income (loss) (10.4 ) 13.7 — — 3.3 Net current period other comprehensive income (loss) 1.4 (13.0 ) 2.1 37.1 27.6 Balance, December 31, 2013 $ 5.6 $ (23.7 ) $ (19.6 ) $ 10.0 $ (27.7 ) The following table summarizes the amounts reclassified from accumulated other comprehensive income: (In millions) Income Statement Location Amounts Reclassified from Accumulated Other Comprehensive Income For the Years Ended December 31, 2015 2014 2013 Gains (losses) on securities available for sale Other income (expense) $ (2.0 ) $ 9.9 $ 15.9 Income tax benefit (expense) 0.7 (3.5 ) (5.5 ) Gains (losses) on cash flow hedges Revenues 173.2 6.8 (13.2 ) Other income (expense) (0.1 ) — — Income tax benefit (expense) (0.8 ) (0.5 ) (0.5 ) Total reclassifications, net of tax $ 171.0 $ 12.7 $ (3.3 ) |
Earnings per Share
Earnings per Share | 12 Months Ended |
Dec. 31, 2015 | |
Earnings Per Share [Abstract] | |
Earnings per Share | Earnings per Share Basic and diluted earnings per share are calculated as follows: For the Years Ended December 31, (In millions) 2015 2014 2013 Numerator: Net income attributable to Biogen Inc. $ 3,547.0 $ 2,934.8 $ 1,862.3 Denominator: Weighted average number of common shares outstanding 230.7 236.4 236.9 Effect of dilutive securities: Stock options and employee stock purchase plan 0.1 0.1 0.3 Time-vested restricted stock units 0.3 0.5 0.8 Market stock units 0.1 0.2 0.3 Dilutive potential common shares 0.5 0.8 1.4 Shares used in calculating diluted earnings per share 231.2 237.2 238.3 Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant. Earnings per share for the years ended December 31, 2015 , 2014 and 2013 , reflects, on a weighted average basis, the repurchase of 4.6 million shares, 1.0 million shares and 0.9 million shares, respectively, of our common stock under our share repurchase authorizations. |
Share-based Payments
Share-based Payments | 12 Months Ended |
Dec. 31, 2015 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Share-based Payments | Share-based Payments Share-based Compensation Expense The following table summarizes share-based compensation expense included in our consolidated statements of income: For the Years Ended December 31, (In millions) 2015 2014 2013 Research and development $ 88.6 $ 102.1 $ 95.6 Selling, general and administrative 127.3 150.3 160.3 Reversal of previously accrued incentive compensation included in restructuring charges (8.6 ) — — Subtotal 207.3 252.4 255.9 Capitalized share-based compensation costs (11.0 ) (10.0 ) (9.8 ) Share-based compensation expense included in total cost and expenses 196.3 242.4 246.1 Income tax effect (55.8 ) (72.2 ) (73.3 ) Share-based compensation expense included in net income attributable to Biogen Inc. $ 140.5 $ 170.2 $ 172.8 The following table summarizes share-based compensation expense associated with each of our share-based compensation programs: For the Years Ended December 31, (In millions) 2015 2014 2013 Stock options $ — $ — $ 0.6 Market stock units 38.1 37.4 32.8 Time-vested restricted stock units 119.0 115.4 103.5 Cash settled performance units 22.4 65.5 109.8 Performance units 13.9 21.9 — Employee stock purchase plan 13.9 12.2 9.2 Subtotal 207.3 252.4 255.9 Capitalized share-based compensation costs (11.0 ) (10.0 ) (9.8 ) Share-based compensation expense included in total cost and expenses $ 196.3 $ 242.4 $ 246.1 Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation were $78.2 million , $96.4 million and $73.5 million in 2015 , 2014 and 2013 , respectively. These amounts have been calculated under the alternative transition method. As of December 31, 2015 , unrecognized compensation cost related to unvested share-based compensation was approximately $184.3 million , net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of 1.8 years. Share-Based Compensation Plans We have three share-based compensation plans pursuant to which awards are currently being made: (i) the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006 Directors Plan); (ii) the Biogen Inc. 2008 Amended and Restated Omnibus Equity Plan (2008 Omnibus Plan); and (iii) the Biogen Inc. 2015 Employee Stock Purchase Plan (ESPP). Directors Plan In May 2006, our stockholders approved the 2006 Directors Plan for share-based awards to our directors. Awards granted from the 2006 Directors Plan may include stock options, shares of restricted stock, restricted stock units, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of 1.6 million shares of common stock for issuance under the 2006 Directors Plan. The 2006 Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a 1.5-to-1 ratio. In June 2015, our stockholders approved an amendment to extend the term of the 2006 Directors Plan until June 10, 2025. Omnibus Plans In June 2008, our stockholders approved the 2008 Omnibus Plan for share-based awards to our employees. Awards granted from the 2008 Omnibus Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, shares of phantom stock, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for issuance under the 2008 Omnibus Plan consist of 15.0 million shares reserved for this purpose, plus shares of common stock that remained available for issuance under our 2005 Omnibus Equity Plan on the date that our stockholders approved the 2008 Omnibus Plan, plus shares that were subject to awards under the 2005 Omnibus Equity Plan which remain unissued upon the cancellation, surrender, exchange or termination of such awards. The 2008 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a 1.5-to-1 ratio. We have not made any awards pursuant to the 2005 Omnibus Equity Plan since our stockholders approved the 2008 Omnibus Plan, and do not intend to make any awards pursuant to the 2005 Omnibus Equity Plan in the future, except that unused shares under the 2005 Omnibus Equity Plan have been carried over for use under the 2008 Omnibus Plan. Stock Options We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a ten-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options’ vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were no grants of stock options made in 2015 , 2014 and 2013 . As of December 31, 2015 , all outstanding options were exercisable. The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility, or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January 1, 2006 were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures. The following table summarizes our stock option activity: Shares Weighted Average Exercise Price Outstanding at December 31, 2014 221,000 $ 56.98 Granted — $ — Exercised (114,000 ) $ 59.82 Cancelled — $ — Outstanding at December 31, 2015 107,000 $ 53.94 The total intrinsic values of options exercised in 2015 , 2014 and 2013 totaled $38.0 million , $42.7 million , and $86.2 million , respectively. The aggregate intrinsic values of options outstanding as of December 31, 2015 totaled $27.0 million . The weighted average remaining contractual term for options outstanding as of December 31, 2015 was 3.2 years. The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options: For the Years Ended December 31, (In millions) 2015 2014 2013 Tax benefit realized for stock options $ 11.9 $ 13.0 $ 29.4 Cash received from the exercise of stock options $ 6.3 $ 8.5 $ 28.1 Market Stock Units (MSUs) MSUs awarded to employees prior to 2014 vested in four equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between 0% and 150% of the target number of units granted based on actual stock performance. MSUs awarded to employees in 2014 and 2015 vest in three equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between 0% and 200% of the target number of units granted based on actual stock performance. The vesting of these awards is subject to the respective employee’s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period. The following table summarizes our MSU activity: Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2014 403,000 $ 219.29 Granted (a) 185,000 $ 493.43 Vested (277,000 ) $ 165.63 Forfeited (42,000 ) $ 294.85 Unvested at December 31, 2015 269,000 $ 339.89 (a) MSUs granted in 2015 include approximately 8,000 , 19,000 , 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the 60 calendar day average closing stock price on grant date for MSUs awarded prior to 2014, the 30 calendar day average closing stock price on the date of grant for MSUs awarded in 2014 and 2015, expected volatility of our stock price, risk-free rates of return and expected dividend yield. The assumptions used in our valuation are summarized as follows: For the Years Ended December 31, 2015 2014 2013 Expected dividend yield —% —% —% Range of expected stock price volatility 31.0% - 33.2% 31.7% - 35.1% 21.7% - 25.7% Range of risk-free interest rates 0.2% - 1.0% 0.1% - 0.7% 0.1% - 0.7% 30 calendar day average stock price on grant date $277.35 - $426.27 $280.88 - $335.65 ** 60 calendar day average stock price on grant date ** ** $150.33 - $240.14 Weighted-average per share grant date fair value $493.43 $395.22 $193.45 The total fair values of MSUs vested in 2015 , 2014 and 2013 totaled $109.0 million , $117.4 million , and $50.9 million , respectively. Cash Settled Performance Units (CSPUs) CSPUs awarded to employees vest in three equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee’s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between 0% and 200% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs awarded prior to 2014 are settled in cash based on the 60 calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. CSPUs awarded in 2014 and 2015 will be settled in cash based on the 30 calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period. The following table summarizes our CSPU activity: Shares Unvested at December 31, 2014 335,000 Granted (a) 115,000 Vested (222,000 ) Forfeited (36,000 ) Unvested at December 31, 2015 192,000 (a) CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. The total cash paid in settlement of CSPUs vested in 2015 , 2014 and 2013 totaled $79.8 million , $92.8 million , and $48.3 million , respectively. Performance-vested Restricted Stock Units (PUs) Beginning in the first quarter of 2014, we revised our long term incentive program to include a new type of award granted to certain employees in the form of restricted stock units that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the cash settled performance units, and vest in three equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between 0% and 200% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the 30 calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period. The following table summarizes our PU activity: Shares Unvested at December 31, 2014 57,000 Granted (a) 89,000 Vested (33,000 ) Forfeited (10,000 ) Unvested at December 31, 2015 103,000 (a) PUs granted in 2015 include approximately 42,000 PUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the PUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and PUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. During 2015 , 32,000 PUs were converted to share settlements, of which approximately 11,000 shares were vested and issued. All other PUs that vested in 2015 were settled in cash totaling $12.4 million . Time-Vested Restricted Stock Units (RSUs) RSUs awarded to employees generally vest no sooner than one-third per year over three years on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period. The following table summarizes our RSU activity: Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2014 1,137,000 $ 221.01 Granted (a) 459,000 $ 388.88 Vested (626,000 ) $ 190.65 Forfeited (160,000 ) $ 302.35 Unvested at December 31, 2015 810,000 $ 323.87 (a) RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately 7,000 RSUs granted to our Board of Directors. RSUs granted in 2014 and 2013 had weighted average grant date fair values of $321.72 and $176.53 , respectively. The total fair values of RSUs vested in 2015 , 2014 and 2013 totaled $239.7 million , $281.1 million , and $209.7 million , respectively. Employee Stock Purchase Plan (ESPP) In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June 30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is 6.2 million . The following table summarizes our ESPP activity: For the Years Ended December 31, (In millions, except share amounts) 2015 2014 2013 Shares issued under the 2015 ESPP 78,000 ** ** Shares issued under the 1995 ESPP 98,000 180,000 245,000 Cash received under the 2015 ESPP $ 19.3 ** ** Cash received under the 1995 ESPP $ 30.0 $ 46.4 $ 38.7 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Income Tax Expense Income before income tax provision and the income tax expense consist of the following: For the Years Ended December 31, (In millions) 2015 2014 2013 Income before income taxes (benefit): Domestic $ 3,386.7 $ 2,557.4 $ 1,953.0 Foreign 1,380.6 1,389.2 527.6 Total $ 4,767.3 $ 3,946.6 $ 2,480.6 Income tax expense (benefit): Current: Federal $ 1,214.1 $ 1,159.5 $ 700.9 State 38.6 65.2 98.4 Foreign 54.5 73.4 46.8 Total 1,307.2 1,298.1 846.1 Deferred: Federal $ (129.6 ) $ (280.9 ) $ (200.6 ) State (1.9 ) (21.0 ) (35.9 ) Foreign (14.1 ) (6.3 ) (8.6 ) Total (145.6 ) (308.2 ) (245.1 ) Total income tax expense $ 1,161.6 $ 989.9 $ 601.0 Deferred Tax Assets and Liabilities Significant components of our deferred tax assets and liabilities are summarized as follows: As of December 31, (In millions) 2015 2014 Deferred tax assets: Tax credits $ 189.3 $ 69.0 Inventory, other reserves, and accruals 243.9 217.3 Intangibles, net 328.3 251.7 Net operating loss 24.7 20.6 Share-based compensation 63.8 86.0 Other 35.8 60.0 Valuation allowance (14.1 ) (11.5 ) Total deferred tax assets $ 871.7 $ 693.1 Deferred tax liabilities: Purchased intangible assets $ (440.1 ) $ (432.8 ) Depreciation, amortization and other (102.7 ) (107.0 ) Total deferred tax liabilities $ (542.8 ) $ (539.8 ) In accordance with ASU No. 2015-17, at December 31, 2015 we reclassified $137.1 million of our deferred tax assets classified as current to noncurrent and $1.6 million of our deferred tax liabilities classified as current to noncurrent in our December 31, 2014 consolidated balance sheet, to conform our prior year presentation to our current year presentation. In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. As of December 31, 2015 and 2014 , the total deferred charges and prepaid taxes were $697.9 million and $238.9 million , respectively. During 2013, we recorded a deferred charge of $203.7 million in connection with an intercompany transfer of the intellectual property for ZINBRYTA. The net book value of this deferred charge as of December 31, 2015 and 2014 was $166.3 million and $179.9 million , respectively. The deferred charge will be amortized to income tax expense over the economic life of the ZINBRYTA program. Our regulatory submissions in Europe and the U.S. have been accepted for review by the relevant authorities. If the ZINBRYTA applications are not approved, we may have to accelerate the amortization of this deferred charge and record an expense equal to its remaining net book value. Tax Rate A reconciliation between the U.S. federal statutory tax rate and our effective tax rate is summarized as follows: For the Years Ended December 31, 2015 2014 2013 Statutory rate 35.0 % 35.0 % 35.0 % State taxes 0.5 1.2 3.1 Taxes on foreign earnings (10.0 ) (9.5 ) (6.7 ) Credits and net operating loss utilization (1.3 ) (1.1 ) (2.6 ) Purchased intangible assets 1.0 1.2 1.5 Manufacturing deduction (1.8 ) (1.8 ) (6.6 ) Other permanent items 0.7 0.5 0.8 Contingent consideration and other 0.3 (0.4 ) (0.3 ) Effective tax rate 24.4 % 25.1 % 24.2 % Our effective tax rate for 2015 compared to 2014 benefited from lower anticipated taxes on foreign earnings and reflects a $27.0 million benefit from the 2015 remeasurement of one of our uncertain tax positions, described below under "Accounting for Uncertainty in Income Taxes" . Our effective tax rate for 2014 compared to 2013 increased primarily as a result of the absence of a benefit related to the 2013 change in our uncertain tax position related to our U.S. federal manufacturing deduction and our unconsolidated joint business described below under "Accounting for Uncertainty in Income Taxes" , lower current year expenses eligible for the orphan drug credit and a lower relative manufacturing deduction due to unqualified products, partially offset by a higher percentage of our 2014 income being earned outside the U.S. As of December 31, 2015 , we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately $25.3 million and $127.6 million , respectively, which begin to expire in 2020. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately $91.7 million , which begin to expire in 2016. For state income tax purposes, we also had research and investment credit carry forwards of approximately $125.5 million , which begin to expire in 2016. For foreign income tax purposes, we had $53.4 million of net operating loss carryforwards, which begin to expire in 2021. In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our financial position and results of operations. As of December 31, 2015 , undistributed foreign earnings of non-U.S. subsidiaries included in consolidated retained earnings and other basis differences aggregated approximately $6.0 billion . We intend to reinvest these earnings indefinitely in operations outside the U.S. The residual U.S. tax liability, if cumulative amounts were repatriated, would be between $1.5 billion to $2.0 billion as of December 31, 2015 . Accounting for Uncertainty in Income Taxes A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows: (In millions) 2015 2014 2013 Balance at January 1, $ 131.5 $ 110.1 $ 125.9 Additions based on tax positions related to the current period 10.5 20.8 11.9 Additions for tax positions of prior periods 19.5 86.1 71.7 Reductions for tax positions of prior periods (49.9 ) (23.4 ) (92.1 ) Statute expirations (1.2 ) (1.6 ) (1.9 ) Settlements (42.5 ) (60.5 ) (5.4 ) Balance at December 31, $ 67.9 $ 131.5 $ 110.1 We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S. federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local, or non-U.S. income tax examinations for years before 2004. Included in the balance of unrecognized tax benefits as of December 31, 2015 , 2014 and 2013 are $15.7 million , $53.6 million and $32.5 million (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In 2015 , we recognized a net interest expense of $3.1 million . During 2014 , we recognized net interest expense of $4.1 million . In 2013 , we recognized a net interest expense of approximately $4.5 million . We have accrued approximately $12.5 million and $17.6 million for the payment of interest as of December 31, 2015 and 2014 , respectively. In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for fiscal 2009, regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates. The audits of our tax filings for 2010 through 2013 are not completed but have been prepared in a manner consistent with prior filings, with similar transactions. In December 2015, we received draft assessments for these periods. The total amount assessed for all periods is $60.9 million , including interest. For all periods potentially under dispute, we believe that positions taken in our tax filings are valid and we are contesting the assessment vigorously. Federal Uncertain Tax Positions During 2013, we received updated technical guidance from the IRS concerning our current and prior year filings and calculation of our U.S. federal manufacturing deduction and overall tax classification of our unconsolidated joint business. Based on this guidance we reevaluated the level of our unrecognized benefits related to uncertain tax positions, and recorded a $49.8 million income tax benefit. This benefit is for a previously unrecognized position and relates to years 2005 through 2012. We recorded an offsetting expense of $11.3 million for non-income based state taxes, which is recorded in other income (expense) in our consolidated statements of income. In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately $130 million in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hillerød, Denmark. We believe that these items represent valid deductible business expenses and are vigorously defending our position. We have initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years. During the year ended December 31, 2015 , the net effect of adjustments to our uncertain tax positions was a net benefit of approximately $25.0 million . It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations. |
Other Consolidated Financial St
Other Consolidated Financial Statement Detail | 12 Months Ended |
Dec. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Other Consolidated Financial Statement Detail | Other Consolidated Financial Statement Detail Supplemental Cash Flow Information Supplemental disclosure of cash flow information for the years ended December 31, 2015 , 2014 and 2013 , is as follows: For the Years Ended December 31, (In millions) 2015 2014 2013 Cash paid during the year for: Interest $ 39.1 $ 41.2 $ 53.6 Income taxes $ 1,674.8 $ 1,163.2 $ 643.2 Non-cash Investing and Financing Activity In the fourth quarter of 2015, we accrued $300.0 million upon reaching $7.0 billion in total cumulative sales of Fumapharm Products. The amount, net of tax benefit, was accounted for as an increase to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm and is expected to be paid in the first quarter of 2016. For additional information related to this transaction, please read Note 21, Commitment and Contingencies to these consolidated financial statements. In connection with the construction of our manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $59.1 million in our consolidated balance sheet. For additional information related to this transaction, please read Note 10, Property, Plant and Equipment to these consolidated financial statements. In February 2015, upon completion of our acquisition of Convergence, we recorded a contingent consideration obligation of $274.5 million as part of the purchase price. For additional information related to this transaction, please read Note 2, Acquisitions to these consolidated financial statements. In July and November 2013, the construction of two office buildings in Cambridge, Massachusetts was completed and we started leasing the facilities. Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we did not have any unusual or significant continuing involvement. Consequently, we derecognized the buildings and their associated financing obligation of approximately $161.5 million from our consolidated balance sheet. Other Income (Expense), Net Components of other income (expense), net, are summarized as follows: For the Years Ended December 31, (In millions) 2015 2014 2013 Interest income $ 22.1 $ 12.2 $ 8.2 Interest expense (95.5 ) (29.5 ) (31.9 ) Impairments on investments — — (2.8 ) Gain (loss) on investments, net (3.8 ) 11.8 21.7 Foreign exchange gains (losses), net (32.7 ) (11.6 ) (15.2 ) Other, net (13.8 ) (8.7 ) (14.9 ) Total other income (expense), net $ (123.7 ) $ (25.8 ) $ (34.9 ) Other Current Assets Other current assets includes prepaid taxes totaling approximately $550.6 million and $57.6 million as of December 31, 2015 and 2014 , respectively. Accrued Expenses and Other Accrued expenses and other consists of the following: As of December 31, (In millions) 2015 2014 Revenue-related reserves for discounts and allowances $ 518.1 $ 359.2 Current portion of contingent consideration obligations 504.7 265.5 Employee compensation and benefits 270.8 393.8 Royalties and licensing fees 167.9 172.4 Deferred revenue 55.7 120.9 Other 579.6 505.9 Total accrued expenses and other $ 2,096.8 $ 1,817.7 Other Long-Term Liabilities Other long-term liabilities consists of the following: As of December 31, (In millions) 2015 2014 Contingent consideration obligation $ 301.3 $ 200.0 Employee compensation and benefits 235.4 200.7 Other 369.1 249.4 Total other long-term liabilities $ 905.8 $ 650.1 Pricing of TYSABRI in Italy - AIFA In the fourth quarter of 2011, Biogen Italia SRL (formerly Biogen Idec Italia SRL), our Italian subsidiary, received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded by EUR 30.7 million a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In December 2011, we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit in the Price Determination Resolution should apply as written to only “the first 24 months” of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. In July 2013, we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR 33.3 million . The agreement was sent to the Avvocatura Generale dello Stato (Attorney General) for its opinion. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR 15.4 million at June 30, 2013, which approximated 50% of the claim related to the period from mid-February 2009 through mid-February 2011. In October 2014, we proposed a revised settlement for the period from February 2009 through January 2013 of EUR 35.6 million to be paid in one payment. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized $53.5 million of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. We have approximately EUR 75 million recorded as accrued expenses and long-term deferred revenue in our consolidated balance sheets for this matter as of December 31, 2015 and 2014 , respectively. |
Investments in Variable Interes
Investments in Variable Interest Entities | 12 Months Ended |
Dec. 31, 2015 | |
Investments in Variable Interest Entities [Abstract] | |
Investments in Variable Interest Entities | Investments in Variable Interest Entities Consolidated Variable Interest Entities Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities. Neurimmune SubOne AG In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer’s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab (BIIB037), for the treatment of Alzheimer’s disease resulted from this collaboration. In September 2015, we announced that the first patient had been enrolled in a Phase 3 trial for aducanumab, which triggered a $60.0 million milestone payment due to Neurimmune. As we consolidate the financial results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the third quarter of 2015. Based upon our current development plans for aducanumab, we may pay Neurimmune up to $275.0 million in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products. We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity’s economic performance and are required to fund 100% of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune. Amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration that we reimburse are reflected in research and development expense in our consolidated statements of income. During the years ending December 31, 2015 , 2014 and 2013 , these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved. The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts. Rodin Therapeutics, Inc. In December 2015, we paid $8.0 million for preferred stock in Rodin Therapeutics, Inc. (Rodin) and entered into an option and collaboration agreement which gives us the right to purchase all remaining outstanding shares of Rodin, at any time until 35 days after acceptance of an Investigational New Drug (IND) application by the FDA. Rodin is a discovery-stage biotechnology company developing novel therapeutics for neurological disorders. We committed to make additional investments in Rodin’s preferred shares of $4.0 million , if certain development milestones are achieved. If we exercise our option to purchase the outstanding shares of Rodin, we could pay additional amounts upon achievement of clinical and commercial milestones. Through our fixed price option to purchase Rodin, purchases of equity, our collaboration and presence on the program advisory committee and Rodin Board of Directors, we are deemed to be the primary beneficiary of Rodin, a variable interest entity. Therefore, we consolidate the results of Rodin. As part of the initial consolidation of Rodin, we recorded an IPR&D intangible asset of approximately $8.7 million and assigned approximately $10.9 million to minority interest in our stockholder's equity. The assets and liabilities of Rodin are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Rodin other than contractually required amounts. Unconsolidated Variable Interest Entities We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. As of December 31, 2015 and 2014 , the total carrying value of our investments in biotechnology companies totaled $29.2 million and $7.9 million , respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments. We have entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. |
Collaborative and Other Relatio
Collaborative and Other Relationships | 12 Months Ended |
Dec. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaborative and Other Relationships | Collaborative and Other Relationships In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration. Depending on the collaborative arrangement, we may record funding receivables or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below. Genentech (Roche Group) We collaborate with Genentech on the development and commercialization of RITUXAN. In addition, in the U.S., we share operating profits and losses relating to GAZYVA with Genentech. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of GAZYVA in the U.S. Our collaboration agreement will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in the collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech’s offer or purchase Genentech’s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity. RITUXAN Genentech is responsible for the worldwide manufacturing of RITUXAN. Development and commercialization rights and responsibilities under this collaboration are divided as follows: U.S. We share with Genentech co-exclusive rights to develop, commercialize and market RITUXAN in the U.S. Canada We and Genentech have assigned our rights under our collaboration agreement with respect to Canada to the Roche Group. Outside the U.S. and Canada We have granted Genentech exclusive rights to develop, commercialize and market RITUXAN outside the U.S. and Canada. Under the terms of separate sublicense agreements between Genentech and the Roche Group, development and commercialization of RITUXAN outside the U.S. and Canada is the responsibility of the Roche Group and its sublicensees. We do not have any direct contractual arrangements with the Roche Group or it sublicensees. Under the terms of the collaboration agreement, the Roche Group pays us royalties between 10% and 12% on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting 11 years from the first commercial sale of RITUXAN on a country-by-country basis. The royalty periods for the substantial portion of the royalty-bearing sales in the rest of world markets expired during 2012 and 2013. We expect future revenue on sales of RITUXAN in the rest of world will be limited to our share of pre-tax co-promotion profits in Canada. GAZYVA Prior to FDA approval of GAZYVA, we recognized 35% of the development and commercialization expenses as research and development expense and selling, general and administrative expense, respectively, in our consolidated statements of income. After GAZYVA was approved by the FDA in the fourth quarter of 2013, we began to recognize our share of the development and commercialization expenses as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. Commercialization of GAZYVA will impact our percentage of the co-promotion profits for RITUXAN, as summarized in the table below. Ocrelizumab Genentech is solely responsible for development and commercialization of ocrelizumab, a humanized anti-CD20 monoclonal antibody currently in development for MS, and funding future costs. Genentech cannot develop ocrelizumab in CLL, NHL or RA. We will receive tiered royalties between 13.5% and 24% on U.S. net sales of ocrelizumab if approved for commercial sale by the FDA. There will be a 50% reduction to these royalties if a biosimilar to ocrelizumab is approved in the U.S. In addition, we will receive a 3% royalty on worldwide net sales of ocrelizumab outside the U.S., with the royalty period lasting 11 years from the first commercial sale of ocrelizumab on a country-by-country basis. Commercialization of ocrelizumab will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Profit-sharing Formulas RITUXAN Profit Share Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a 30% share on the first $50.0 million of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events: Until GAZYVA First Non-CLL FDA Approval 40.0 % After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date 39.0 % After First GAZYVA Threshold Date until Second GAZYVA Threshold Date 37.5 % After Second GAZYVA Threshold Date 35.0 % First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL. First GAZYVA Threshold Date means the earlier of (1) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least $150.0 million or (2) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $150.0 million . Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $500.0 million . The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication. We expect our share of RITUXAN pre-tax profits in the U.S. to decrease to 39% from 40% if GAZYVA is approved by the FDA in RITUXAN-refractory indolent non-Hodgkin’s lymphoma. In addition, should the FDA approve an anti-CD20 product other than ocrelizumab or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between 30% and 38% based on certain events. GAZYVA Profit Share Our current pretax profit-sharing formula for GAZYVA provides for a 35% share on the first $50.0 million of operating profits earned each calendar year. Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events: Until First GAZYVA Threshold Date 39.0 % After First GAZYVA Threshold Date until Second GAZYVA Threshold Date 37.5 % After Second GAZYVA Threshold Date 35.0 % In 2015 , 2014 , and 2013 , our share of operating losses on GAZYVA was 35% . Unconsolidated Joint Business Revenues During the first quarter of 2013, we reduced our share of RITUXAN revenues from unconsolidated joint business by approximately $49.7 million , of which revenue on sales in the rest of world for RITUXAN was reduced by $41.2 million and pre-tax profits in the U.S. were reduced by $8.5 million , to reflect our share of the royalties and interest awarded to Hoechst in its arbitration with Genentech. Revenues from unconsolidated joint business are summarized as follows: For the Years Ended December 31, (In millions) 2015 2014 2013 Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1) $ 1,269.8 $ 1,117.1 $ 1,087.3 Revenue on sales in the rest of world for RITUXAN 69.4 78.3 38.7 Total unconsolidated joint business revenues $ 1,339.2 $ 1,195.4 $ 1,126.0 (1) GAZYVA sales began in the fourth quarter of 2013. In 2015 , 2014 , and 2013 , the 40% profit-sharing threshold was met during the first quarter. Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. We incurred $25.7 million in development expense for 2013 . After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from unconsolidated joint business. Elan On April 2, 2013, we acquired full ownership of all remaining rights to TYSABRI from Elan that we did not already own or control. Upon the closing of the transaction, our collaboration agreement with Elan was terminated. For additional information related to this transaction, please read Note 2, Acquisitions to these consolidated financial statements. We previously collaborated with Elan on the development, manufacture and commercialization of TYSABRI. Under the terms of our collaboration agreement, we manufactured TYSABRI and collaborated with Elan on the product’s marketing, commercial distribution and ongoing development activities. The agreement was designed to effect an equal sharing of profits and losses generated by the activities of our collaboration. Under the agreement, however, once sales of TYSABRI exceeded specific thresholds, Elan was required to make milestone payments to us in order to continue sharing equally in the collaboration’s results. In the U.S., we previously sold TYSABRI to Elan who then sold the product to third-party distributors. Our sales price to Elan in the U.S. was set prior to the beginning of each quarterly period to effect an approximate equal sharing of the gross profit between Elan and us. We recognized revenue for sales in the U.S. of TYSABRI upon Elan’s shipment of the product to the third-party distributors, at which time all revenue recognition criteria had been met. We incurred manufacturing and distribution costs, research and development expenses, commercial expenses, and general and administrative expenses related to TYSABRI. We recorded these expenses to their respective line items in our consolidated statements of income when they were incurred. Research and development and sales and marketing expenses were shared equally with Elan and the reimbursement of these expenses was recorded as reductions of the respective expense categories. During 2013 , we recorded $11.7 million as a reduction of research and development expense resulting from reimbursements from Elan. In addition, for 2013 , we recorded $20.6 million as a reduction of selling, general and administrative expense resulting from reimbursements from Elan. In the rest of world, we previously were responsible for distributing TYSABRI to customers and were primarily responsible for all operating activities. Generally, we recognized revenue for sales of TYSABRI in the rest of world at the time of product delivery to our customers. We made payments to Elan which effected an equal sharing of rest of world collaboration operating profits. These payments also included the reimbursement we paid to Elan for half of the third-party royalties that Elan paid on behalf of the collaboration relating to rest of world sales. These amounts were reflected in the collaboration profit sharing line in our consolidated statements of income. For 2013 , $85.4 million was reflected in the collaboration profit sharing line for our collaboration with Elan. Acorda In 2009, we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine in markets outside the U.S. We also have responsibility for regulatory activities and the future clinical development of related products in those markets. Under the terms of the collaboration and license agreement, we pay Acorda tiered royalties based on the level of ex-U.S. net sales. We may pay up to $375.0 million of additional milestone payments to Acorda, based on the successful achievement of certain regulatory and commercial milestones. The next expected milestone would be $15.0 million , due if ex-U.S. net sales reach $100.0 million over a period of four consecutive quarters. We will capitalize these additional milestones as intangible assets upon achievement of the milestone which will then be amortized utilizing an economic consumption model and recognized as amortization of acquired intangible assets. Royalty payments are recognized as a cost of goods sold. In connection with the collaboration and license agreement, we have also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. During the years ending December 31, 2015 , 2014 and 2013 , total cost of sales related to royalties and commercial supply of FAMPRYA reflected in our consolidated statement of income were $30.6 million , $29.2 million and $24.3 million , respectively. Swedish Orphan Biovitrum AB (publ) In January 2007, we acquired 100% of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. In February 2010, we restructured the collaboration agreement and assumed full development responsibilities and costs, as well as manufacturing rights. In addition, the cross-royalty rates were reduced and commercial rights for certain territories were changed. As a result, we have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Biogen Direct Territory). Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. (References to the collaboration agreement refer to the amended and restated collaboration agreement). In November 2014, Sobi exercised its option to assume final development and commercialization activities in the Sobi Territory for ELOCTA (the trade name for ELOCTATE in the E.U.). In July 2015, Sobi exercised its option to assume final development and commercialization of ALPROLIX within the Sobi Territory. Upon each exercise of opt-in right under the terms of the collaboration agreement, Sobi made a $10.0 million payment in escrow. Upon EMA regulatory approval of each such product, Sobi will be liable to reimburse us 50% of the sum of all shared manufacturing and development expenses incurred by us from October 1, 2009 through the earlier of the date on which Sobi is registered as the marketing authorization holder for the applicable product or 90 days post-regulatory approval, as well as 100% of certain development expenses incurred exclusively for the benefit of the Sobi Territory (the Opt-In Consideration). This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent terms of the products. ELOCTA was approved by the EC in November 2015. Through December 31, 2015 , approximately $200 million in expenditures for ELOCTA, net of the $10.0 million escrow payment discussed above, are reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ELOCTA within the Sobi Territory. Approximately $175 million in expenditures for ALPROLIX may be reimbursable by Sobi under the collaboration agreement due to its election to assume final development and commercialization of ALPROLIX within the Sobi Territory. The escrow payment made with respect to ALPROLIX will be applied to the amount of the Opt-In Consideration to be reimbursed by Sobi upon EMA regulatory approval. To effect Sobi’s reimbursement to us for the Opt-In Consideration exceeding the escrow payment for the applicable product, the cross-royalty cash payment structure for direct sales in each company’s respective territories will be adjusted until the Opt-In Consideration is paid in full (the Reimbursement Period). The mechanism for reimbursement is outlined in the table below. Under the collaboration agreement, cash payments are as follows: Rates post Sobi Opt-In (3) Royalty and Net Revenue Share Rates: Method Rate prior to 1st commercial sale in the Sobi Territory: Base Rate following 1st commercial sale in the Sobi Territory: Rate during the Reimbursement Period: Sobi rate to Biogen on net sales in the Sobi Territory Royalty N/A 10 or 12% Base Rate Biogen rate to Sobi on net sales in the Biogen North America Territory Royalty 2% 10 or 12% Base Rate Biogen rate to Sobi on net sales in the Biogen Direct Territory Royalty 2% 15 or 17% Base Rate Biogen rate to Sobi on net revenue (1) from the Biogen Distributor Territory (2) Net 10% 50% Base Rate (1) Net revenue represents Biogen’s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities. (2) The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor. (3) A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales. If the reimbursement of the Opt-in Consideration has not been achieved within six years of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within 90 days of the six year anniversary date of the first commercial sale. We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table above. Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement. In addition, if EMA approval for ALPROLIX is not granted within 18 months of the filing date, Sobi shall have the right to require that the escrow payment be refunded and revoke its option right for such product. AbbVie Biotherapeutics, Inc. We have a collaboration agreement with AbbVie Biotherapeutics, Inc., a subsidiary of AbbVie, Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS. Under the agreement, we and AbbVie will conduct ZINBRYTA co-promotion activities in the E.U., U.S. and Canada territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. We are responsible for all manufacturing activities in the Collaboration Territory. In the U.S., AbbVie will recognize revenues on sales to third parties and we will recognize our 50% share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. In the E.U. and Canada, we will reflect revenues on sales to third parties in product revenues, net in our consolidated statements of income. We will record the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income when these costs are incurred. The reimbursement with AbbVie for the 50% sharing of the co-promotion profits or losses in the E.U. and Canada will be recognized in our total costs and expenses. Outside of the Collaboration Territory, we are solely responsible for development and commercialization where we will pay a tiered royalty to AbbVie on net sales in the low to high teens. We are the responsible party for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and will record these activities to their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures from AbbVie. During 2015 , we made milestone payments of $16.0 million for the development of ZINBRYTA as a result of filing for regulatory approval in the U.S. and E.U. during the year. These payments were recorded as research and development expense in our consolidated statements of income. We may incur up to an additional $32.0 million of milestone payments related to the development of ZINBRYTA, of which $20.0 million is due upon regulatory approval in the U.S. and $12.0 million is due upon regulatory approval in the E.U. These future payments will be capitalized as an intangible asset in our consolidated balance sheets. A summary of activity related to this collaboration is as follows: For the Years Ended December 31, (In millions) 2015 2014 2013 Total development expense incurred by the collaboration $ 113.8 $ 117.8 $ 133.4 Biogen’s share of development expense reflected in our consolidated statements of income $ 60.8 $ 67.4 $ 71.0 Ionis Pharmaceuticals, Inc. Long-Term Strategic Research Collaboration In September 2013, we entered into a six year research collaboration with Ionis Pharmaceuticals, Inc. (Ionis), formerly known as Isis Pharmaceuticals Inc. under which both companies collaborate to perform discovery level research and then develop and commercialize antisense or other therapeutics for the treatment of neurological disorders. Under the collaboration, Ionis will perform research on a set of neurological targets identified within the agreement. Once the research has reached a specific stage of development, we will make the determination whether antisense is the preferred approach to develop a therapeutic candidate or whether another modality is preferred. If antisense is selected, Ionis will continue development and identify a product candidate. If another modality is used, we will assume the responsibility for identifying a product candidate and developing it. Under the terms of this agreement, we paid Ionis an upfront amount of $100.0 million . Of this payment, we recorded prepaid research and discovery services of approximately $25.0 million , representing the value of the Ionis full time equivalent employee resources which are required by the collaboration to provide research and discovery services to us over the next six years. The remaining $75.0 million of the upfront payment was recorded as research and development expense as it represented the purchase of intellectual property that had not reached technological feasibility. Ionis is also eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us. During the years ending December 31, 2015 and 2014 , we triggered milestones of $20.0 million and $20.0 million , respectively, related to the advancement of IONIS-SOD1 Rx for the treatment of ALS and other neurological targets identified. For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $70.0 million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to $130.0 million , plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. For product candidates using a different modality, we will be responsible for global development through all stages and will pay Ionis up to $90.0 million upon the achievement of certain regulatory milestones and royalties on future sales if we successfully develop the product candidate. Product Collaborations In December, June and January 2012, we entered into three separate exclusive, worldwide option and collaboration agreements with Ionis under which both companies will develop and commercialize antisense therapeutics for up to three gene targets, Ionis’ product candidates for the treatment of myotonic dystrophy type 1 (DM1), and the antisense investigational candidate nusinersen (ISIS-SMN Rx ) for the treatment of spinal muscular atrophy (SMA), respectively. Antisense Therapeutics Under the terms of the December 2012 agreement relating to the development and commercialization of up to three gene targets we provided Ionis with an upfront payment of $30.0 million and will make potential additional payments, prior to licensing, of up to $10.0 million based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 , we triggered a $10.0 million milestone payment. Ionis will be responsible for global development of any product candidate through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $70.0 million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another $130.0 million in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales if we successfully develop the product candidate after option exercise. IONIS-DMPK Rx Under the terms of the June 2012 agreement for the DM1 candidate, we provided Ionis with an upfront payment of $12.0 million and agreed to make potential additional payments, prior to licensing, of up to $59.0 million based on the development of the selected product candidate. During 2015, we amended the agreement to adjust the amount of potential additional payments by an additional $4.2 million due to changes in the clinical trial design. During 2015 , 2014 and 2013 , we triggered milestones of $2.8 million , $14.0 million and $10.0 million , respectively, related to the selection and advancement of IONIS-DMPK Rx to treat DM1. Ionis will be responsible for global development of any product candidate through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We also have an option to license the product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $70.0 million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive up to another $130.0 million in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales if we successfully develop the product candidate after option exercise. During the years ending December 31, 2015 , 2014 and 2013 , $9.0 million , $10.9 million and $11.2 million , respectively, were reflected in research and development expense in our consolidated statements of income. Nusinersen Under the terms of the January 2012 agreement for the antisense investigational drug candidate, nusinersen, we paid Ionis $29.0 million as an upfront payment. During 2014, we amended the agreement to adjust the amount of potential additional payments and terms of the exercise of our opt-in right to license nusinersen. Consistent with the initial agreement, Ionis remains responsible for conducting the pivotal/Phase 3 trials. We are providing input on the clinical trial design and regulatory strategy for the development of nusinersen. During 2015 and 2014 , we triggered clinical trial payments of $42.8 million and $57.3 million related to the advancement of the program. We are recognizing these payments as research and development expenses as the trial costs are incurred. During 2015, we amended the agreement and may pay up to an additional $92.0 million due to changes in the clinical trial design. We may exercise our opt-in right upon completion of and data review of the first successful Phase 2/3 trial or completion of both Phase 2/3 trials. An amendment in December 2014 provided for additional opt-in scenarios, based on the filing or the acceptance of a new drug application or marketing authorization application with the FDA or EMA. Under the amended collaboration agreement, we may pay Ionis up to approximately $325.0 million in a license fee and payments, including $100.0 million in payments associated with the clinical development of nusinersen prior to licensing, a license fee and $150.0 million in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales of nusinersen if we successfully develop nusinersen after option exercise. During the years ending December 31, 2015 , 2014 and 2013 , $74.9 million , $27.7 million and $13.6 million , respectively, were reflected in research and development expense in our consolidated statements of income. Eisai Co., Ltd. BAN2401 and E2609 Collaboration On March 4, 2014, we entered into a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of Alzheimer’s disease, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor, (Eisai Collaboration Agreement). Under the Eisai Collaboration Agreement, Eisai serves as the global operational and regulatory lead for both compounds and all costs, including research, development, sales and marketing expenses, will be shared equally by us and Eisai. Following marketing approval in major markets, such as the U.S., the E.U. and Japan, we will co-promote BAN2401 and E2609 with Eisai and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. The Eisai Collaboration Agreement also provides the parties with certain rights and obligations in the event of a change in control of either party. The Eisai Collaboration Agreement also provides Eisai an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer’s disease (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, we will execute a separate collaboration agreement with Eisai on terms and conditions that mirror the Eisai Collaboration Agreement. Aducanumab Option Eisai may exercise the Aducanumab Option after either (i) completion of both the current Phase 1b clinical trial for aducanumab and the current Phase 2 clinical trial for BAN2401 (Post-Phase 2 Aducanumab Option), or (ii) completion of the Phase 3 clinical trial for aducanumab (Post-Phase 3 Aducanumab Option) under certain conditions. The consideration we will receive if Eisai exercises the Post-Phase 2 Aducanumab Option depends on the development status of BAN2401. If BAN2401 is then determined to advance to Phase 3, we will be entitled to receive a single payment from Eisai upon regulatory approval of aducanumab and we will no longer be required to pay Eisai any milestone payments for products containing BAN2401 under the Eisai Collaboration Agreement. If the development of BAN2401 has instead been terminated, we will receive development and commercial milestone payments from Eisai (Post-Phase 2 Aducanumab Milestone Payments). If Eisai does not exercise its Post-Phase 2 Aducanumab Option, we may elect to terminate the Eisai Collaboration Agreement with respect to BAN2401 but, under certain co |
Litigation
Litigation | 12 Months Ended |
Dec. 31, 2015 | |
Loss Contingency, Information about Litigation Matters [Abstract] | |
Litigation | Litigation We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies regarding contingencies, see Note 1, Summary of Significant Accounting Policies . Patent Matters Forward Pharma German Patent Litigation On November 18, 2014 Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE 20 2005 022 112 U1, which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently extended its allegations to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2,801,355, which was issued in May 2015 and expires in October 2025. Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. A hearing has been scheduled for early 2016. Interference Proceeding with Forward Pharma In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma’s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for early 2017. Inter Partes Review Proceeding On September 28, 2015, the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund, filed a petition with the USPTO for inter partes review of the '514 patent, which we opposed. The USPTO has not yet decided whether to institute review. European Patent Office Oppositions Several parties have filed oppositions in the European Patent Office requesting revocation of our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The '537 patent expires in 2028. A hearing has been scheduled for early 2016. Patent Licensing Matter We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777 (Expression of Factor VII and IX Activities in Mammalian Cells) and pay royalties on sales of ALPROLIX. An estimate of the possible loss or range of loss cannot be made at this time. Patent Revocation Matter In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127 (“Administration of agents to treat inflammation”) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023. On January 11, 2016 the same entity brought an action in the District Court of The Hague seeking to revoke the Dutch counterpart of the '127 patent. A hearing has been scheduled in the Dutch action for early 2017. No hearing has yet been scheduled in the UK action. '755 Patent Litigation On May 28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S. District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the “Consolidated '755 Patent Actions.” Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set. Italian National Medicines Agency In the fourth quarter of 2011, Biogen Italia SRL received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On December 23, 2011, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only “the first 24 months” of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013. Government Matters We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government in this matter. We also received a subpoena from the federal government for documents relating to our relationship with certain pharmacy benefit managers, with which we cooperated. We do not anticipate any further involvement. Qui Tam Litigation On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. The actions, which have been administratively consolidated, allege sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seek single and treble damages, civil penalties, interest, attorneys’ fees and costs. The United States declined to intervene in two of the actions, both of which have since been voluntarily dismissed, and has not made an intervention decision in the other two actions, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time. Securities Litigation We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. §78j(b) and §78t(a) and 17 C.F.R. §240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. Product Liability and Other Legal Proceedings We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Leases We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense under these leases, net of amounts recognized in relation to exiting our Weston, Massachusetts facility, which terminate at various dates through 2028, amounted to $68.6 million and $62.4 million in 2015 and 2014 , respectively. Rent expense was $56.1 million in 2013 . In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. As of December 31, 2015 , minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows: (In millions) 2016 2017 2018 2019 2020 Thereafter Total Minimum lease payments (1) $ 75.9 $ 75.7 $ 67.9 $ 66.7 $ 63.2 $ 382.7 $ 732.1 Less: income from subleases (6.0 ) (6.0 ) (6.3 ) (6.3 ) (6.3 ) (28.9 ) (59.8 ) Net minimum lease payments $ 69.9 $ 69.7 $ 61.6 $ 60.4 $ 56.9 $ 353.8 $ 672.3 (1) As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of $27.2 million in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement. Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of December 31, 2015 or 2014 . Eisai Financing Arrangement During 2015 we amended our existing lease related to Eisai's oral solid dose products manufacturing facility in RTP, North Carolina where we manufacture our and Eisai's oral solid dose products. For additional information, please read Note 10, Property, Plant and Equipment to these consolidated financial statements. As of December 31, 2015 , the net present value of the future minimum lease payments were as follows: (In millions) As of December 31, 2015 2016 $ 2.0 2017 2.0 2018 16.7 2019 — 2020 — Thereafter — Total 20.7 Less: interest (0.9 ) Net present value of the future minimum lease payments $ 19.8 Tax Related Obligations We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December 31, 2015 , we have approximately $45.4 million of net liabilities associated with uncertain tax positions. Other Funding Commitments As of December 31, 2015 , we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $25.0 million on our consolidated balance sheet for expenditures incurred by CROs as of December 31, 2015 . We have approximately $559.0 million in cancellable future commitments based on existing CRO contracts as of December 31, 2015 . Contingent Development, Regulatory and Commercial Milestone Payments Based on our development plans as of December 31, 2015 , we could make potential future milestone payments to third parties of up to approximately $2.8 billion as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of December 31, 2015 , such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. Manufacturing Commitments On December 1, 2015, we purchased land in Solothurn, Switzerland where we plan to build a biologics manufacturing facility over the next several years. As of December 31, 2015 , we had contractual commitments of $126.4 million for the construction of this facility. TYSABRI Contingent Payments In 2013, we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion . Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo in December 2013. Following that acquisition, we began making these royalty payments to Perrigo. Contingent Consideration related to Business Combinations In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (formerly Biogen Idec International Neuroscience GmbH) (BIN), Biogen Hemophilia Inc. (formerly Biogen Idec Hemophilia Inc.) (BIH) and Fumapharm AG, we agreed to make additional payments based upon the achievement of certain milestone events. As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January 1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $1.3 billion in remaining milestones related to these acquisitions. For additional information related to our acquisition of Convergence please read Note 2, Acquisitions , to these consolidated financial statements. BIH In connection with our acquisition of BIH, formerly Syntonix, in 2007, we agreed to pay up to an additional $80.0 million if certain milestone events associated with the development of BIH’s lead product, ALPROLIX are achieved. The first $40.0 million contingent payment was achieved in 2010. We paid an additional $20.0 million during the second quarter of 2014 as ALPROLIX was approved for the treatment of hemophilia B. A second $20.0 million contingent payment will occur if, prior to the tenth anniversary of the closing date, a marketing authorization is granted by the EMA for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved. Fumapharm AG In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid $220.0 million upon closing of the transaction and agreed to pay an additional $15.0 million if a Fumapharm Product was approved for MS in the U.S. or E.U. In the second quarter of 2013, we paid this $15.0 million contingent payment as TECFIDERA was approved in the U.S. for MS by the FDA. We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period, as defined in the acquisition agreement. During 2015 , we paid $850.0 million in contingent payments as we reached the $4.0 billion , $5.0 billion and $6.0 billion cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2014, second quarter of 2015 and third quarter of 2015, respectively, and accrued $300.0 million upon reaching $7.0 billion in total cumulative sales of Fumapharm Products in the fourth quarter of 2015. We will owe an additional $300.0 million contingent payment for every additional $1.0 billion in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed $3.0 billion , until such time as the cumulative sales level reaches $20.0 billion , at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60 days following the end of the quarter in which the applicable cumulative sales level has been reached. |
Guarantees
Guarantees | 12 Months Ended |
Dec. 31, 2015 | |
Guarantees [Abstract] | |
Guarantees | Guarantees As of December 31, 2015 and 2014 , we did not have significant liabilities recorded for guarantees. We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of December 31, 2015 and 2014 . |
Employee Benefit Plans
Employee Benefit Plans | 12 Months Ended |
Dec. 31, 2015 | |
Compensation and Retirement Disclosure [Abstract] | |
Employee Benefit Plans | Employee Benefit Plans We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits. 401(k) Savings Plan We maintain a 401(k) Savings Plan which is available to substantially all regular employees in the U.S. over the age of 21 . Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan’s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions. Expense related to our 401(k) Savings Plan totaled $51.8 million , $49.3 million and $39.3 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Deferred Compensation Plan We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees, which are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of December 31, 2015 and 2014 totaled approximately $126.9 million and $105.2 million , respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants. Pension Plans Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries in which we maintain an operating presence. Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by Swiss government and was 1.75% in 2015 and 2014 and 1.5% in 2013 , respectively. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee’s contribution. Minimum employee contributions are based on the respective employee’s age, salary, and gender. As of December 31, 2015 and 2014 , the the Swiss plan had an unfunded net pension obligation of approximately $42.4 million and $31.9 million , respectively, and plan assets which totaled approximately $63.9 million and $43.9 million , respectively. In 2015 , 2014 and 2013 , we recognized expense totaling $12.9 million , $9.8 million and $10.9 million , respectively, related to our Swiss plan. The obligations under the German plans are unfunded and totaled $27.6 million and $24.8 million as of December 31, 2015 and 2014 , respectively. Net periodic pension cost related to the German plans totaled $4.0 million , $3.5 million and $3.3 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Segment Information | Segment Information We operate as one operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee. Revenue by product is summarized as follows: For the Years Ended December 31, 2015 2014 2013 (In millions) United States Rest of World Total United States Rest of World Total United States Rest of World Total Multiple Sclerosis (MS): TECFIDERA $ 2,908.2 $ 730.2 $ 3,638.4 $ 2,426.6 $ 482.6 $ 2,909.2 $ 864.4 $ 11.7 $ 876.1 AVONEX 1,790.2 840.0 2,630.2 1,956.7 1,056.4 3,013.1 1,902.4 1,103.1 3,005.5 PLEGRIDY 227.1 111.4 338.5 27.8 16.7 44.5 — — — TYSABRI 1,103.1 783.0 1,886.1 1,025.1 934.4 1,959.5 814.2 712.3 1,526.5 FAMPYRA — 89.7 89.7 — 80.2 80.2 — 74.0 74.0 Hemophilia: ELOCTATE 308.3 11.4 319.7 58.4 — 58.4 — — — ALPROLIX 208.9 25.6 234.5 72.1 3.9 76.0 — — — Other product revenues: FUMADERM — 51.4 51.4 — 62.5 62.5 — 60.2 60.2 Total product revenues $ 6,545.8 $ 2,642.7 $ 9,188.5 $ 5,566.7 $ 2,636.7 $ 8,203.4 $ 3,581.0 $ 1,961.3 $ 5,542.3 Geographic Information The following tables contain certain financial information by geographic area: December 31, 2015 (In millions) U.S. Europe (1) Germany Asia Other Total Product revenues from external customers $ 6,545.8 $ 1,497.6 $ 668.1 $ 143.7 $ 333.3 $ 9,188.5 Unconsolidated joint business revenues $ 1,269.8 $ 3.5 $ — $ — $ 65.9 $ 1,339.2 Other revenues from external customers $ 142.0 $ 29.6 $ 1.6 $ 62.9 $ — $ 236.1 Long-lived assets $ 1,296.5 $ 879.4 $ 2.3 $ 7.7 $ 1.7 $ 2,187.6 December 31, 2014 (In millions) U.S. Europe (1) Germany Asia Other Total Product revenues from external customers $ 5,566.7 $ 1,383.9 $ 811.8 $ 112.8 $ 328.2 $ 8,203.4 Unconsolidated joint business revenues $ 1,117.1 $ 7.7 $ — $ — $ 70.6 $ 1,195.4 Other revenues from external customers $ 212.6 $ 31.6 $ 1.8 $ 58.5 $ — $ 304.5 Long-lived assets $ 1,055.5 $ 701.9 $ 2.5 $ 2.6 $ 3.2 $ 1,765.7 December 31, 2013 (In millions) U.S. Europe (1) Germany Asia Other Total Product revenues from external customers $ 3,581.0 $ 1,170.2 $ 417.7 $ 93.2 $ 280.2 $ 5,542.3 Unconsolidated joint business revenues $ 1,087.3 $ 1.6 $ — $ 3.2 $ 33.9 $ 1,126.0 Other revenues from external customers $ 193.5 $ 26.1 $ 1.2 $ 43.1 $ — $ 263.9 Long-lived assets $ 984.4 $ 758.3 $ 2.5 $ 2.1 $ 3.3 $ 1,750.7 (1) Represents amounts related to Europe less those attributable to Germany. Revenues from Unconsolidated Joint Business Approximately 12% , 12% and 16% of our total revenues in 2015 , 2014 and 2013 , respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, Collaborative and Other Relationships to these consolidated financial statements. Significant Customers We recorded revenue from two wholesalers accounting for 34% and 26% of gross product revenues in 2015 , 33% and 27% of gross product revenues in 2014 , and 32% and 24% of gross product revenues in 2013 , respectively. Other As of December 31, 2015 , 2014 and 2013 , approximately $684.9 million , $676.0 million and $731.1 million , respectively, of our long-lived assets were related to our manufacturing facilities in Denmark. |
Quarterly Financial Data (Unaud
Quarterly Financial Data (Unaudited) | 12 Months Ended |
Dec. 31, 2015 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Data (Unaudited) | Quarterly Financial Data (Unaudited) (In millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Total Year 2015 (a) (b) (c) (d) Product revenues, net $ 2,172.3 $ 2,198.6 $ 2,391.7 $ 2,425.9 $ 9,188.5 Unconsolidated joint business revenues $ 330.6 $ 337.5 $ 337.2 $ 333.9 $ 1,339.2 Other revenues $ 52.0 $ 55.6 $ 49.0 $ 79.5 $ 236.1 Total revenues $ 2,555.0 $ 2,591.6 $ 2,777.9 $ 2,839.3 $ 10,763.8 Gross profit (1) $ 2,242.6 $ 2,305.5 $ 2,467.9 $ 2,507.5 $ 9,523.4 Net income $ 820.2 $ 924.8 $ 1,019.5 $ 828.7 $ 3,593.2 Net income attributable to Biogen Inc. $ 822.5 $ 927.3 $ 965.6 $ 831.6 $ 3,547.0 Net income per share: Basic earnings per share attributable to Biogen Inc. $ 3.50 $ 3.94 $ 4.16 $ 3.77 $ 15.38 Diluted earnings per share attributable to Biogen Inc. $ 3.49 $ 3.93 $ 4.15 $ 3.77 $ 15.34 Weighted-average shares used in calculating: Basic earnings per share attributable to Biogen Inc. 235.0 235.3 232.2 220.4 230.7 Diluted earnings per share attributable to Biogen Inc. 235.6 235.7 232.6 220.8 231.2 (In millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Total Year 2014 (e) (f) (g) (f) (f) Product revenues, net $ 1,742.8 $ 2,056.3 $ 2,117.3 $ 2,287.0 $ 8,203.4 Unconsolidated joint business revenues $ 296.9 $ 303.3 $ 290.7 $ 304.5 $ 1,195.4 Other revenues $ 90.1 $ 61.9 $ 103.4 $ 49.2 $ 304.5 Total revenues $ 2,129.8 $ 2,421.5 $ 2,511.4 $ 2,640.7 $ 9,703.3 Gross profit (1) $ 1,850.5 $ 2,129.6 $ 2,208.8 $ 2,343.4 $ 8,532.3 Net income $ 479.7 $ 723.1 $ 856.1 $ 882.6 $ 2,941.6 Net income attributable to Biogen Inc. $ 480.0 $ 714.5 $ 856.9 $ 883.5 $ 2,934.8 Net income per share: Basic earnings per share attributable to Biogen Inc. $ 2.03 $ 3.02 $ 3.63 $ 3.75 $ 12.42 Diluted earnings per share attributable to Biogen Inc. $ 2.02 $ 3.01 $ 3.62 $ 3.74 $ 12.37 Weighted-average shares used in calculating: Basic earnings per share attributable to Biogen Inc. 236.8 236.7 236.2 235.5 236.4 Diluted earnings per share attributable to Biogen Inc. 237.8 237.4 237.0 236.3 237.2 (1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets. (a) Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of $48.1 million recorded upon entering into the collaboration agreement with AGTC. (b) Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a $60.0 million charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab. (c) Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of $60.0 million recorded upon entering into the collaboration agreement with MTPC. (d) Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling $93.4 million . (e) Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of $117.7 million recorded upon entering into the collaboration agreement with Eisai. (f) Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014. Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014. (g) Product revenues, net and total revenues for the second quarter of 2014 include the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA. |
Summary of Significant Accoun33
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Business Overview | Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL, and other potential anti-CD20 therapies. In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise to extend our mission to improve the lives of patients living with serious diseases through the development, manufacture and marketing of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). |
Consolidation | Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners. |
Use of Estimates | The preparation of our consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions. |
Revenue Recognition | We recognize revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; our price to the customer is fixed or determinable; and collectability is reasonably assured. Product Revenues Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon delivery. Product revenues are recorded net of applicable reserves for discounts and allowances. Reserves for Discounts and Allowances We establish reserves for trade term discounts, wholesaler incentives, Medicaid rebates, co-payment assistance (copay), Veterans Administration (VA) and Public Health Service (PHS) discounts, managed care rebates, product returns and other governmental rebates or applicable allowances, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. Product revenue reserves are categorized as follows: discounts, contractual adjustments and returns. Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments. Contractual adjustments primarily relate to Medicaid and managed care rebates, patient copay assistance, VA and PHS discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances. • Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid, and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. • Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consists of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit. • Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer’s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period. • Copay represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end. • Other governmental rebates or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare. Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product. In addition to the discounts, rebates and product returns described above and classified as a reduction of revenue, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenue. To the extent we can demonstrate a separable benefit and fair value for these services, we classify these payments in selling, general and administrative expenses. Revenues from Unconsolidated Joint Business Revenues from unconsolidated joint business consists of (i) our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; (ii) reimbursement of our selling and development expenses in the U.S. for RITUXAN; and (iii) revenue on sales in the rest of world for RITUXAN, which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales outside the U.S. and Canada by the Roche Group and its sublicensees. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by Genentech in the U.S. and by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less the cost to manufacture, third-party royalty expenses, distribution, selling, and marketing expenses, and joint development expenses incurred by Genentech, the Roche Group and us. We record our share of the pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales outside the U.S. on a cash basis as we do not have the ability to estimate these profits or royalty revenue in the period incurred. Additionally, our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. includes estimates made by Genentech and those estimates are subject to change. Actual results may differ from our estimates. For additional information related to our collaboration with Genentech, please read Note 19, Collaborative and Other Relationships , to these consolidated financial statements. Royalty Revenues We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. If we are unable to reasonably estimate royalty revenue or do not have access to the information, then we record royalty revenues on a cash basis. Multiple-Element Revenue Arrangements We may enter into transactions that involve the sale of products and related services under multiple element arrangements. In accounting for these transactions, we assess the elements of the contract and whether each element has standalone value and allocate revenue to the various elements based on their estimated selling price as a component of total revenues. The selling price of a revenue generating element can be based on current selling prices offered by us or another party for current products or management’s best estimate of a selling price. Revenue allocated to an individual element is recognized when all other revenue recognition criteria are met for that element. |
Fair Value Measurements | We have certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1 — Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access; • Level 2 — Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates; and • Level 3 — Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The majority of our financial assets have been classified as Level 2. Our financial assets (which include our cash equivalents, derivative contracts, marketable debt securities, and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. We validate the prices provided by our third-party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources and analyzing pricing data in certain instances. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December 31, 2015 and 2014 , respectively. Other The carrying amounts reflected in the consolidated balance sheets for current accounts receivable, due from unconsolidated joint business, other current assets, accounts payable, and accrued expenses and other, approximate fair value due to their short-term maturities. |
Cash and Cash Equivalents | We consider only those investments which are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December 31, 2015 and 2014 , cash equivalents were comprised of money market funds and commercial paper, overnight reverse repurchase agreements, and other debt securities with maturities less than 90 days from the date of purchase. |
Accounts Receivable | The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant. In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country’s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our consolidated statement of income. The credit and economic conditions in certain countries in the E.U. continue to remain uncertain and have, from time to time, led to a lengthening of time to collect our accounts receivable in some of these countries. In recent years, our collection efforts in Portugal and select regions of Spain have been subject to significant payment delays due to government funding and reimbursement practices. As a result, a portion of these receivables have been routinely collected beyond our contractual payment terms and over periods in excess of one year. Our accounts receivable collection efforts in Portugal and Spain have improved during 2015 with our receivables in Spain now expected to be collected within one year. Our net accounts receivable balance from product sales in Portugal and Spain totaled $62.4 million and $90.2 million as of December 31, 2015 and 2014 , respectively, of which $6.1 million and $12.6 million were classified as non-current and included in investments and other assets in our consolidated balance sheets. |
Concentration of Credit Risk | Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives, and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties. Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable arise from product sales in the U.S. and Europe and have standard payment terms which generally require payment within 30 to 90 days . We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. As of December 31, 2015 and 2014 , two wholesale distributors individually accounted for approximately 35.4% and 23.1% , and 34.4% and 23.3% , of accounts receivable, net, respectively. |
Marketable Securities and Other Investments | Marketable Debt Securities Available-for-sale debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis. Marketable Equity Securities Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheet. When assessing whether a decline in the fair value of a marketable equity security is other-than-temporary, we consider the fair market value of the security, the duration of the security’s decline, and prospects for the underlying business, including favorable or adverse clinical trial results, new product initiatives and new collaborative agreements with the companies in which we have invested. Non-Marketable Equity Securities We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the cost method or the equity method of accounting, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any decline in their value has occurred that would be other-than-temporary, based on the implied value of recent company financings, public market prices of comparable companies, and general market conditions and are included in investments and other assets in our consolidated balance sheet. Evaluating Investments for Other-than-Temporary Impairments We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income. For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss. Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. For equity securities, when assessing whether a decline in value is other-than-temporary, we consider the fair market value of the security, the duration of the security’s decline, and the financial condition of the issuer. We then consider our intent and ability to hold the equity security for a period of time sufficient to recover our carrying value. Where we have determined that we lack the intent and ability to hold an equity security to its expected recovery, the security’s decline in fair value is deemed to be other-than-temporary and is reflected in earnings as an impairment loss. |
Equity Method of Accounting | In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity. In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company, and other relevant factors such as the presence of a collaboration or other business relationship. Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceed the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. |
Inventory | Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when selected for use in a clinical manufacturing campaign. Capitalization of Inventory Costs We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies. Obsolescence and Unmarketable Inventory We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring which we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales. |
Property, Plant and Equipment | Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits. Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold. In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from three to five years . We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows: Asset Category Useful Lives Land Not depreciated Buildings 15 to 40 years Leasehold Improvements Lesser of the useful life or the term of the respective lease Furniture and Fixtures 5 to 7 years Machinery and Equipment 5 to 20 years Computer Software and Hardware 3 to 5 years When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts on our consolidated balance sheet and include any resulting gain or loss in our consolidated statement of income. |
Intangible Assets | Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January 1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable. Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded as amortization of acquired intangible assets in our consolidated statements of income. Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd (Elan), an affiliate of Elan Corporation, plc. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to TYSABRI and AVONEX using the economic consumption method based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI and AVONEX is performed annually during our long range planning cycle, which is generally updated in the third quarter of each year, and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of TYSABRI or AVONEX. Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives, however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. |
Acquired In-process Research and Development (IPR&D) | Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction. If we acquire a business as defined under applicable accounting standards, then the acquired IPR&D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business, then the acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&D exceeds its fair value, then the intangible asset is written-down to its fair value. Certain IPR&D programs have a fair value that is not significantly in excess of carrying value, including our program for the treatment of TGN. Such programs could become impaired if assumptions used in determining the fair value change. |
Goodwill | Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill might not be recoverable. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then we would need to determine the implied fair value of our reporting unit’s goodwill. If the carrying value of our reporting unit’s goodwill exceeds its implied fair value, then we would record an impairment loss equal to the difference. As described in Note 24, Segment Information to these consolidated financial statements, we operate in one operating segment which we consider our only reporting unit. |
Impairment of Long-Lived Assets | Long-lived assets to be held and used, including property, plant and equipment and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell. |
Contingent Consideration | The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions that qualify as business combinations completed after January 1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue these contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step, and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. |
Derivative Instruments and Hedging Activities | We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of derivatives are recorded each period in current earnings or accumulated other comprehensive income (loss), depending on whether a derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes. We assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings. |
Translation of Foreign Currencies | The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net, in net income. |
Royalty Cost of Sales | We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year. That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. |
Accounting for Share-Based Compensation | Our share-based compensation programs grant awards that have included stock options, restricted stock units which vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units which settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date on which the employee is retirement eligible. The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options’ vesting periods. The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures, when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned. The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period. We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs and PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs and PUs are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. The purchase price of common stock under our ESPP is equal to 85% of the lesser of (i) the fair market value per share of the common stock on the first business day of an offering period and (ii) the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes model. The fair value of the look-back provision plus the 15% discount is recognized as compensation expense over the 90 day purchase period. |
Research and Development Expenses | Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable, and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets on our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program. From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note 19, Collaborative and Other Relationships to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of unconsolidated joint business revenues. For collaborations with commercialized products, if we are the principal, we record revenue and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue. |
Selling, General and Administrative Expenses | Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs. Advertising costs are expensed as incurred. For the years ended December 31, 2015 , 2014 and 2013 , advertising costs totaled $108.6 million , $92.9 million and $72.7 million , respectively. |
Income Taxes | The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. All tax effects associated with intercompany transfers of assets in our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through the consolidated statement of income when the asset transferred is sold to a third party or otherwise recovered through amortization of the asset's remaining economic life. If the asset transferred becomes impaired, for example through the discontinuation of a research program, we will expense any remaining deferred charge or prepaid tax. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense. |
Contingencies | We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position. |
Earnings per Share | Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. |
New Accounting Pronouncements | From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption. In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations. In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expanded secured borrowing accounting to include repurchase-to-maturity transactions and repurchase financings and set forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. We adopted this standard on April 1, 2015 and expanded our disclosures presented in Note 8, Financial Instruments to these consolidated financial statements. The adoption of this standard did not have an impact on our financial position or results of operations. In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The new standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU No. 2015-15, Interest - Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. We adopted these standards as of September 30, 2015 with retroactive application. The adoption of these standards did not have a significant impact on our financial position or results of operations. For additional information, please read Note 11, Indebtedness to these consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. Under this standard, if a cloud computing arrangement includes a software license, the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations. In May 2015, the FASB issued ASU No. 2015-07, Fair Value Measurement (Topic 820): Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). The new standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The new standard will be effective for us on January 1, 2016. Early application is permitted. We maintain investments in certain venture capital funds which primarily invest in small, privately-owned, venture-backed biotechnology companies. The value of our investments in these venture capital funds is estimated using the net asset value of the fund and has been included in the fair value hierarchy disclosure as a Level 3 measurement. These venture capital investments are not material to our financial position or results of operations. We adopted this standard as of June 30, 2015 and our investments in venture capital funds are no longer included in our disclosures reflected in Note 7, Fair Value Measurements to these consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The new standard applies only to inventory for which cost is determined by methods other than last-in, first-out and the retail inventory method, which includes inventory that is measured using first-in, first-out or average cost. Inventory within the scope of this standard is required to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and sets forth new disclosure requirements related to the adjustments. The new standard will be effective for us on January 1, 2016. The adoption of this standard is not expected to have an impact on our financial position or results of operations. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December 31, 2015 with retroactive application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our December 31, 2014 consolidated balance sheet, to conform our prior year presentation to our current year presentation. For additional information, please read Note 16, Income Taxes to these consolidated financial statements. |
Summary of Significant Accoun34
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Property, plant and equipment estimated useful lives | Asset Category Useful Lives Land Not depreciated Buildings 15 to 40 years Leasehold Improvements Lesser of the useful life or the term of the respective lease Furniture and Fixtures 5 to 7 years Machinery and Equipment 5 to 20 years Computer Software and Hardware 3 to 5 years |
Acquisitions Acquisitions (Tabl
Acquisitions Acquisitions (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Business Combinations [Abstract] | |
Purchase price | (In millions) Cash portion of consideration $ 200.1 Contingent consideration 274.5 Total purchase price $ 474.6 |
Estimated fair values of separately identifiable assets acquired and liabilities assumed | (In millions) In-process research and development $ 424.6 Other intangible assets 7.6 Goodwill 128.3 Deferred tax liability (84.9 ) Other, net (1.0 ) Total purchase price $ 474.6 |
Restructuring Restructuring (Ta
Restructuring Restructuring (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Restructuring and Related Activities [Abstract] | |
Charges and spending related to our restructuring efforts | (In millions) Workforce Reduction Pipeline Programs Total Restructuring charges incurred during the fourth quarter of 2015 $ 86.2 $ 7.2 $ 93.4 Previously accrued incentive compensation 15.9 — 15.9 Reserves established 102.1 7.2 109.3 Amounts paid through December 31, 2015 (68.4 ) (3.6 ) (72.0 ) Restructuring reserve as of December 31, 2015 $ 33.7 $ 3.6 $ 37.3 |
Revenue Reserves (Tables)
Revenue Reserves (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Reserves for Discounts and Allowances [Abstract] | |
Analysis of the change in reserves | (In millions) Discounts Contractual Adjustments Returns Total 2015 Beginning balance $ 47.6 $ 387.1 $ 49.1 $ 483.8 Current provisions relating to sales in current year 459.7 1,732.1 37.6 2,229.4 Adjustments relating to prior years (1.3 ) (16.3 ) (14.7 ) (32.3 ) Payments/returns relating to sales in current year (405.9 ) (1,258.1 ) (2.6 ) (1,666.6 ) Payments/returns relating to sales in prior years (44.0 ) (296.1 ) (11.5 ) (351.6 ) Ending balance $ 56.1 $ 548.7 $ 57.9 $ 662.7 (In millions) Discounts Contractual Adjustments Returns Total 2014 Beginning balance $ 47.0 $ 345.5 $ 33.7 $ 426.2 Current provisions relating to sales in current year 347.3 1,265.4 39.1 1,651.8 Adjustments relating to prior years (1.0 ) (28.5 ) 13.5 (16.0 ) Payments/returns relating to sales in current year (299.7 ) (933.4 ) (4.1 ) (1,237.2 ) Payments/returns relating to sales in prior years (46.0 ) (261.9 ) (33.1 ) (341.0 ) Ending balance $ 47.6 $ 387.1 $ 49.1 $ 483.8 (In millions) Discounts Contractual Adjustments Returns Total 2013 Beginning balance $ 14.3 $ 196.0 $ 26.8 $ 237.1 Current provisions relating to sales in current year 236.3 861.3 22.9 1,120.5 Adjustments relating to prior years (0.7 ) (16.4 ) 1.1 (16.0 ) Payments/returns relating to sales in current year (189.7 ) (560.4 ) — (750.1 ) Payments/returns relating to sales in prior years (13.2 ) (135.0 ) (17.1 ) (165.3 ) Ending balance $ 47.0 $ 345.5 $ 33.7 $ 426.2 |
Total reserves, included in consolidated balance sheets | As of December 31, (In millions) 2015 2014 Reduction of accounts receivable $ 144.6 $ 124.6 Component of accrued expenses and other 518.1 359.2 Total revenue-related reserves $ 662.7 $ 483.8 |
Inventory (Tables)
Inventory (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Inventory Disclosure [Abstract] | |
Components of inventory | As of December 31, (In millions) 2015 2014 Raw materials $ 213.0 $ 128.3 Work in process 577.6 511.5 Finished goods 143.0 164.2 Total inventory $ 933.6 $ 804.0 Balance Sheet Classification: Inventory $ 893.4 $ 804.0 Investments and other assets 40.2 — Total inventory $ 933.6 $ 804.0 |
Intangible Assets and Goodwill
Intangible Assets and Goodwill (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible assets | As of December 31, 2015 As of December 31, 2014 (In millions) Estimated Life Cost Accumulated Amortization Net Cost Accumulated Amortization Net Out-licensed patents 13-23 years $ 543.3 $ (506.0 ) $ 37.3 $ 543.3 $ (481.7 ) $ 61.6 Developed technology 15-23 years 3,005.3 (2,552.9 ) 452.4 3,005.3 (2,396.8 ) 608.5 In-process research and development Indefinite until commercialization 730.5 — 730.5 314.1 — 314.1 Trademarks and tradenames Indefinite 64.0 — 64.0 64.0 — 64.0 Acquired and in-licensed rights and patents 6-18 years 3,303.2 (502.3 ) 2,800.9 3,280.4 (300.1 ) 2,980.3 Total intangible assets $ 7,646.3 $ (3,561.2 ) $ 4,085.1 $ 7,207.1 $ (3,178.6 ) $ 4,028.5 |
Estimated future amortization of intangible assets | (In millions) As of December 31, 2015 2016 $ 346.4 2017 318.6 2018 291.0 2019 275.1 2020 269.1 Total $ 1,500.2 |
Summary of roll forward of the changes in goodwill | As of December 31, (In millions) 2015 2014 Goodwill, beginning of year $ 1,760.2 $ 1,232.9 Increase to goodwill 908.1 527.3 Other (4.5 ) — Goodwill, end of year $ 2,663.8 $ 1,760.2 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Fair Value Disclosures [Abstract] | |
Summary of assets and liabilities recorded at fair value | (In millions) As of Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 909.5 $ — $ 909.5 $ — Marketable debt securities: Corporate debt securities 1,510.9 — 1,510.9 — Government securities 2,875.9 — 2,875.9 — Mortgage and other asset backed securities 494.1 — 494.1 — Marketable equity securities 37.5 37.5 — — Derivative contracts 27.2 — 27.2 — Plan assets for deferred compensation 40.1 — 40.1 — Total $ 5,895.2 $ 37.5 $ 5,857.7 $ — Liabilities: Derivative contracts $ 14.7 $ — $ 14.7 $ — Contingent consideration obligations 506.0 — — 506.0 Total $ 520.7 $ — $ 14.7 $ 506.0 (In millions) As of Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 716.3 $ — $ 716.3 $ — Marketable debt securities: Corporate debt securities 1,063.0 — 1,063.0 — Government securities 849.8 — 849.8 — Mortgage and other asset backed securities 198.3 — 198.3 — Marketable equity securities 6.9 6.9 — — Derivative contracts 72.7 — 72.7 — Plan assets for deferred compensation 36.9 — 36.9 — Total $ 2,943.9 $ 6.9 $ 2,937.0 $ — Liabilities: Derivative contracts $ 5.4 $ — $ 5.4 $ — Contingent consideration obligations 215.5 — — 215.5 Total $ 220.9 $ — $ 5.4 $ 215.5 |
Summary of fair and carrying value of debt instruments | As of December 31, (In millions) 2015 2014 Notes payable to Fumedica $ 9.4 $ 12.6 6.875% Senior Notes due March 1, 2018 602.6 634.6 2.900% Senior Notes due September 15, 2020 1,497.5 — 3.625% Senior Notes due September 15, 2022 1,014.2 — 4.050% Senior Notes due September 15, 2025 1,764.6 — 5.200% Senior Notes due September 15, 2045 1,757.6 — Total $ 6,645.9 $ 647.2 |
Fair value of contingent consideration obligations | As of December 31, (In millions) 2015 2014 Fair value, beginning of year $ 215.5 $ 280.9 Additions 274.5 — Changes in fair value 30.5 (38.9 ) Payments (14.5 ) (26.5 ) Fair value, end of year $ 506.0 $ 215.5 |
Financial Instruments (Tables)
Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Investments, All Other Investments [Abstract] | |
Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents | As of December 31, (In millions) 2015 2014 Commercial paper $ 21.9 $ 54.2 Overnight reverse repurchase agreements 134.7 305.0 Money market funds 673.8 321.2 Short-term debt securities 79.1 35.9 Total $ 909.5 $ 716.3 |
Marketable securities including strategic investments | As of December 31, 2015 (In millions) Fair Value Gross Unrealized Gains Gross Unrealized Losses Amortized Cost Corporate debt securities Current $ 394.3 $ — $ (0.5 ) $ 394.8 Non-current 1,116.6 0.1 (4.1 ) 1,120.6 Government securities Current 1,723.4 0.1 (1.1 ) 1,724.4 Non-current 1,152.5 — (3.1 ) 1,155.6 Mortgage and other asset backed securities Current 2.8 — — 2.8 Non-current 491.3 0.1 (1.8 ) 493.0 Total marketable debt securities $ 4,880.9 $ 0.3 $ (10.6 ) $ 4,891.2 Marketable equity securities, non-current $ 37.5 $ 9.2 $ — $ 28.3 As of December 31, 2014 (In millions) Fair Value Gross Unrealized Gains Gross Unrealized Losses Amortized Cost Corporate debt securities Current $ 370.4 $ — $ (0.2 ) $ 370.6 Non-current 692.6 0.2 (1.5 ) 693.9 Government securities Current 269.9 — (0.1 ) 270.0 Non-current 579.9 0.3 (0.4 ) 580.0 Mortgage and other asset backed securities Current 0.2 — — 0.2 Non-current 198.1 0.2 (0.2 ) 198.1 Total marketable debt securities $ 2,111.1 $ 0.7 $ (2.4 ) $ 2,112.8 Marketable equity securities, non-current $ 6.9 $ 1.2 $ (0.2 ) $ 5.9 |
Summary of contractual maturities: Available-for-sale securities | As of December 31, 2015 As of December 31, 2014 (In millions) Estimated Fair Value Amortized Cost Estimated Fair Value Amortized Cost Due in one year or less $ 2,120.5 $ 2,122.0 $ 640.5 $ 640.8 Due after one year through five years 2,575.9 2,583.9 1,343.7 1,345.2 Due after five years 184.5 185.3 126.9 126.8 Total available-for-sale securities $ 4,880.9 $ 4,891.2 $ 2,111.1 $ 2,112.8 |
Proceeds from marketable securities, excluding strategic investments | For the Years Ended December 31, (In millions) 2015 2014 2013 Proceeds from maturities and sales $ 4,063.0 $ 2,718.9 $ 5,190.1 Realized gains $ 1.5 $ 0.7 $ 6.6 Realized losses $ 3.5 $ 0.5 $ 2.1 |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Foreign currency forward contracts that were entered into to hedge forecasted revenue | Notional Amount As of December 31, Foreign Currency: (In millions) 2015 2014 Euro $ 945.5 $ 1,174.6 Swiss francs 80.8 — Canadian dollar 76.7 56.7 British pound sterling — 34.5 Australian dollar — 19.9 Japanese yen — 16.6 Total foreign currency forward contracts $ 1,103.0 $ 1,302.3 |
Summary of the effect of derivatives designated as hedging instruments on our consolidated statements of income | For the Years Ended December 31, Net Gains/(Losses) Reclassified from AOCI into Net Income (Effective Portion) Net Gains/(Losses) Recognized into Net Income (Ineffective Portion) Location 2015 2014 2013 Location 2015 2014 2013 Revenue $ 173.2 $ 6.8 $ (13.2 ) Other income (expense) $ 4.9 $ (1.5 ) $ (0.2 ) |
Summary of the fair value for our outstanding derivatives | (In millions) Balance Sheet Location Fair Value Hedging Instruments: Asset derivatives Other current assets $ 16.6 Investments and other assets $ 0.3 Liability derivatives Accrued expenses and other $ 10.2 Other long-term liabilities $ 2.5 Other Derivatives: Asset derivatives Other current assets $ 10.3 Liability derivatives Accrued expenses and other $ 2.0 (In millions) Balance Sheet Location Fair Value Hedging Instruments: Asset derivatives Other current assets $ 69.5 Investments and other assets $ 1.9 Other Derivatives: Asset derivatives Other current assets $ 1.3 Liability derivatives Accrued expenses and other $ 5.4 |
Property, Plant and Equipment (
Property, Plant and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Property, Plant and Equipment [Abstract] | |
Components of property, plant and equipment, net | As of December 31, (In millions) 2015 2014 Land $ 74.7 $ 56.9 Buildings 1,035.6 947.7 Leasehold improvements 166.6 155.5 Machinery and equipment 1,079.6 1,011.3 Computer software and hardware 647.1 547.8 Furniture and fixtures 72.9 64.3 Construction in progress 441.2 168.6 Total cost 3,517.7 2,952.1 Less: accumulated depreciation (1,330.1 ) (1,186.4 ) Total property, plant and equipment, net $ 2,187.6 $ 1,765.7 |
Property plant and equipment purchase price allocation [Table Text Block] | (In millions) Buildings $ 58.6 Machinery and equipment 25.9 Land 20.3 Total purchase price $ 104.8 |
Indebtedness (Tables)
Indebtedness (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Debt Disclosure [Abstract] | |
Summary of Indebtedness | As of December 31, (In millions) 2015 2014 Current portion: Notes payable to Fumedica $ 3.1 $ 3.1 Financing arrangement for the purchase of the RTP facility 1.7 — Current portion of notes payable and other financing arrangements $ 4.8 $ 3.1 Non-current portion: 2008 Senior Notes 6.875% Senior Notes due March 1, 2018 $ 565.3 $ 571.7 2015 Senior Notes 2.900% Senior Notes due September 15, 2020 1,485.5 — 3.625% Senior Notes due September 15, 2022 992.2 — 4.050% Senior Notes due September 15, 2025 1,733.4 — 5.200% Senior Notes due September 15, 2045 1,721.1 — Notes payable to Fumedica 5.9 8.6 Financing arrangement for the purchase of the RTP facility 18.1 — Non-current portion of notes payable and other financing arrangements $ 6,521.5 $ 580.3 |
Total debt maturities | (In millions) As of December 31, 2015 2016 $ 3.2 2017 3.2 2018 553.2 2019 — 2020 1,500.0 2021 and thereafter 4,500.0 Total $ 6,559.6 |
Equity (Tables)
Equity (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Summary of common stock | As of December 31, 2015 As of December 31, 2014 (In millions) Authorized Issued Outstanding Authorized Issued Outstanding Common stock 1,000.0 241.2 218.6 1,000.0 257.1 234.6 |
Accumulated Other Comprehensi46
Accumulated Other Comprehensive Income (Loss) (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Income (Loss) | (In millions) Unrealized Gains (Losses) on Securities Available for Sale Unrealized Gains (Losses) on Cash Flow Hedges Unfunded Status of Postretirement Benefit Plans Translation Adjustments Total Balance, December 31, 2014 $ (0.4 ) $ 71.7 $ (31.6 ) $ (99.2 ) $ (59.5 ) Other comprehensive income (loss) before reclassifications (1.7 ) 110.8 (6.2 ) (96.4 ) 6.5 Amounts reclassified from accumulated other comprehensive income (loss) 1.3 (172.3 ) — — (171.0 ) Net current period other comprehensive income (loss) (0.4 ) (61.5 ) (6.2 ) (96.4 ) (164.5 ) Balance, December 31, 2015 $ (0.8 ) $ 10.2 $ (37.8 ) $ (195.6 ) $ (224.0 ) (In millions) Unrealized Gains (Losses) on Securities Available for Sale Unrealized Gains (Losses) on Cash Flow Hedges Unfunded Status of Postretirement Benefit Plans Translation Adjustments Total Balance, December 31, 2013 $ 5.6 $ (23.7 ) $ (19.6 ) $ 10.0 $ (27.7 ) Other comprehensive income (loss) before reclassifications 0.4 101.7 (12.0 ) (109.2 ) (19.1 ) Amounts reclassified from accumulated other comprehensive income (loss) (6.4 ) (6.3 ) — — (12.7 ) Net current period other comprehensive income (loss) (6.0 ) 95.4 (12.0 ) (109.2 ) (31.8 ) Balance, December 31, 2014 $ (0.4 ) $ 71.7 $ (31.6 ) $ (99.2 ) $ (59.5 ) (In millions) Unrealized Gains (Losses) on Securities Available for Sale Unrealized Gains (Losses) on Cash Flow Hedges Unfunded Status of Postretirement Benefit Plans Translation Adjustments Total Balance, December 31, 2012 $ 4.2 $ (10.7 ) $ (21.7 ) $ (27.1 ) $ (55.3 ) Other comprehensive income (loss) before reclassifications 11.8 (26.7 ) 2.1 37.1 24.3 Amounts reclassified from accumulated other comprehensive income (loss) (10.4 ) 13.7 — — 3.3 Net current period other comprehensive income (loss) 1.4 (13.0 ) 2.1 37.1 27.6 Balance, December 31, 2013 $ 5.6 $ (23.7 ) $ (19.6 ) $ 10.0 $ (27.7 ) |
Reclassification out of Accumulated Other Comprehensive Income | (In millions) Income Statement Location Amounts Reclassified from Accumulated Other Comprehensive Income For the Years Ended December 31, 2015 2014 2013 Gains (losses) on securities available for sale Other income (expense) $ (2.0 ) $ 9.9 $ 15.9 Income tax benefit (expense) 0.7 (3.5 ) (5.5 ) Gains (losses) on cash flow hedges Revenues 173.2 6.8 (13.2 ) Other income (expense) (0.1 ) — — Income tax benefit (expense) (0.8 ) (0.5 ) (0.5 ) Total reclassifications, net of tax $ 171.0 $ 12.7 $ (3.3 ) |
Earnings per Share (Tables)
Earnings per Share (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Earnings Per Share [Abstract] | |
Basic and diluted earnings per share | For the Years Ended December 31, (In millions) 2015 2014 2013 Numerator: Net income attributable to Biogen Inc. $ 3,547.0 $ 2,934.8 $ 1,862.3 Denominator: Weighted average number of common shares outstanding 230.7 236.4 236.9 Effect of dilutive securities: Stock options and employee stock purchase plan 0.1 0.1 0.3 Time-vested restricted stock units 0.3 0.5 0.8 Market stock units 0.1 0.2 0.3 Dilutive potential common shares 0.5 0.8 1.4 Shares used in calculating diluted earnings per share 231.2 237.2 238.3 |
Share-Based Payments (Tables)
Share-Based Payments (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Share-based compensation expense included in consolidated statements of income | For the Years Ended December 31, (In millions) 2015 2014 2013 Research and development $ 88.6 $ 102.1 $ 95.6 Selling, general and administrative 127.3 150.3 160.3 Reversal of previously accrued incentive compensation included in restructuring charges (8.6 ) — — Subtotal 207.3 252.4 255.9 Capitalized share-based compensation costs (11.0 ) (10.0 ) (9.8 ) Share-based compensation expense included in total cost and expenses 196.3 242.4 246.1 Income tax effect (55.8 ) (72.2 ) (73.3 ) Share-based compensation expense included in net income attributable to Biogen Inc. $ 140.5 $ 170.2 $ 172.8 |
Summary of share-based compensation expense associated with each of our share-based compensating programs | For the Years Ended December 31, (In millions) 2015 2014 2013 Stock options $ — $ — $ 0.6 Market stock units 38.1 37.4 32.8 Time-vested restricted stock units 119.0 115.4 103.5 Cash settled performance units 22.4 65.5 109.8 Performance units 13.9 21.9 — Employee stock purchase plan 13.9 12.2 9.2 Subtotal 207.3 252.4 255.9 Capitalized share-based compensation costs (11.0 ) (10.0 ) (9.8 ) Share-based compensation expense included in total cost and expenses $ 196.3 $ 242.4 $ 246.1 |
Stock option activity | Shares Weighted Average Exercise Price Outstanding at December 31, 2014 221,000 $ 56.98 Granted — $ — Exercised (114,000 ) $ 59.82 Cancelled — $ — Outstanding at December 31, 2015 107,000 $ 53.94 |
Tax benefit and cash received from stock option exercises | For the Years Ended December 31, (In millions) 2015 2014 2013 Tax benefit realized for stock options $ 11.9 $ 13.0 $ 29.4 Cash received from the exercise of stock options $ 6.3 $ 8.5 $ 28.1 |
Market stock units activity | Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2014 403,000 $ 219.29 Granted (a) 185,000 $ 493.43 Vested (277,000 ) $ 165.63 Forfeited (42,000 ) $ 294.85 Unvested at December 31, 2015 269,000 $ 339.89 |
Assumptions used in valuation of market based stock units | For the Years Ended December 31, 2015 2014 2013 Expected dividend yield —% —% —% Range of expected stock price volatility 31.0% - 33.2% 31.7% - 35.1% 21.7% - 25.7% Range of risk-free interest rates 0.2% - 1.0% 0.1% - 0.7% 0.1% - 0.7% 30 calendar day average stock price on grant date $277.35 - $426.27 $280.88 - $335.65 ** 60 calendar day average stock price on grant date ** ** $150.33 - $240.14 Weighted-average per share grant date fair value $493.43 $395.22 $193.45 |
Cash settled performance shares activity | Shares Unvested at December 31, 2014 335,000 Granted (a) 115,000 Vested (222,000 ) Forfeited (36,000 ) Unvested at December 31, 2015 192,000 |
Performance units activity | Shares Unvested at December 31, 2014 57,000 Granted (a) 89,000 Vested (33,000 ) Forfeited (10,000 ) Unvested at December 31, 2015 103,000 |
Time-vested restricted stock units activity | Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2014 1,137,000 $ 221.01 Granted (a) 459,000 $ 388.88 Vested (626,000 ) $ 190.65 Forfeited (160,000 ) $ 302.35 Unvested at December 31, 2015 810,000 $ 323.87 |
Shares issued under employee stock purchase plan | For the Years Ended December 31, (In millions, except share amounts) 2015 2014 2013 Shares issued under the 2015 ESPP 78,000 ** ** Shares issued under the 1995 ESPP 98,000 180,000 245,000 Cash received under the 2015 ESPP $ 19.3 ** ** Cash received under the 1995 ESPP $ 30.0 $ 46.4 $ 38.7 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Income Tax Disclosure [Abstract] | |
Income before income tax provision and the income tax expense | For the Years Ended December 31, (In millions) 2015 2014 2013 Income before income taxes (benefit): Domestic $ 3,386.7 $ 2,557.4 $ 1,953.0 Foreign 1,380.6 1,389.2 527.6 Total $ 4,767.3 $ 3,946.6 $ 2,480.6 Income tax expense (benefit): Current: Federal $ 1,214.1 $ 1,159.5 $ 700.9 State 38.6 65.2 98.4 Foreign 54.5 73.4 46.8 Total 1,307.2 1,298.1 846.1 Deferred: Federal $ (129.6 ) $ (280.9 ) $ (200.6 ) State (1.9 ) (21.0 ) (35.9 ) Foreign (14.1 ) (6.3 ) (8.6 ) Total (145.6 ) (308.2 ) (245.1 ) Total income tax expense $ 1,161.6 $ 989.9 $ 601.0 |
Components of deferred tax assets and liabilities | As of December 31, (In millions) 2015 2014 Deferred tax assets: Tax credits $ 189.3 $ 69.0 Inventory, other reserves, and accruals 243.9 217.3 Intangibles, net 328.3 251.7 Net operating loss 24.7 20.6 Share-based compensation 63.8 86.0 Other 35.8 60.0 Valuation allowance (14.1 ) (11.5 ) Total deferred tax assets $ 871.7 $ 693.1 Deferred tax liabilities: Purchased intangible assets $ (440.1 ) $ (432.8 ) Depreciation, amortization and other (102.7 ) (107.0 ) Total deferred tax liabilities $ (542.8 ) $ (539.8 ) |
Reconciliation between the U.S. federal statutory tax rate and effective tax rate | For the Years Ended December 31, 2015 2014 2013 Statutory rate 35.0 % 35.0 % 35.0 % State taxes 0.5 1.2 3.1 Taxes on foreign earnings (10.0 ) (9.5 ) (6.7 ) Credits and net operating loss utilization (1.3 ) (1.1 ) (2.6 ) Purchased intangible assets 1.0 1.2 1.5 Manufacturing deduction (1.8 ) (1.8 ) (6.6 ) Other permanent items 0.7 0.5 0.8 Contingent consideration and other 0.3 (0.4 ) (0.3 ) Effective tax rate 24.4 % 25.1 % 24.2 % |
Reconciliation of beginning and ending amount of unrecognized tax benefits | (In millions) 2015 2014 2013 Balance at January 1, $ 131.5 $ 110.1 $ 125.9 Additions based on tax positions related to the current period 10.5 20.8 11.9 Additions for tax positions of prior periods 19.5 86.1 71.7 Reductions for tax positions of prior periods (49.9 ) (23.4 ) (92.1 ) Statute expirations (1.2 ) (1.6 ) (1.9 ) Settlements (42.5 ) (60.5 ) (5.4 ) Balance at December 31, $ 67.9 $ 131.5 $ 110.1 |
Other Consolidated Financial 50
Other Consolidated Financial Statement Detail (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Supplementary cash flow information | For the Years Ended December 31, (In millions) 2015 2014 2013 Cash paid during the year for: Interest $ 39.1 $ 41.2 $ 53.6 Income taxes $ 1,674.8 $ 1,163.2 $ 643.2 |
Other income (expense), net | For the Years Ended December 31, (In millions) 2015 2014 2013 Interest income $ 22.1 $ 12.2 $ 8.2 Interest expense (95.5 ) (29.5 ) (31.9 ) Impairments on investments — — (2.8 ) Gain (loss) on investments, net (3.8 ) 11.8 21.7 Foreign exchange gains (losses), net (32.7 ) (11.6 ) (15.2 ) Other, net (13.8 ) (8.7 ) (14.9 ) Total other income (expense), net $ (123.7 ) $ (25.8 ) $ (34.9 ) |
Accrued expenses and other | As of December 31, (In millions) 2015 2014 Revenue-related reserves for discounts and allowances $ 518.1 $ 359.2 Current portion of contingent consideration obligations 504.7 265.5 Employee compensation and benefits 270.8 393.8 Royalties and licensing fees 167.9 172.4 Deferred revenue 55.7 120.9 Other 579.6 505.9 Total accrued expenses and other $ 2,096.8 $ 1,817.7 |
Other long-term liabilities | As of December 31, (In millions) 2015 2014 Contingent consideration obligation $ 301.3 $ 200.0 Employee compensation and benefits 235.4 200.7 Other 369.1 249.4 Total other long-term liabilities $ 905.8 $ 650.1 |
Collaborative and Other Relat51
Collaborative and Other Relationships (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Co-promotion profit sharing formula | Until GAZYVA First Non-CLL FDA Approval 40.0 % After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date 39.0 % After First GAZYVA Threshold Date until Second GAZYVA Threshold Date 37.5 % After Second GAZYVA Threshold Date 35.0 % First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL. First GAZYVA Threshold Date means the earlier of (1) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least $150.0 million or (2) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $150.0 million . Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $500.0 million . The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication. |
Pretax profit sharing formula | Until First GAZYVA Threshold Date 39.0 % After First GAZYVA Threshold Date until Second GAZYVA Threshold Date 37.5 % After Second GAZYVA Threshold Date 35.0 % |
Revenues from unconsolidated joint business | For the Years Ended December 31, (In millions) 2015 2014 2013 Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1) $ 1,269.8 $ 1,117.1 $ 1,087.3 Revenue on sales in the rest of world for RITUXAN 69.4 78.3 38.7 Total unconsolidated joint business revenues $ 1,339.2 $ 1,195.4 $ 1,126.0 |
Mechanism for reimbursement, under the amended agreement amounts payable | Rates post Sobi Opt-In (3) Royalty and Net Revenue Share Rates: Method Rate prior to 1st commercial sale in the Sobi Territory: Base Rate following 1st commercial sale in the Sobi Territory: Rate during the Reimbursement Period: Sobi rate to Biogen on net sales in the Sobi Territory Royalty N/A 10 or 12% Base Rate Biogen rate to Sobi on net sales in the Biogen North America Territory Royalty 2% 10 or 12% Base Rate Biogen rate to Sobi on net sales in the Biogen Direct Territory Royalty 2% 15 or 17% Base Rate Biogen rate to Sobi on net revenue (1) from the Biogen Distributor Territory (2) Net 10% 50% Base Rate (1) Net revenue represents Biogen’s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities. (2) The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor. (3) A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales. |
Summary of activity related to collaboration with AbbVie Inc. | For the Years Ended December 31, (In millions) 2015 2014 2013 Total development expense incurred by the collaboration $ 113.8 $ 117.8 $ 133.4 Biogen’s share of development expense reflected in our consolidated statements of income $ 60.8 $ 67.4 $ 71.0 |
Summary of activity related to collaboration with Eisai | For the Years Ended December 31, (In millions) 2015 2014 2013 Total development expense incurred by the collaboration $ 84.1 $ 57.5 $ — Biogen’s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income $ 40.4 $ 29.1 $ — |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Minimum rental commitments under non-cancelable leases | (In millions) 2016 2017 2018 2019 2020 Thereafter Total Minimum lease payments (1) $ 75.9 $ 75.7 $ 67.9 $ 66.7 $ 63.2 $ 382.7 $ 732.1 Less: income from subleases (6.0 ) (6.0 ) (6.3 ) (6.3 ) (6.3 ) (28.9 ) (59.8 ) Net minimum lease payments $ 69.9 $ 69.7 $ 61.6 $ 60.4 $ 56.9 $ 353.8 $ 672.3 (1) As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of $27.2 million in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement. |
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] | (In millions) As of December 31, 2015 2016 $ 2.0 2017 2.0 2018 16.7 2019 — 2020 — Thereafter — Total 20.7 Less: interest (0.9 ) Net present value of the future minimum lease payments $ 19.8 |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Segment Reporting [Abstract] | |
Revenue by product | For the Years Ended December 31, 2015 2014 2013 (In millions) United States Rest of World Total United States Rest of World Total United States Rest of World Total Multiple Sclerosis (MS): TECFIDERA $ 2,908.2 $ 730.2 $ 3,638.4 $ 2,426.6 $ 482.6 $ 2,909.2 $ 864.4 $ 11.7 $ 876.1 AVONEX 1,790.2 840.0 2,630.2 1,956.7 1,056.4 3,013.1 1,902.4 1,103.1 3,005.5 PLEGRIDY 227.1 111.4 338.5 27.8 16.7 44.5 — — — TYSABRI 1,103.1 783.0 1,886.1 1,025.1 934.4 1,959.5 814.2 712.3 1,526.5 FAMPYRA — 89.7 89.7 — 80.2 80.2 — 74.0 74.0 Hemophilia: ELOCTATE 308.3 11.4 319.7 58.4 — 58.4 — — — ALPROLIX 208.9 25.6 234.5 72.1 3.9 76.0 — — — Other product revenues: FUMADERM — 51.4 51.4 — 62.5 62.5 — 60.2 60.2 Total product revenues $ 6,545.8 $ 2,642.7 $ 9,188.5 $ 5,566.7 $ 2,636.7 $ 8,203.4 $ 3,581.0 $ 1,961.3 $ 5,542.3 |
Geographic information | December 31, 2015 (In millions) U.S. Europe (1) Germany Asia Other Total Product revenues from external customers $ 6,545.8 $ 1,497.6 $ 668.1 $ 143.7 $ 333.3 $ 9,188.5 Unconsolidated joint business revenues $ 1,269.8 $ 3.5 $ — $ — $ 65.9 $ 1,339.2 Other revenues from external customers $ 142.0 $ 29.6 $ 1.6 $ 62.9 $ — $ 236.1 Long-lived assets $ 1,296.5 $ 879.4 $ 2.3 $ 7.7 $ 1.7 $ 2,187.6 December 31, 2014 (In millions) U.S. Europe (1) Germany Asia Other Total Product revenues from external customers $ 5,566.7 $ 1,383.9 $ 811.8 $ 112.8 $ 328.2 $ 8,203.4 Unconsolidated joint business revenues $ 1,117.1 $ 7.7 $ — $ — $ 70.6 $ 1,195.4 Other revenues from external customers $ 212.6 $ 31.6 $ 1.8 $ 58.5 $ — $ 304.5 Long-lived assets $ 1,055.5 $ 701.9 $ 2.5 $ 2.6 $ 3.2 $ 1,765.7 December 31, 2013 (In millions) U.S. Europe (1) Germany Asia Other Total Product revenues from external customers $ 3,581.0 $ 1,170.2 $ 417.7 $ 93.2 $ 280.2 $ 5,542.3 Unconsolidated joint business revenues $ 1,087.3 $ 1.6 $ — $ 3.2 $ 33.9 $ 1,126.0 Other revenues from external customers $ 193.5 $ 26.1 $ 1.2 $ 43.1 $ — $ 263.9 Long-lived assets $ 984.4 $ 758.3 $ 2.5 $ 2.1 $ 3.3 $ 1,750.7 |
Quarterly Financial Data (Una54
Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Quarterly Financial Information Disclosure [Abstract] | |
Quarterly Financial Data (Unaudited) | (In millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Total Year 2015 (a) (b) (c) (d) Product revenues, net $ 2,172.3 $ 2,198.6 $ 2,391.7 $ 2,425.9 $ 9,188.5 Unconsolidated joint business revenues $ 330.6 $ 337.5 $ 337.2 $ 333.9 $ 1,339.2 Other revenues $ 52.0 $ 55.6 $ 49.0 $ 79.5 $ 236.1 Total revenues $ 2,555.0 $ 2,591.6 $ 2,777.9 $ 2,839.3 $ 10,763.8 Gross profit (1) $ 2,242.6 $ 2,305.5 $ 2,467.9 $ 2,507.5 $ 9,523.4 Net income $ 820.2 $ 924.8 $ 1,019.5 $ 828.7 $ 3,593.2 Net income attributable to Biogen Inc. $ 822.5 $ 927.3 $ 965.6 $ 831.6 $ 3,547.0 Net income per share: Basic earnings per share attributable to Biogen Inc. $ 3.50 $ 3.94 $ 4.16 $ 3.77 $ 15.38 Diluted earnings per share attributable to Biogen Inc. $ 3.49 $ 3.93 $ 4.15 $ 3.77 $ 15.34 Weighted-average shares used in calculating: Basic earnings per share attributable to Biogen Inc. 235.0 235.3 232.2 220.4 230.7 Diluted earnings per share attributable to Biogen Inc. 235.6 235.7 232.6 220.8 231.2 (In millions, except per share amounts) First Quarter Second Quarter Third Quarter Fourth Quarter Total Year 2014 (e) (f) (g) (f) (f) Product revenues, net $ 1,742.8 $ 2,056.3 $ 2,117.3 $ 2,287.0 $ 8,203.4 Unconsolidated joint business revenues $ 296.9 $ 303.3 $ 290.7 $ 304.5 $ 1,195.4 Other revenues $ 90.1 $ 61.9 $ 103.4 $ 49.2 $ 304.5 Total revenues $ 2,129.8 $ 2,421.5 $ 2,511.4 $ 2,640.7 $ 9,703.3 Gross profit (1) $ 1,850.5 $ 2,129.6 $ 2,208.8 $ 2,343.4 $ 8,532.3 Net income $ 479.7 $ 723.1 $ 856.1 $ 882.6 $ 2,941.6 Net income attributable to Biogen Inc. $ 480.0 $ 714.5 $ 856.9 $ 883.5 $ 2,934.8 Net income per share: Basic earnings per share attributable to Biogen Inc. $ 2.03 $ 3.02 $ 3.63 $ 3.75 $ 12.42 Diluted earnings per share attributable to Biogen Inc. $ 2.02 $ 3.01 $ 3.62 $ 3.74 $ 12.37 Weighted-average shares used in calculating: Basic earnings per share attributable to Biogen Inc. 236.8 236.7 236.2 235.5 236.4 Diluted earnings per share attributable to Biogen Inc. 237.8 237.4 237.0 236.3 237.2 (1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets. (a) Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of $48.1 million recorded upon entering into the collaboration agreement with AGTC. (b) Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a $60.0 million charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab. (c) Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of $60.0 million recorded upon entering into the collaboration agreement with MTPC. (d) Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling $93.4 million . (e) Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of $117.7 million recorded upon entering into the collaboration agreement with Eisai. (f) Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014. Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014. (g) Product revenues, net and total revenues for the second quarter of 2014 include the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA. |
Summary of Significant Accoun55
Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Property, Plant and Equipment | |||
Current balance included within accounts receivable, net | $ 1,227 | $ 1,292.4 | |
Business (Textual) | |||
Interest in subsidiary (less than given percentage) | 100.00% | ||
Payment terms of accounts receivable arising from product sales | 30 to 90 days | ||
Estimated useful lives of leasehold improvements | Lesser of the useful life or the term of the respective lease | ||
Purchase price of common stock under ESPP | 85% of the lower of (i) the market value per share of the common stock on the participant's entry date into an offering period or (ii) the market value per share of the common stock on the purchase date | ||
Percentage of market value per share of common stock | 85.00% | ||
Compensation expense over purchase period | The fair value of the look-back provision plus the 15% discount | ||
Discount rate recognized in compensation expense | 15.00% | ||
Advertising costs | $ 108.6 | $ 92.9 | $ 72.7 |
Minimum | Building | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 15 years | ||
Minimum | Furniture and Fixtures | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 5 years | ||
Minimum | Machinery and Equipment | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 5 years | ||
Minimum | Computer Equipment | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 3 years | ||
Maximum | Building | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 40 years | ||
Maximum | Furniture and Fixtures | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 7 years | ||
Maximum | Machinery and Equipment | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 20 years | ||
Maximum | Computer Equipment | |||
Property, Plant and Equipment | |||
Property, plant and equipment, useful life | 5 years | ||
Distributor One | |||
Property, Plant and Equipment | |||
Percentage receivables of wholesale distributor accounted in consolidated receivables | 35.40% | 34.40% | |
Distributor Two | |||
Property, Plant and Equipment | |||
Percentage receivables of wholesale distributor accounted in consolidated receivables | 23.10% | 23.30% | |
Spain and Portugal | |||
Property, Plant and Equipment | |||
Current balance included within accounts receivable, net | $ 62.4 | $ 90.2 | |
Non-current balance included within investments and other assets | $ 6.1 | $ 12.6 |
Acquisitions Acquisitions (Deta
Acquisitions Acquisitions (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended | |
Feb. 28, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | |
Business Acquisition [Line Items] | |||
Contingent consideration obligation | $ 274.5 | $ 0 | |
Convergence Pharmaceuticals | |||
Business Acquisition [Line Items] | |||
Cash portion of consideration | $ 200.1 | ||
Contingent consideration obligation | 274.5 | ||
Total purchase price | $ 474.6 |
Acquisitions Acquisitions (De57
Acquisitions Acquisitions (Details 1) - USD ($) $ in Millions | Dec. 31, 2015 | Feb. 12, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Business Acquisition [Line Items] | ||||
Goodwill | $ 2,663.8 | $ 1,760.2 | $ 1,232.9 | |
Convergence Pharmaceuticals | ||||
Business Acquisition [Line Items] | ||||
In-process research and development | $ 424.6 | |||
Other intangible assets | 7.6 | |||
Goodwill | 128.3 | |||
Deferred tax liability | (84.9) | |||
Other, net | (1) | |||
Total purchase price | $ 474.6 |
Acquisitions (Details Textual)
Acquisitions (Details Textual) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||
Feb. 28, 2015 | Dec. 31, 2015 | Jun. 30, 2013 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Feb. 12, 2015 | Apr. 02, 2013 | |
Business Acquisition [Line Items] | ||||||||
Potential future milestone payments | $ 2,800 | $ 2,800 | ||||||
Contingent consideration obligation | 274.5 | $ 0 | ||||||
Maximum contingent consideration in the form of development and approval milestones | 1,300 | 1,300 | ||||||
Acquisition of TYSABRI rights | 0 | 0 | $ 3,262.7 | |||||
Deferred revenue | $ 55.7 | $ 55.7 | $ 120.9 | |||||
Convergence Pharmaceuticals | ||||||||
Business Acquisition [Line Items] | ||||||||
Cash portion of consideration | $ 200.1 | |||||||
Potential future milestone payments | $ 450 | |||||||
Contingent consideration obligation | 274.5 | |||||||
Increase in contingent consideration liability | 36 | |||||||
Increase in goodwill | $ 36 | |||||||
Discount rate | 2.00% | 3.00% | ||||||
In-process research and development | 424.6 | |||||||
Other intangible assets | 7.6 | |||||||
TYSABRI product | ||||||||
Business Acquisition [Line Items] | ||||||||
Acquisition of TYSABRI rights | $ 3,250 | |||||||
Deferred revenue | $ 84.4 | |||||||
Other intangible assets | $ 3,180 | |||||||
Future contingent payment for the first 12 months | 12.00% | |||||||
Future contingent payment for annual worldwide net sales up to $2.0 billion | 18.00% | |||||||
Future contingent payment threshold | $ 2,000 | |||||||
Future contingent payment for annual worldwide net sales that exceed $2.0 billion | 25.00% | |||||||
Raxatrigine | Convergence Pharmaceuticals | ||||||||
Business Acquisition [Line Items] | ||||||||
Potential future milestone payments | 350 | |||||||
Discount rate | 11.00% | |||||||
Maximum contingent consideration in the form of development and approval milestones | 145 | |||||||
In-process research and development | 200 | |||||||
Neuropathic pain indications | Convergence Pharmaceuticals | ||||||||
Business Acquisition [Line Items] | ||||||||
Maximum contingent consideration in the form of development and approval milestones | 415 | |||||||
In-process research and development | $ 220 |
Restructuring Restructuring (De
Restructuring Restructuring (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Oct. 21, 2015 | |
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges | $ 93.4 | $ 93.4 | $ 0 | $ 0 | |
Previously accrued incentive compensation | 15.9 | ||||
Restructuring amounts paid | (72) | ||||
Restructuring reserve | 37.3 | 37.3 | $ 109.3 | ||
Workforce reduction | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges | 86.2 | ||||
Previously accrued incentive compensation | 15.9 | ||||
Restructuring amounts paid | (68.4) | ||||
Restructuring reserve | 33.7 | 33.7 | 102.1 | ||
Pipeline programs | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring charges | 7.2 | ||||
Previously accrued incentive compensation | 0 | ||||
Restructuring amounts paid | (3.6) | ||||
Restructuring reserve | $ 3.6 | $ 3.6 | $ 7.2 |
Restructuring Restructuring (60
Restructuring Restructuring (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring and related cost, expected percentage of positions eliminated | 11.00% | |||
Previously accrued incentive compensation | $ 120 | $ 120 | ||
Previously accrued incentive compensation | 15.9 | |||
Total restructuring charges expected | 105 | 105 | ||
Restructuring charges | 93.4 | $ 93.4 | $ 0 | $ 0 |
Workforce reduction | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Previously accrued incentive compensation | 15.9 | |||
Restructuring charges | 86.2 | |||
Pipeline programs | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Previously accrued incentive compensation | 0 | |||
Restructuring charges | $ 7.2 |
Revenue Reserves (Details)
Revenue Reserves (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Analysis of the amount of, and change in, reserves | |||
Beginning balance | $ 483.8 | $ 426.2 | $ 237.1 |
Current provisions relating to sales in current year | 2,229.4 | 1,651.8 | 1,120.5 |
Adjustments relating to prior years | (32.3) | (16) | (16) |
Payments/returns relating to sales in current year | (1,666.6) | (1,237.2) | (750.1) |
Payments/returns relating to sales in prior years | (351.6) | (341) | (165.3) |
Ending balance | 662.7 | 483.8 | 426.2 |
Discounts | |||
Analysis of the amount of, and change in, reserves | |||
Beginning balance | 47.6 | 47 | 14.3 |
Current provisions relating to sales in current year | 459.7 | 347.3 | 236.3 |
Adjustments relating to prior years | (1.3) | (1) | (0.7) |
Payments/returns relating to sales in current year | (405.9) | (299.7) | (189.7) |
Payments/returns relating to sales in prior years | (44) | (46) | (13.2) |
Ending balance | 56.1 | 47.6 | 47 |
Contractual Adjustments | |||
Analysis of the amount of, and change in, reserves | |||
Beginning balance | 387.1 | 345.5 | 196 |
Current provisions relating to sales in current year | 1,732.1 | 1,265.4 | 861.3 |
Adjustments relating to prior years | (16.3) | (28.5) | (16.4) |
Payments/returns relating to sales in current year | (1,258.1) | (933.4) | (560.4) |
Payments/returns relating to sales in prior years | (296.1) | (261.9) | (135) |
Ending balance | 548.7 | 387.1 | 345.5 |
Returns | |||
Analysis of the amount of, and change in, reserves | |||
Beginning balance | 49.1 | 33.7 | 26.8 |
Current provisions relating to sales in current year | 37.6 | 39.1 | 22.9 |
Adjustments relating to prior years | (14.7) | 13.5 | 1.1 |
Payments/returns relating to sales in current year | (2.6) | (4.1) | 0 |
Payments/returns relating to sales in prior years | (11.5) | (33.1) | (17.1) |
Ending balance | $ 57.9 | $ 49.1 | $ 33.7 |
Revenue Reserves (Details 1)
Revenue Reserves (Details 1) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 |
Total reserves | $ 662.7 | $ 483.8 | $ 426.2 | $ 237.1 |
Reduction of accounts receivable | ||||
Total reserves | 144.6 | 124.6 | ||
Component of accrued expenses and other | ||||
Total reserves | $ 518.1 | $ 359.2 |
Inventory (Details)
Inventory (Details) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Components of inventories | ||
Raw materials | $ 213 | $ 128.3 |
Work in process | 577.6 | 511.5 |
Finished goods | 143 | 164.2 |
Total inventory | 933.6 | 804 |
Inventory, current | 893.4 | 804 |
Inventory, noncurrent | $ 40.2 | $ 0 |
Inventory (Details Textual)
Inventory (Details Textual) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Inventory [Line Items] | |||
Write-downs on excess, obsolete, unmarketable or other inventory | $ 41.9 | $ 50.6 | $ 47.3 |
ZINBRYTA | |||
Inventory [Line Items] | |||
Pre-approval inventory | 24.7 | $ 6.3 | |
BENEPALI | |||
Inventory [Line Items] | |||
Pre-approval inventory | 18.4 | ||
FLIXABI | |||
Inventory [Line Items] | |||
Pre-approval inventory | $ 24.2 |
Intangible Assets and Goodwil65
Intangible Assets and Goodwill (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Feb. 12, 2015 | |
Finite-Lived Intangible Assets [Line Items] | ||||
Goodwill | $ 2,663.8 | $ 1,760.2 | $ 1,232.9 | |
Intangible assets | ||||
Total intangible assets, gross | 7,646.3 | 7,207.1 | ||
Accumulated Amortization | (3,561.2) | (3,178.6) | ||
Intangible assets, net | 4,085.1 | 4,028.5 | ||
Intangible Assets and Goodwill (Additional Textual) | ||||
Expected future amortization expense, 2016 | 346.4 | |||
Expected future amortization expense, 2017 | 318.6 | |||
Expected future amortization expense, 2018 | 291 | |||
Expected future amortization expense, 2019 | 275.1 | |||
Expected future amortization expense, 2020 | 269.1 | |||
FiniteLivedIntangibleAssetsFutureAmortization | 1,500.2 | |||
Amortization of acquired intangible assets | 382.6 | 489.8 | $ 342.9 | |
Out-licensed patents | ||||
Intangible assets | ||||
Cost | 543.3 | 543.3 | ||
Accumulated Amortization | (506) | (481.7) | ||
Net | $ 37.3 | 61.6 | ||
Intangible Assets and Goodwill (Additional Textual) | ||||
Impairment of out-licensed patent | 34.7 | |||
Out-licensed patents | Minimum | ||||
Intangible assets | ||||
Estimated life, (In Years) | 13 years | |||
Out-licensed patents | Maximum | ||||
Intangible assets | ||||
Estimated life, (In Years) | 23 years | |||
Developed technology | ||||
Intangible assets | ||||
Cost | $ 3,005.3 | 3,005.3 | ||
Accumulated Amortization | (2,552.9) | (2,396.8) | ||
Net | $ 452.4 | 608.5 | ||
Developed technology | Minimum | ||||
Intangible assets | ||||
Estimated life, (In Years) | 15 years | |||
Developed technology | Maximum | ||||
Intangible assets | ||||
Estimated life, (In Years) | 23 years | |||
Acquired and in-licensed rights and patents | ||||
Intangible assets | ||||
Cost | $ 3,303.2 | 3,280.4 | ||
Accumulated Amortization | (502.3) | (300.1) | ||
Net | $ 2,800.9 | 2,980.3 | ||
Acquired and in-licensed rights and patents | Minimum | ||||
Intangible assets | ||||
Estimated life, (In Years) | 6 years | |||
Acquired and in-licensed rights and patents | Maximum | ||||
Intangible assets | ||||
Estimated life, (In Years) | 18 years | |||
In-process research and development | ||||
Intangible assets | ||||
Indefinite lived intangible assets useful life | Indefinite | |||
Cost and net | $ 730.5 | 314.1 | ||
Accumulated Amortization | $ 0 | 0 | ||
Intangible Assets and Goodwill (Additional Textual) | ||||
Impairment of in-process research and development asset | 16.2 | |||
Trademarks and trade names | ||||
Intangible assets | ||||
Indefinite lived intangible assets useful life | Indefinite | |||
Cost and net | $ 64 | 64 | ||
Accumulated Amortization | 0 | $ 0 | ||
AVONEX | Developed technology | ||||
Intangible assets | ||||
Net | 443.9 | |||
TYSABRI product | Acquired and in-licensed rights and patents | ||||
Intangible assets | ||||
Net | $ 2,742.9 | |||
Convergence Pharmaceuticals | ||||
Finite-Lived Intangible Assets [Line Items] | ||||
Goodwill | $ 128.3 | |||
Intangible Assets and Goodwill (Additional Textual) | ||||
In-process research and development | $ 424.6 |
Intangible Assets and Goodwil66
Intangible Assets and Goodwill (Details 1) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Goodwill [Line Items] | |||
Income tax expense | $ 1,161.6 | $ 989.9 | $ 601 |
Accumulated impairment losses related to goodwill | 0 | ||
Summary of roll forward of the changes in goodwill | |||
Goodwill, beginning of period | 1,760.2 | 1,232.9 | |
Increase to goodwill | 908.1 | 527.3 | |
Other goodwill adjustments | (4.5) | 0 | |
Goodwill, end of period | 2,663.8 | 1,760.2 | $ 1,232.9 |
Fumapharm AG | TECFIDERA | |||
Goodwill [Line Items] | |||
Income tax expense | 120.2 | 72.7 | |
Summary of roll forward of the changes in goodwill | |||
Increase to goodwill | $ 900 | $ 600 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 |
Assets: | |||
Marketable debt securities | $ 4,880.9 | $ 2,111.1 | |
Fair Value, Measurements, Recurring | |||
Assets: | |||
Cash equivalents | 909.5 | 716.3 | |
Investments | 37.5 | 6.9 | |
Derivative contracts | 27.2 | 72.7 | |
Plan assets for deferred compensation | 40.1 | 36.9 | |
Total | 5,895.2 | 2,943.9 | |
Liabilities: | |||
Derivative contracts | 14.7 | 5.4 | |
Contingent consideration obligations | 506 | 215.5 | $ 280.9 |
Total | 520.7 | 220.9 | |
Fair Value, Measurements, Recurring | Corporate debt securities | |||
Assets: | |||
Marketable debt securities | 1,510.9 | 1,063 | |
Fair Value, Measurements, Recurring | Government securities | |||
Assets: | |||
Marketable debt securities | 2,875.9 | 849.8 | |
Fair Value, Measurements, Recurring | Mortgage and other asset backed securities | |||
Assets: | |||
Marketable debt securities | 494.1 | 198.3 | |
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | |||
Assets: | |||
Cash equivalents | 0 | 0 | |
Investments | 37.5 | 6.9 | |
Derivative contracts | 0 | 0 | |
Plan assets for deferred compensation | 0 | 0 | |
Total | 37.5 | 6.9 | |
Liabilities: | |||
Derivative contracts | 0 | 0 | |
Contingent consideration obligations | 0 | 0 | |
Total | 0 | 0 | |
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities | |||
Assets: | |||
Marketable debt securities | 0 | 0 | |
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities | |||
Assets: | |||
Marketable debt securities | 0 | 0 | |
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities | |||
Assets: | |||
Marketable debt securities | 0 | 0 | |
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | |||
Assets: | |||
Cash equivalents | 909.5 | 716.3 | |
Investments | 0 | 0 | |
Derivative contracts | 27.2 | 72.7 | |
Plan assets for deferred compensation | 40.1 | 36.9 | |
Total | 5,857.7 | 2,937 | |
Liabilities: | |||
Derivative contracts | 14.7 | 5.4 | |
Contingent consideration obligations | 0 | 0 | |
Total | 14.7 | 5.4 | |
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities | |||
Assets: | |||
Marketable debt securities | 1,510.9 | 1,063 | |
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities | |||
Assets: | |||
Marketable debt securities | 2,875.9 | 849.8 | |
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities | |||
Assets: | |||
Marketable debt securities | 494.1 | 198.3 | |
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | |||
Assets: | |||
Cash equivalents | 0 | 0 | |
Investments | 0 | 0 | |
Derivative contracts | 0 | 0 | |
Plan assets for deferred compensation | 0 | 0 | |
Total | 0 | 0 | |
Liabilities: | |||
Derivative contracts | 0 | 0 | |
Contingent consideration obligations | 506 | 215.5 | |
Total | 506 | 215.5 | |
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities | |||
Assets: | |||
Marketable debt securities | 0 | 0 | |
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities | |||
Assets: | |||
Marketable debt securities | 0 | 0 | |
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities | |||
Assets: | |||
Marketable debt securities | $ 0 | $ 0 |
Fair Value Measurements (Deta68
Fair Value Measurements (Details 1) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Summary of fair and carrying value of debt instruments | ||
Total fair value | $ 6,645.9 | $ 647.2 |
Notes Payable to Fumedica | ||
Summary of fair and carrying value of debt instruments | ||
Notes payable, fair value | 9.4 | 12.6 |
6.875% Senior Notes due 2018 | ||
Summary of fair and carrying value of debt instruments | ||
Notes payable, fair value | 602.6 | 634.6 |
2.90% Senior Notes due 2020 | ||
Summary of fair and carrying value of debt instruments | ||
Notes payable, fair value | 1,497.5 | 0 |
3.625% Senior Notes due 2022 | ||
Summary of fair and carrying value of debt instruments | ||
Notes payable, fair value | 1,014.2 | 0 |
4.05% Senior Notes due 2025 | ||
Summary of fair and carrying value of debt instruments | ||
Notes payable, fair value | 1,764.6 | 0 |
5.20% Senior Notes due 2045 | ||
Summary of fair and carrying value of debt instruments | ||
Notes payable, fair value | $ 1,757.6 | $ 0 |
Fair Value Measurements (Deta69
Fair Value Measurements (Details 2) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Sep. 30, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Business Acquisition, Contingent Consideration [Line Items] | ||||
Additions | $ 274.5 | $ 0 | ||
(Gain) loss on fair value remeasurement of contingent consideration | $ (49.4) | 30.5 | (38.9) | $ (0.5) |
Payments | (14.5) | (26.5) | ||
Fair Value, Measurements, Recurring | ||||
Business Acquisition, Contingent Consideration [Line Items] | ||||
Fair value, beginning of period | 215.5 | 280.9 | ||
Fair value, end of period | $ 506 | $ 215.5 | $ 280.9 |
Fair Value Measurements (Deta70
Fair Value Measurements (Details Textual) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
Feb. 28, 2015 | Dec. 31, 2015 | Sep. 30, 2014 | Mar. 31, 2012 | Sep. 30, 2011 | Dec. 31, 2010 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Feb. 12, 2015 | |
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Contingent consideration obligations | $ 301.3 | $ 301.3 | $ 200 | |||||||
Fair value measurements, changes in valuation techniques | 0 | 0 | ||||||||
(Gain) loss on fair value remeasurement of contingent consideration | $ 49.4 | $ (30.5) | $ 38.9 | $ 0.5 | ||||||
Additions | 274.5 | 0 | ||||||||
Potential future milestone payments | 2,800 | 2,800 | ||||||||
Maximum contingent consideration in the form of development and approval milestones | 1,300 | 1,300 | ||||||||
Convergence Pharmaceuticals | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Additions | $ 274.5 | |||||||||
Potential future milestone payments | $ 450 | |||||||||
Contingent consideration obligations | $ 297.5 | 297.5 | ||||||||
Discount rate used for net cash outflow projections for fair value measurement | 2.00% | 3.00% | ||||||||
In-process research and development | $ 424.6 | |||||||||
Stromedix, Inc. | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Additions | $ 122.2 | |||||||||
Contingent consideration obligations | $ 131.5 | 131.5 | 130.5 | |||||||
Maximum contingent consideration in the form of development and approval milestones | 419 | $ 419 | ||||||||
Discount rate used for net cash outflow projections for fair value measurement | 2.00% | |||||||||
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Additions | $ 38.8 | |||||||||
Contingent consideration obligations | 0 | $ 0 | 15.5 | |||||||
Milestone payments made during period | 14.5 | |||||||||
Biogen Idec International Neuroscience GmbH | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Additions | $ 81.2 | |||||||||
Contingent consideration obligations | 77 | 77 | 69.5 | |||||||
Maximum contingent consideration in the form of development and approval milestones | $ 365 | $ 365 | ||||||||
Discount rate used for net cash outflow projections for fair value measurement | 3.00% | |||||||||
6.875% Senior Notes due 2018 | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Interest rate on senior notes | 6.875% | 6.875% | ||||||||
2.90% Senior Notes due 2020 | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Interest rate on senior notes | 2.90% | 2.90% | ||||||||
3.625% Senior Notes due 2022 | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Interest rate on senior notes | 3.625% | 3.625% | ||||||||
4.05% Senior Notes due 2025 | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Interest rate on senior notes | 4.05% | 4.05% | ||||||||
5.20% Senior Notes due 2045 | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Interest rate on senior notes | 5.20% | 5.20% | ||||||||
Other long-term liabilities | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Contingent consideration obligations | $ 301.3 | $ 301.3 | $ 200 | |||||||
Accrued expenses and other | Convergence Pharmaceuticals | ||||||||||
Business Acquisition, Contingent Consideration [Line Items] | ||||||||||
Contingent consideration obligations | $ 197.2 | $ 197.2 |
Financial Instruments (Details)
Financial Instruments (Details) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | $ 909.5 | $ 716.3 |
Commercial Paper | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | 21.9 | 54.2 |
Overnight Reverse Repurchase Agreements | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | 134.7 | 305 |
Money Market Funds | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | 673.8 | 321.2 |
Short-term Debt Securities | ||
Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents | ||
Cash equivalents | $ 79.1 | $ 35.9 |
Financial Instruments (Details
Financial Instruments (Details 1) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Marketable Debt and Equity Securities | ||
Fair Value | $ 4,880.9 | $ 2,111.1 |
Gross Unrealized Gains | 0.3 | 0.7 |
Gross Unrealized Losses | (10.6) | (2.4) |
Amortized Cost | 4,891.2 | 2,112.8 |
Corporate debt securities Current | ||
Marketable Debt and Equity Securities | ||
Fair Value | 394.3 | 370.4 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | (0.5) | (0.2) |
Amortized Cost | 394.8 | 370.6 |
Corporate debt securities Non-current | ||
Marketable Debt and Equity Securities | ||
Fair Value | 1,116.6 | 692.6 |
Gross Unrealized Gains | 0.1 | 0.2 |
Gross Unrealized Losses | (4.1) | (1.5) |
Amortized Cost | 1,120.6 | 693.9 |
Government securities Current | ||
Marketable Debt and Equity Securities | ||
Fair Value | 1,723.4 | 269.9 |
Gross Unrealized Gains | 0.1 | 0 |
Gross Unrealized Losses | (1.1) | (0.1) |
Amortized Cost | 1,724.4 | 270 |
Government securities Non-current | ||
Marketable Debt and Equity Securities | ||
Fair Value | 1,152.5 | 579.9 |
Gross Unrealized Gains | 0 | 0.3 |
Gross Unrealized Losses | (3.1) | (0.4) |
Amortized Cost | 1,155.6 | 580 |
Mortgage and other asset backed securities Current | ||
Marketable Debt and Equity Securities | ||
Fair Value | 2.8 | 0.2 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Amortized Cost | 2.8 | 0.2 |
Mortgage and other asset backed securities Non-current | ||
Marketable Debt and Equity Securities | ||
Fair Value | 491.3 | 198.1 |
Gross Unrealized Gains | 0.1 | 0.2 |
Gross Unrealized Losses | (1.8) | (0.2) |
Amortized Cost | 493 | 198.1 |
Marketable equity securities | ||
Marketable Debt and Equity Securities | ||
Fair Value | 37.5 | 6.9 |
Gross Unrealized Gains | 9.2 | 1.2 |
Gross Unrealized Losses | 0 | (0.2) |
Amortized Cost | $ 28.3 | $ 5.9 |
Financial Instruments (Detail73
Financial Instruments (Details 2) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Summary of Contractual Maturities: Available-for-Sale Securities | ||
Due in one year or less, Estimated Fair Value | $ 2,120.5 | $ 640.5 |
Due in one year or less, Amortized Cost | 2,122 | 640.8 |
Due after one year through five years, Estimated Fair Value | 2,575.9 | 1,343.7 |
Due after one year through five years, Amortized Cost | 2,583.9 | 1,345.2 |
Due after five years, Estimated Fair Value | 184.5 | 126.9 |
Due after five years, Amortized Cost | 185.3 | 126.8 |
Total available-for-sale securities, Fair Value | 4,880.9 | 2,111.1 |
Total available-for-sale securities, Amortized Cost | $ 4,891.2 | $ 2,112.8 |
Financial Instruments (Detail74
Financial Instruments (Details 3) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Proceeds from Marketable Debt Securities | |||
Proceeds from maturities and sales | $ 4,063 | $ 2,718.9 | $ 5,190.1 |
Realized gains | 1.5 | 0.7 | 6.6 |
Realized losses | $ (3.5) | $ (0.5) | $ (2.1) |
Financial Instruments (Detail75
Financial Instruments (Details Textual 1) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Financial Instruments (Textual) | ||
Original maturities of commercial paper and short-term debt securities | less than 90 days | |
Overnight reverse repurchase agreements, percent of total assets | 0.71% | 2.10% |
Average maturity of marketable securities, months | 16 months | 15 months |
Financial Instruments (Detail76
Financial Instruments (Details Textual 2) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Strategic Investments | ||
Business Acquisition [Line Items] | ||
Strategic investment portfolio | $ 96 | $ 47.8 |
Derivative Instruments (Details
Derivative Instruments (Details) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | $ 1,103 | $ 1,302.3 |
Not Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | 721 | 365.2 |
Foreign Exchange Contract | Other current assets | Designated as Hedging Instrument | ||
Summary of derivatives designated as hedging instruments | ||
Asset derivatives | 16.6 | 69.5 |
Foreign Exchange Contract | Other current assets | Not Designated as Hedging Instrument | ||
Summary of derivatives designated as hedging instruments | ||
Asset derivatives | 10.3 | 1.3 |
Foreign Exchange Contract | Investments and other assets | Designated as Hedging Instrument | ||
Summary of derivatives designated as hedging instruments | ||
Asset derivatives | 0.3 | 1.9 |
Foreign Exchange Contract | Accrued expenses and other | Designated as Hedging Instrument | ||
Summary of derivatives designated as hedging instruments | ||
Liability derivatives | 10.2 | |
Foreign Exchange Contract | Accrued expenses and other | Not Designated as Hedging Instrument | ||
Summary of derivatives designated as hedging instruments | ||
Liability derivatives | 2 | 5.4 |
Foreign Exchange Contract | Other long-term liabilities | Designated as Hedging Instrument | ||
Summary of derivatives designated as hedging instruments | ||
Liability derivatives | 2.5 | |
Euro | Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | 945.5 | 1,174.6 |
Swiss francs | Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | 80.8 | 0 |
Canadian dollar | Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | 76.7 | 56.7 |
British pound sterling | Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | 0 | 34.5 |
Australian dollar | Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | 0 | 19.9 |
Japanese yen | Designated as Hedging Instrument | ||
Derivatives, Fair Value [Line Items] | ||
Aggregate notional amount | $ 0 | $ 16.6 |
Derivative Instruments (Detai78
Derivative Instruments (Details 1) - Revenue - Foreign Exchange Contract - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Revenue | |||
Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income | |||
Amount Reclassified from Accumulated Other Comprehensive Income into Income Gain/(Loss) (Effective Portion) | $ 173.2 | $ 6.8 | $ (13.2) |
Other income (expense) | |||
Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income | |||
Net gains (losses) in earnings of foreign currency forward contracts due to hedge ineffectiveness | $ 4.9 | $ (1.5) | $ (0.2) |
Derivative Instruments (Detai79
Derivative Instruments (Details Textual) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Derivatives, Fair Value [Line Items] | |||
Gain on treasury rate lock settlement | $ 6.5 | $ (19.1) | $ 24.3 |
Lower range of durations of foreign currency forward contracts | 1 month | 1 month | |
Higher range of durations of foreign currency forward contracts | 18 months | 15 months | |
Gain/Loss on fair value of foreign currency forward contracts | $ (1.8) | $ 72.1 | (23.6) |
Expected settlement time for contracts, in months | 18 months | ||
Net gains (losses) of other income (expense) related to foreign currency forward contracts | $ 23.8 | 15.5 | $ 5.2 |
Designated as Hedging Instrument | |||
Derivatives, Fair Value [Line Items] | |||
Aggregate notional amount | 1,103 | 1,302.3 | |
Not Designated as Hedging Instrument | |||
Derivatives, Fair Value [Line Items] | |||
Aggregate notional amount | 721 | $ 365.2 | |
Interest rate lock | |||
Derivatives, Fair Value [Line Items] | |||
Gain on treasury rate lock settlement | 8.5 | ||
Interest rate lock | Designated as Hedging Instrument | |||
Derivatives, Fair Value [Line Items] | |||
Aggregate notional amount | 1,100 | ||
Interest rate swap | Designated as Hedging Instrument | |||
Derivatives, Fair Value [Line Items] | |||
Aggregate notional amount | $ 675 | ||
4.05% Senior Notes due 2025 | |||
Derivatives, Fair Value [Line Items] | |||
Interest rate on senior notes | 4.05% | ||
5.20% Senior Notes due 2045 | |||
Derivatives, Fair Value [Line Items] | |||
Interest rate on senior notes | 5.20% | ||
2.90% Senior Notes due 2020 | |||
Derivatives, Fair Value [Line Items] | |||
Interest rate on senior notes | 2.90% |
Property, Plant and Equipment80
Property, Plant and Equipment (Details) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Property, Plant and Equipment [Abstract] | ||
Land | $ 74.7 | $ 56.9 |
Buildings | 1,035.6 | 947.7 |
Leasehold improvements | 166.6 | 155.5 |
Machinery and equipment | 1,079.6 | 1,011.3 |
Computer software and hardware | 647.1 | 547.8 |
Furniture and fixtures | 72.9 | 64.3 |
Construction in progress | 441.2 | 168.6 |
Total cost | 3,517.7 | 2,952.1 |
Less: accumulated depreciation | (1,330.1) | (1,186.4) |
Total property, plant and equipment, net | $ 2,187.6 | $ 1,765.7 |
Property, Plant and Equipment P
Property, Plant and Equipment Property, Plant and Equipment (Details 1) - Eisai $ in Millions | 3 Months Ended |
Sep. 30, 2015USD ($) | |
Property, Plant and Equipment | |
Research Triangle Park facility purchase | $ 104.8 |
Building | |
Property, Plant and Equipment | |
Research Triangle Park facility purchase | 58.6 |
Machinery and Equipment | |
Property, Plant and Equipment | |
Research Triangle Park facility purchase | 25.9 |
Land | |
Property, Plant and Equipment | |
Research Triangle Park facility purchase | $ 20.3 |
Property, Plant and Equipment82
Property, Plant and Equipment (Details Textual) SFr in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | ||||
Dec. 31, 2015USD ($) | Dec. 31, 2015CHF (SFr) | Sep. 30, 2015USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | |
Property, Plant and Equipment | ||||||
Depreciation expense | $ 217.9 | $ 198.4 | $ 187.8 | |||
Interest cost capitalization related to construction in progress | 10.4 | 6.4 | 7.8 | |||
Construction in progress | $ 441.2 | 441.2 | $ 168.6 | |||
Solothurn | ||||||
Property, Plant and Equipment | ||||||
Construction in progress | 99 | 99 | ||||
Cambridge Leases | ||||||
Property, Plant and Equipment | ||||||
Charges recognized to vacate building | $ 27.2 | |||||
Eisai | ||||||
Property, Plant and Equipment | ||||||
Solothurn, Switzerland land purchase | $ 104.8 | |||||
Term of original lease | 10 years | |||||
Term of amended lease | 3 years | |||||
Capital lease obligation | 19.8 | $ 20.3 | $ 19.8 | |||
Land | Solothurn | ||||||
Property, Plant and Equipment | ||||||
Solothurn, Switzerland land purchase | $ 62.5 | SFr 64.4 | ||||
Land | Eisai | ||||||
Property, Plant and Equipment | ||||||
Solothurn, Switzerland land purchase | $ 20.3 |
Indebtedness (Details)
Indebtedness (Details) SFr in Millions, $ in Millions | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2006CHF (SFr) |
Current portion: | |||
Financing arrangement for the purchase of the RTP facility | $ 1.7 | $ 0 | |
Current portion of notes payable and other financing arrangements | 4.8 | 3.1 | |
Non-current portion: | |||
Non-current notes payable | 6,559.6 | ||
Financing arrangement for the purchase of the RTP facility | 18.1 | 0 | |
Non-current portion of notes payable and other financing arrangements | 6,521.5 | 580.3 | |
Note payable to Fumedica | |||
Current portion: | |||
Notes payable to Fumedica | 3.1 | 3.1 | |
Non-current portion: | |||
Non-current notes payable | 5.9 | 8.6 | SFr 61.4 |
6.875% Senior Notes due 2018 | |||
Non-current portion: | |||
Non-current notes payable | 565.3 | 571.7 | |
2.90% Senior Notes due 2020 | |||
Non-current portion: | |||
Non-current notes payable | 1,485.5 | 0 | |
3.625% Senior Notes due 2022 | |||
Non-current portion: | |||
Non-current notes payable | 992.2 | 0 | |
4.05% Senior Notes due 2025 | |||
Non-current portion: | |||
Non-current notes payable | 1,733.4 | 0 | |
5.20% Senior Notes due 2045 | |||
Non-current portion: | |||
Non-current notes payable | $ 1,721.1 | $ 0 |
Indebtedness (Details 1)
Indebtedness (Details 1) $ in Millions | Dec. 31, 2015USD ($) |
Total debt maturities | |
2,016 | $ 3.2 |
2,017 | 3.2 |
2,018 | 553.2 |
2,019 | 0 |
2,020 | 1,500 |
2021 and thereafter | 4,500 |
Total | $ 6,559.6 |
Indebtedness (Details Textual)
Indebtedness (Details Textual) SFr in Millions | 1 Months Ended | 12 Months Ended | |||||||
Dec. 31, 2008USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2013USD ($) | Dec. 31, 2015CHF (SFr) | Sep. 30, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2014CHF (SFr) | Mar. 04, 2008USD ($) | Dec. 31, 2006CHF (SFr) | |
Debt Instrument | |||||||||
Principal amount of senior notes | $ 6,000,000,000 | ||||||||
Redemptions percentage of 2015 notes | 100.00% | ||||||||
Redemption percentage for change in control provision on the 2015 Senior Notes | 101.00% | ||||||||
Debt issuance costs | $ 47,500,000 | ||||||||
Notes payable and other financing arrangements | 6,559,600,000 | ||||||||
Senior unsecured revolving credit facility maximum borrowing capacity | $ 1,000,000,000 | $ 750,000,000 | |||||||
Term of credit facility | 5 years | 364 days | |||||||
Amount outstanding under the credit facility | $ 0 | ||||||||
6.875% Senior Notes due 2018 | |||||||||
Debt Instrument | |||||||||
Principal amount of senior notes | $ 550,000,000 | ||||||||
Interest rate on senior notes | 6.875% | ||||||||
Redemption percentage par value of senior notes | 99.184% | ||||||||
Percentage of redemption of notes | 100.00% | ||||||||
Increased carrying amount of interest rate swap | $ 62,800,000 | ||||||||
Interest to be amortized on debt | $ 17,800,000 | ||||||||
Note payable to Fumedica | |||||||||
Debt Instrument | |||||||||
Notes payable and other financing arrangements | 5,900,000 | $ 8,600,000 | SFr 61.4 | ||||||
Par value of notes payable | 9,000,000 | SFr 8.9 | 11,700,000 | SFr 11.6 | |||||
2.90% Senior Notes due 2020 | |||||||||
Debt Instrument | |||||||||
Principal amount of senior notes | $ 1,500,000,000 | ||||||||
Interest rate on senior notes | 2.90% | 2.90% | |||||||
Redemption percentage par value of senior notes | 99.792% | 99.792% | |||||||
Notes payable and other financing arrangements | $ 1,485,500,000 | 0 | |||||||
3.625% Senior Notes due 2022 | |||||||||
Debt Instrument | |||||||||
Principal amount of senior notes | $ 1,000,000,000 | ||||||||
Interest rate on senior notes | 3.625% | 3.625% | |||||||
Redemption percentage par value of senior notes | 99.92% | 99.92% | |||||||
Notes payable and other financing arrangements | $ 992,200,000 | 0 | |||||||
4.05% Senior Notes due 2025 | |||||||||
Debt Instrument | |||||||||
Principal amount of senior notes | $ 1,750,000,000 | ||||||||
Interest rate on senior notes | 4.05% | 4.05% | |||||||
Redemption percentage par value of senior notes | 99.764% | 99.764% | |||||||
Notes payable and other financing arrangements | $ 1,733,400,000 | 0 | |||||||
5.20% Senior Notes due 2045 | |||||||||
Debt Instrument | |||||||||
Principal amount of senior notes | $ 1,750,000,000 | ||||||||
Interest rate on senior notes | 5.20% | 5.20% | |||||||
Redemption percentage par value of senior notes | 99.294% | 99.294% | |||||||
Notes payable and other financing arrangements | $ 1,721,100,000 | 0 | |||||||
6.875% Senior Notes due 2018 | |||||||||
Debt Instrument | |||||||||
Interest rate on senior notes | 6.875% | 6.875% | |||||||
Debt issuance costs | $ 1,800,000 | ||||||||
Notes payable and other financing arrangements | 565,300,000 | $ 571,700,000 | |||||||
Interest rate swap | 2.90% Senior Notes due 2020 | |||||||||
Debt Instrument | |||||||||
Fair value of the interest rate swaps | 1,800,000 | ||||||||
Eisai | |||||||||
Debt Instrument | |||||||||
Capital lease obligation | $ 19,800,000 | $ 20,300,000 |
Equity (Details)
Equity (Details) - shares shares in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Summary of common stock | ||
Common stock, shares authorized | 1,000 | 1,000 |
Common stock, shares issued | 241.2 | 257.1 |
Common stock, shares outstanding | 218.6 | 234.6 |
Equity (Details Textual)
Equity (Details Textual) - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Jun. 30, 2015 | Mar. 31, 2011 | |
Class of Stock [Line Items] | |||||
Preferred stock, shares authorized | 8,000 | ||||
Equity (Textual) | |||||
Authorized amount of share repurchases under the 2015 Share Repurchase Program | $ 5,000 | ||||
Repurchase of common stock, shares | 16,800 | 2,900 | |||
Repurchase of common stock, value | $ 5,000 | $ 886.8 | $ 400.3 | ||
Common stock shares authorized for repurchase | 1,300 | 20,000 | |||
Series A | |||||
Class of Stock [Line Items] | |||||
Preferred stock, shares authorized | 1,750 | ||||
Series X junior participating | |||||
Class of Stock [Line Items] | |||||
Preferred stock, shares authorized | 1,000 | ||||
Undesignated | |||||
Class of Stock [Line Items] | |||||
Preferred stock, shares authorized | 5,250 |
Accumulated Other Comprehensi88
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated other comprehensive income (loss), net of tax beginning balance | $ (59.5) | $ (27.7) | $ (55.3) |
Other comprehensive income (loss), before reclassifications | 6.5 | (19.1) | 24.3 |
Amounts reclassified from accumulated other comprehensive income (loss) | (171) | (12.7) | 3.3 |
Net current period other comprehensive income (loss) | (164.5) | 31.8 | 27.6 |
Accumulated other comprehensive income (loss), net of tax ending balance | (224) | (59.5) | (27.7) |
Accumulated Net Unrealized Investment Gain (Loss) [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated other comprehensive income (loss), net of tax beginning balance | (0.4) | 5.6 | 4.2 |
Other comprehensive income (loss), before reclassifications | (1.7) | 0.4 | 11.8 |
Amounts reclassified from accumulated other comprehensive income (loss) | 1.3 | (6.4) | (10.4) |
Net current period other comprehensive income (loss) | 0.4 | 6 | (1.4) |
Accumulated other comprehensive income (loss), net of tax ending balance | (0.8) | (0.4) | 5.6 |
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated other comprehensive income (loss), net of tax beginning balance | 71.7 | (23.7) | (10.7) |
Other comprehensive income (loss), before reclassifications | 110.8 | 101.7 | (26.7) |
Amounts reclassified from accumulated other comprehensive income (loss) | (172.3) | (6.3) | 13.7 |
Net current period other comprehensive income (loss) | 61.5 | (95.4) | 13 |
Accumulated other comprehensive income (loss), net of tax ending balance | 10.2 | 71.7 | (23.7) |
Accumulated Defined Benefit Plans Adjustment [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated other comprehensive income (loss), net of tax beginning balance | (31.6) | (19.6) | (21.7) |
Other comprehensive income (loss), before reclassifications | (6.2) | (12) | 2.1 |
Amounts reclassified from accumulated other comprehensive income (loss) | 0 | 0 | 0 |
Net current period other comprehensive income (loss) | 6.2 | 12 | (2.1) |
Accumulated other comprehensive income (loss), net of tax ending balance | (37.8) | (31.6) | (19.6) |
Accumulated Translation Adjustment [Member] | |||
Accumulated Other Comprehensive Income (Loss) [Line Items] | |||
Accumulated other comprehensive income (loss), net of tax beginning balance | (99.2) | 10 | (27.1) |
Other comprehensive income (loss), before reclassifications | (96.4) | (109.2) | 37.1 |
Amounts reclassified from accumulated other comprehensive income (loss) | 0 | 0 | 0 |
Net current period other comprehensive income (loss) | 96.4 | 109.2 | (37.1) |
Accumulated other comprehensive income (loss), net of tax ending balance | $ (195.6) | $ (99.2) | $ 10 |
Accumulated Other Comprehensi89
Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||||||||||
Other income (expense) | $ (123.7) | $ (25.8) | $ (34.9) | ||||||||
Income tax expense | 1,161.6 | 989.9 | 601 | ||||||||
Product, net | $ (2,425.9) | $ (2,391.7) | $ (2,198.6) | $ (2,172.3) | $ (2,287) | $ (2,117.3) | $ (2,056.3) | $ (1,742.8) | (9,188.5) | (8,203.4) | (5,542.3) |
Net income attributable to Biogen Inc. | $ 831.6 | $ 965.6 | $ 927.3 | $ 822.5 | $ 883.5 | $ 856.9 | $ 714.5 | $ 480 | 3,547 | 2,934.8 | 1,862.3 |
Reclassification out of Accumulated Other Comprehensive Income [Member] | |||||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||||||||||
Net income attributable to Biogen Inc. | 171 | 12.7 | (3.3) | ||||||||
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | |||||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||||||||||
Other income (expense) | (2) | 9.9 | 15.9 | ||||||||
Income tax expense | 0.7 | (3.5) | (5.5) | ||||||||
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | |||||||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | |||||||||||
Other income (expense) | (0.1) | 0 | 0 | ||||||||
Income tax expense | (0.8) | (0.5) | (0.5) | ||||||||
Product, net | $ (173.2) | $ (6.8) | $ (13.2) |
Earnings per Share (Details)
Earnings per Share (Details) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Numerator: | |||||||||||
Net income attributable to Biogen Idec Inc | $ 831.6 | $ 965.6 | $ 927.3 | $ 822.5 | $ 883.5 | $ 856.9 | $ 714.5 | $ 480 | $ 3,547 | $ 2,934.8 | $ 1,862.3 |
Denominator: | |||||||||||
Weighted average number of common shares outstanding | 220.4 | 232.2 | 235.3 | 235 | 235.5 | 236.2 | 236.7 | 236.8 | 230.7 | 236.4 | 236.9 |
Effect of dilutive securities: | |||||||||||
Dilutive potential common shares | 0.5 | 0.8 | 1.4 | ||||||||
Shares used in calculating diluted earnings per share | 220.8 | 232.6 | 235.7 | 235.6 | 236.3 | 237 | 237.4 | 237.8 | 231.2 | 237.2 | 238.3 |
Earnings per share (Textual) | |||||||||||
Repurchase of common stock | 4.6 | 1 | 0.9 | ||||||||
Stock options and employee stock purchase plan | |||||||||||
Effect of dilutive securities: | |||||||||||
Stock options and employee stock purchase plan | 0.1 | 0.1 | 0.3 | ||||||||
Time-vested restricted stock units | |||||||||||
Effect of dilutive securities: | |||||||||||
Stock options and employee stock purchase plan | 0.3 | 0.5 | 0.8 | ||||||||
Market stock units | |||||||||||
Effect of dilutive securities: | |||||||||||
Stock options and employee stock purchase plan | 0.1 | 0.2 | 0.3 |
Share-Based Payments (Details)
Share-Based Payments (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Share-based Compensation Expense included in consolidated statements of income | |||
Share-based compensation expense | $ (183.2) | $ (165) | $ (146.2) |
Subtotal | 207.3 | 252.4 | 255.9 |
Capitalized share-based compensation costs | (11) | (10) | (9.8) |
Share-based compensation expense included in total costs and expenses | 196.3 | 242.4 | 246.1 |
Income tax effect | (55.8) | (72.2) | (73.3) |
Research and development | |||
Share-based Compensation Expense included in consolidated statements of income | |||
Share-based compensation expense | (88.6) | (102.1) | (95.6) |
Selling, general and administrative | |||
Share-based Compensation Expense included in consolidated statements of income | |||
Share-based compensation expense | (127.3) | (150.3) | (160.3) |
Restructuring charges | |||
Share-based Compensation Expense included in consolidated statements of income | |||
Share-based compensation expense | (8.6) | 0 | 0 |
Total share-based compensation expense, net of tax | |||
Share-based Compensation Expense included in consolidated statements of income | |||
Share-based compensation expense | $ (140.5) | $ (170.2) | $ (172.8) |
Share-Based Payments (Details 1
Share-Based Payments (Details 1) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | $ 183.2 | $ 165 | $ 146.2 |
Subtotal | 207.3 | 252.4 | 255.9 |
Capitalized share-based compensation costs | (11) | (10) | (9.8) |
Share-based compensation expense included in total costs and expenses | 196.3 | 242.4 | 246.1 |
Stock options | |||
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | 0 | 0 | 0.6 |
Market stock units | |||
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | 38.1 | 37.4 | 32.8 |
Time-vested restricted stock units | |||
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | 119 | 115.4 | 103.5 |
Cash settled performance units | |||
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | 22.4 | 65.5 | 109.8 |
Performance units | |||
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | 13.9 | 21.9 | 0 |
Employee stock purchase plan | |||
Summary of share based compensation expense associated with different programs | |||
Share-based compensation expense | $ 13.9 | $ 12.2 | $ 9.2 |
Share-Based Payments (Details 2
Share-Based Payments (Details 2) | 12 Months Ended |
Dec. 31, 2015$ / sharesshares | |
Stock Option Activity | |
Beginning Balance, Outstanding shares | shares | 221,000 |
Beginning Balance, Weighted Average Exercise Price | $ / shares | $ 56.98 |
Shares, Granted | shares | 0 |
Weighted Average Exercise Price, Granted | $ / shares | $ 0 |
Shares, Exercised | shares | (114,000) |
Weighted Average Exercise Price, Exercised | $ / shares | $ 59.82 |
Shares, Cancelled | shares | 0 |
Weighted Average Exercise Price, Cancelled | $ / shares | $ 0 |
Ending Balance, Outstanding shares | shares | 107,000 |
Ending Balance, Weighted Average Exercise Price | $ / shares | $ 53.94 |
Share-Based Payments (Details 3
Share-Based Payments (Details 3) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Tax benefit and cash received from stock option | |||
Tax benefit realized for stock options | $ 11.9 | $ 13 | $ 29.4 |
Cash received from the exercise of stock options | $ 6.3 | $ 8.5 | $ 28.1 |
Share-Based Payments (Details 4
Share-Based Payments (Details 4) - Market stock units - $ / shares | 12 Months Ended | ||||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |||
Market stock units activity | |||||
Beginning Balance, Unvested, Shares | 403,000 | ||||
Beginning Balance, Weighted Average Grant Date Fair Value | $ 219.29 | ||||
Shares, Granted | [1] | 185,000 | |||
Weighted Average Grant Date Fair Value, Granted | $ 493.43 | [1] | $ 395.22 | $ 193.45 | |
Shares, Vested | (277,000) | ||||
Weighted Average Grant Date Fair Value, Vested | $ 165.63 | ||||
Shares, Forfeited | (42,000) | ||||
Weighted Average Grant Date Fair Value, Forfeited | $ 294.85 | ||||
Ending Balance, Unvested, Shares | 269,000 | 403,000 | |||
Ending Balance, Weighted Average Grant Date Fair Value | $ 339.89 | $ 219.29 | |||
[1] | MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. |
Share-Based Payments (Details 5
Share-Based Payments (Details 5) - Market stock units - USD ($) | 12 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | ||
Assumptions used in valuation of market based stock units | ||||
Expected dividend yield | 0.00% | 0.00% | 0.00% | |
Minimum range of risk-free interest rates | 0.20% | 0.10% | 0.10% | |
Maximum range of risk-free interest rates | 1.00% | 0.70% | 0.70% | |
Average stock price on grant date minimum | $ 227.35 | $ 280.88 | $ 150.33 | |
Average stock price on grant date maximum | $ 426.27 | $ 335.65 | $ 240.14 | |
Weighted average grant date fair value | $ 493.43 | [1] | $ 395.22 | $ 193.45 |
Minimum | ||||
Assumptions used in valuation of market based stock units | ||||
Range of expected stock price volatility | 31.00% | 31.70% | 21.70% | |
Maximum | ||||
Assumptions used in valuation of market based stock units | ||||
Range of expected stock price volatility | 33.20% | 35.10% | 25.70% | |
[1] | MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. |
Share-Based Payments (Details 6
Share-Based Payments (Details 6) - Cash settled performance units | 12 Months Ended | |
Dec. 31, 2015shares | ||
Cash settled performance shares | ||
Beginning Balance, Unvested, Shares | 335,000,000 | |
Shares, Granted | 115,000,000 | [1] |
Shares, Vested | (222,000,000) | |
Shares, Forfeited | (36,000,000) | |
Ending Balance, Unvested, Shares | 192,000,000 | |
[1] | CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. |
Share-based Payments Share-Base
Share-based Payments Share-Based Payments (Details 7) - Performance units | 12 Months Ended | |
Dec. 31, 2015shares | ||
Share-based Compensation Arrangement by Share-based Payment Award | ||
Beginning Balance, Unvested, Shares | 57,000,000 | |
Shares, Granted | 89,000,000 | [1] |
Shares, Vested | (33,000,000) | |
Shares, Forfeited | (10,000,000) | |
Ending Balance, Unvested, Shares | 103,000,000 | |
[1] | CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. |
Share-Based Payments (Details 8
Share-Based Payments (Details 8) - Time-vested restricted stock units - $ / shares | 12 Months Ended | ||||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |||
Time-vested restricted stock units | |||||
Beginning Balance, Unvested, Shares | 1,137,000 | ||||
Beginning Balance, Weighted Average Grant Date Fair Value | $ 221.01 | ||||
Shares, Granted | [1] | 459,000 | |||
Weighted Average Grant Date Fair Value, Granted | $ 388.88 | [1] | $ 321.72 | $ 176.53 | |
Shares, Vested | (626,000) | ||||
Weighted Average Grant Date Fair Value, Vested | $ 190.65 | ||||
Shares, Forfeited | (160,000) | ||||
Weighted Average Grant Date Fair Value, Forfeited | $ 302.35 | ||||
Ending Balance, Unvested, Shares | 810,000 | 1,137,000 | |||
Ending Balance, Weighted Average Grant Date Fair Value | $ 323.87 | $ 221.01 | |||
[1] | RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately 7,000 RSUs granted to our Board of Directors. |
Share-Based Payments (Details 9
Share-Based Payments (Details 9) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] | |||
Shares issued under ESPP | 6,200,000 | ||
2015 ESPP | |||
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] | |||
Shares issued under ESPP | 78,000 | ||
Cash received under ESPP | $ 19.3 | ||
1995 ESPP | |||
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] | |||
Shares issued under ESPP | 98,000 | 180,000 | 245,000 |
Cash received under ESPP | $ 30 | $ 46.4 | $ 38.7 |
Share-Based Payments (Details T
Share-Based Payments (Details Textual) $ / shares in Units, $ in Millions | 12 Months Ended | ||||
Dec. 31, 2015USD ($)PlanIncrement$ / sharesshares | Dec. 31, 2014USD ($)$ / sharesshares | Dec. 31, 2013USD ($)Increment$ / sharesshares | |||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Shares issued under ESPP | 6,200,000 | ||||
Share-Based Payments (Textual) | |||||
Windfall tax benefits from vesting of stock awards, exercises of stock options and ESPP participation | $ | $ 78.2 | $ 96.4 | $ 73.5 | ||
Unrecognized compensation cost related to unvested share-based compensation | $ | $ 184.3 | ||||
Weighted-average period to recognize the cost of unvested awards | 1 year 9 months | ||||
Number of share-based compensation plans pursuant to which awards are currently being made | Plan | 3 | ||||
Number of shares granted under stock options | 0 | 0 | 0 | ||
Total intrinsic value of options exercised | $ | $ 38 | $ 42.7 | $ 86.2 | ||
Aggregate intrinsic values of options outstanding | $ | $ 27 | ||||
Weighted average remaining contractual term for options outstanding | 3 years 2 months | ||||
Market stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of equal annual increments | Increment | 3 | 4 | |||
Percentage of earnings of the target number of units granted based on actual stock performance (Minimum) | 0.00% | 0.00% | |||
Percentage of earnings of the target number of units granted based on actual stock performance (Maximum) | 200.00% | 150.00% | |||
Number of shares granted | [1] | 185,000 | |||
Number of days for calculation of average closing stock price | 30 days | 60 days | |||
Total fair value of vested awards | $ | $ 109 | $ 117.4 | $ 50.9 | ||
Weighted average grant date fair value | $ / shares | $ 493.43 | [1] | $ 395.22 | $ 193.45 | |
Cash settled performance units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of equal annual increments | Increment | 3 | ||||
Percentage of earnings of the target number of units granted based on actual stock performance (Minimum) | 0.00% | ||||
Percentage of earnings of the target number of units granted based on actual stock performance (Maximum) | 200.00% | ||||
Number of shares granted | [2] | 115,000,000 | |||
Number of days for calculation of average closing stock price | 30 days | 60 days | |||
Cash in settlement of CSPS awards upon vesting | $ | $ 79.8 | $ 92.8 | $ 48.3 | ||
Performance units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of equal annual increments | Increment | 3 | ||||
Percentage of earnings of the target number of units granted based on actual stock performance (Minimum) | 0.00% | ||||
Percentage of earnings of the target number of units granted based on actual stock performance (Maximum) | 200.00% | ||||
Number of shares granted | [2] | 89,000,000 | |||
PUs converted to share settlements | 32,000 | ||||
Number of days for calculation of average closing stock price | 30 days | ||||
Cash in settlement of CSPS awards upon vesting | $ | $ 12.4 | ||||
Time-vested restricted stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [3] | 459,000 | |||
Total fair value of vested awards | $ | $ 239.7 | $ 281.1 | $ 209.7 | ||
Weighted average grant date fair value | $ / shares | $ 388.88 | [3] | $ 321.72 | $ 176.53 | |
Directors Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Total number of shares of common stock for issuance | 1,600,000 | ||||
Ratio of total number of shares reserved under the plan | 1.5-to-1 | ||||
Omnibus Plans | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Total number of shares of common stock for issuance | 15,000,000 | ||||
Ratio of total number of shares reserved under the plan | 1.5-to-1 | ||||
Attainment Of Performance Criteria in 2014 | Market stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [1] | 8,000 | |||
Attainment Of Performance Criteria in 2014 | Cash settled performance units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [2] | 48,000 | |||
Attainment Of Performance Criteria in 2014 | Performance units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [2] | 42,000 | |||
Attainment Of Performance Criteria in 2013 | Market stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [1] | 19,000 | |||
Attainment Of Performance Criteria in 2012 | Market stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [1] | 24,000 | |||
Attainment Of Performance Criteria in 2011 | Market stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [1] | 34,000 | |||
Director [Member] | Time-vested restricted stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
Number of shares granted | [3] | 7,000 | |||
Settlement of PUs | Performance units | |||||
Share-based Compensation Arrangement by Share-based Payment Award | |||||
PUs converted to share settlements | 11,000 | ||||
[1] | MSUs granted in 2015 include approximately 8,000, 19,000, 24,000 and 34,000 MSUs issued in 2015 based upon the attainment of performance criteria set for 2014, 2013, 2012 and 2011, respectively, in relation to awards granted in those years. The remainder of MSUs granted during 2015 include awards granted in conjunction with our annual awards made in February 2015 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. | ||||
[2] | CSPUs granted in 2015 include approximately 48,000 CSPUs issued in 2015 based upon the attainment of performance criteria set for 2014 in relation to awards granted in 2014. The remainder of the CSPUs granted in 2015 include awards granted in conjunction with our annual awards made in February 2015 and CSPUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. | ||||
[3] | RSUs granted in 2015 primarily represent RSUs granted in conjunction with our annual awards made in February 2015 and awards made in conjunction with the hiring of new employees. RSUs granted in 2015 also include approximately 7,000 RSUs granted to our Board of Directors. |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Income before income taxes (benefit): | |||
Domestic | $ 3,386.7 | $ 2,557.4 | $ 1,953 |
Foreign | 1,380.6 | 1,389.2 | 527.6 |
Income before income tax expense and equity in loss of investee, net of tax | 4,767.3 | 3,946.6 | 2,480.6 |
Current | |||
Federal | 1,214.1 | 1,159.5 | 700.9 |
State | 38.6 | 65.2 | 98.4 |
Foreign | 54.5 | 73.4 | 46.8 |
Total | 1,307.2 | 1,298.1 | 846.1 |
Deferred | |||
Federal | (129.6) | (280.9) | (200.6) |
State | (1.9) | (21) | (35.9) |
Foreign | (14.1) | (6.3) | (8.6) |
Total | (145.6) | (308.2) | (245.1) |
Total income tax expense | $ 1,161.6 | $ 989.9 | $ 601 |
Income Taxes (Details 1)
Income Taxes (Details 1) - USD ($) $ in Millions | Dec. 31, 2015 | Dec. 31, 2014 |
Components of deferred tax assets and liabilities | ||
Tax credits | $ 189.3 | $ 69 |
Inventory, other reserves, and accruals | 243.9 | 217.3 |
Intangibles, net | 328.3 | 251.7 |
Net operating loss | 24.7 | 20.6 |
Share-based compensation | 63.8 | 86 |
Other | 35.8 | 60 |
Valuation allowance | (14.1) | (11.5) |
Total deferred tax assets | 871.7 | 693.1 |
Purchased intangible assets | (440.1) | (432.8) |
Depreciation, amortization and other | (102.7) | (107) |
Total deferred tax liabilities | $ 542.8 | $ 539.8 |
Income Taxes (Details 2)
Income Taxes (Details 2) | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Reconciliation between the U.S. federal statutory tax rate and effective tax rate | |||
Statutory rate | 35.00% | 35.00% | 35.00% |
State taxes | 0.50% | 1.20% | 3.10% |
Taxes on foreign earnings | (10.00%) | (9.50%) | (6.70%) |
Credits and net operating loss utilization | (1.30%) | (1.10%) | (2.60%) |
Purchased intangible assets | 1.00% | 1.20% | 1.50% |
Manufacturing deduction | (1.80%) | (1.80%) | (6.60%) |
Permanent items | 0.70% | 0.50% | 0.80% |
Contingent consideration | 0.30% | (0.40%) | (0.30%) |
Effective tax rate | 24.40% | 25.10% | 24.20% |
Income Taxes (Details 3)
Income Taxes (Details 3) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Reconciliation of the beginning and ending of unrecognized tax benefits | |||
Balance at January 1 | $ 131.5 | $ 110.1 | $ 125.9 |
Additions based on tax positions related to the current period | 10.5 | 20.8 | 11.9 |
Additions for tax positions of prior periods | 19.5 | 86.1 | 71.7 |
Reductions for tax positions of prior periods | (49.9) | (23.4) | (92.1) |
Statute expirations | (1.2) | (1.6) | (1.9) |
Settlements | (42.5) | (60.5) | (5.4) |
Balance at December 31 | $ 67.9 | $ 131.5 | $ 110.1 |
Income Taxes (Details Textual)
Income Taxes (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||
Dec. 31, 2011 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Tax Credit Carryforward [Line Items] | ||||
Deferred tax asset, reclassification | $ 137.1 | |||
Deferred tax liability, reclassification | 1.6 | |||
Total deferred charges and prepaid taxes | 697.9 | $ 238.9 | ||
Net book value of deferred charge | 542.8 | 539.8 | ||
Net benefit for a previously unrecognized position | 27 | $ 49.8 | ||
Expense for non-income based state taxes | 11.3 | |||
Proposed Disallowance By Tax Authorities For Payment For Services | $ 130 | |||
Net effect of adjustments to our uncertain tax positions | 25 | |||
Income Taxes (Textual) | ||||
Undistributed Foreign Earnings Of Non Us Subsidiaries | 6,000 | |||
Unrecognized tax benefit | 15.7 | 53.6 | 32.5 | |
Net interest expense | 3.1 | 4.1 | 4.5 | |
Unrecognized Tax Benefits, Interest on Income Taxes Accrued | 12.5 | 17.6 | ||
Notice of assessment of corporate withholding tax including penalties and interest | 60.9 | |||
Minimum | ||||
Tax Credit Carryforward [Line Items] | ||||
Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries | 1,500 | |||
Maximum | ||||
Tax Credit Carryforward [Line Items] | ||||
Estimated Tax Liability On Undistributed Earnings Of Foreign Subsidiaries | 2,000 | |||
General Business | Domestic Country | ||||
Tax Credit Carryforward [Line Items] | ||||
Operating Loss Carryforwards | 25.3 | |||
Tax Credit Carryforward, Amount | 127.6 | |||
General Business | State and Local Jurisdiction | ||||
Tax Credit Carryforward [Line Items] | ||||
Deferred Tax Assets, Operating Loss Carryforwards, State and Local | 91.7 | |||
General Business | Foreign Tax Authority [Member] | ||||
Tax Credit Carryforward [Line Items] | ||||
Operating Loss Carryforwards | 53.4 | |||
Research | State and Local Jurisdiction | ||||
Tax Credit Carryforward [Line Items] | ||||
Tax Credit Carryforward, Amount | 125.5 | |||
ZINBRYTA | ||||
Tax Credit Carryforward [Line Items] | ||||
Deferred tax liability recognized | $ 203.7 | |||
Net book value of deferred charge | $ 166.3 | $ 179.9 |
Other Consolidated Financial107
Other Consolidated Financial Statement Detail (Details) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Revenue-related rebates | $ 662.7 | $ 483.8 | $ 426.2 | $ 237.1 |
Cash Paid During the Year | ||||
Interest | 39.1 | 41.2 | 53.6 | |
Income taxes | 1,674.8 | 1,163.2 | 643.2 | |
Other Nonoperating Income (Expense) [Abstract] | ||||
Interest income | 22.1 | 12.2 | 8.2 | |
Interest expense | 95.5 | 29.5 | 31.9 | |
Impairment on investments | 0 | 0 | 2.8 | |
Gain (loss) on investments, net | (3.8) | 11.8 | 21.7 | |
Foreign exchange gains (losses), net | (32.7) | (11.6) | (15.2) | |
Other, net | (13.8) | (8.7) | (14.9) | |
Total other income (expense), net | (123.7) | (25.8) | $ (34.9) | |
Accrued Liabilities, Current [Abstract] | ||||
Current portion of contingent consideration obligations | 504.7 | 265.5 | ||
Employee compensation and benefits | 270.8 | 393.8 | ||
Royalties and licensing fees | 167.9 | 172.4 | ||
Deferred revenue | 55.7 | 120.9 | ||
Other | 579.6 | 505.9 | ||
Accrued expenses and other | 2,096.8 | 1,817.7 | ||
Other Long-Term Liabilities | ||||
Contingent consideration obligations | 301.3 | 200 | ||
Employee compensation and benefits | 235.4 | 200.7 | ||
Other | 369.1 | 249.4 | ||
Total other long-term liabilities | 905.8 | 650.1 | ||
Component of accrued expenses and other | ||||
Revenue-related rebates | $ 518.1 | $ 359.2 |
Other Consolidated Financial108
Other Consolidated Financial Statement Detail (Details Textual) € in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||
Feb. 28, 2015USD ($) | Dec. 31, 2015USD ($) | Sep. 30, 2015USD ($) | Jun. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Sep. 30, 2014USD ($) | Jun. 30, 2014USD ($) | Mar. 31, 2014USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Dec. 31, 2015EUR (€) | Dec. 31, 2014EUR (€) | Jun. 30, 2013EUR (€) | Dec. 31, 2011EUR (€) | |
Business Acquisition [Line Items] | ||||||||||||||||
Increase to goodwill | $ 908.1 | $ 527.3 | ||||||||||||||
Accrued expenses and other | $ 2,096.8 | $ 1,817.7 | 2,096.8 | 1,817.7 | ||||||||||||
Contingent consideration obligation | 274.5 | 0 | ||||||||||||||
Prepaid taxes | 550.6 | 57.6 | 550.6 | 57.6 | ||||||||||||
Product, net | 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | 9,188.5 | 8,203.4 | $ 5,542.3 | |||||
Accrued expenses and other long-term deferred revenue | 905.8 | $ 650.1 | 905.8 | 650.1 | ||||||||||||
Cambridge Leases | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Derecognition of construction in progress assets | 161.5 | |||||||||||||||
Solothurn | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Accrued expenses and other | 59.1 | 59.1 | ||||||||||||||
Convergence Pharmaceuticals | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Contingent consideration obligation | $ 274.5 | |||||||||||||||
TECFIDERA | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Product, net | 3,638.4 | 2,909.2 | $ 876.1 | |||||||||||||
TECFIDERA | Fumapharm AG | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Increase to goodwill | 900 | $ 600 | ||||||||||||||
TECFIDERA | Seven billion | Fumapharm AG | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Increase to goodwill | 300 | |||||||||||||||
Cumulative sales level | $ 7,000 | $ 7,000 | ||||||||||||||
ITALY | ||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||
Proposed settlement | € | € 35.6 | € 33.3 | € 30.7 | |||||||||||||
Loss contingency accrual | € | € 15.4 | |||||||||||||||
Loss contingency, adjustment related to claim amount, percent | 50.00% | |||||||||||||||
Product, net | $ 53.5 | |||||||||||||||
Accrued expenses and other long-term deferred revenue | € | € 75 |
Investments in Variable Inte109
Investments in Variable Interest Entities (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2015 | Sep. 30, 2015 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Variable Interest Entity [Line Items] | |||||
Net income attributable to noncontrolling interests, net of tax | $ 46.2 | $ 6.8 | $ 0 | ||
Investment in Variable Interest Entities (Textual) | |||||
Additional investments committed to if certain development milestones are achieved | $ 559 | 559 | |||
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | 29.2 | 29.2 | $ 7.9 | ||
Neurimmune | |||||
Variable Interest Entity [Line Items] | |||||
Net income attributable to noncontrolling interests, net of tax | $ 60 | ||||
Investment in Variable Interest Entities (Textual) | |||||
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement | $ 275 | ||||
Percentage of funding for R&D cost required in support of the collaboration agreement | 100.00% | ||||
Rodin Therapeutics | |||||
Investment in Variable Interest Entities (Textual) | |||||
Payments to acquire interest in peferred stock of an affiliates | 8 | ||||
Additional investments committed to if certain development milestones are achieved | 4 | $ 4 | |||
In-process research and development | 8.7 | ||||
Minority interest in our stockholder's equity | $ 10.9 | $ 10.9 |
Collaborative and Other Rela110
Collaborative and Other Relationships (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Revenues from unconsolidated joint business | |||||||||||
Revenue on sales in the rest of world for RITUXAN | $ 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | $ 9,188.5 | $ 8,203.4 | $ 5,542.3 |
Total unconsolidated joint business revenues | $ 333.9 | $ 337.2 | $ 337.5 | $ 330.6 | $ 304.5 | $ 290.7 | $ 303.3 | $ 296.9 | 1,339.2 | 1,195.4 | 1,126 |
U.S | |||||||||||
Revenues from unconsolidated joint business | |||||||||||
Revenue on sales in the rest of world for RITUXAN | 6,545.8 | 5,566.7 | 3,581 | ||||||||
Roche Group - Genentech | |||||||||||
Revenues from unconsolidated joint business | |||||||||||
Total unconsolidated joint business revenues | 1,339.2 | 1,195.4 | 1,126 | ||||||||
Roche Group - Genentech | U.S | |||||||||||
Revenues from unconsolidated joint business | |||||||||||
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ 1,269.8 | 1,117.1 | 1,087.3 | ||||||||
GAZYVA | |||||||||||
After First GA101 Threshold Date | |||||||||||
Until First GAZYVA Threshold Date | 39.00% | 39.00% | |||||||||
After First Threshold Date and until Second Threshold Date | 37.50% | 37.50% | |||||||||
After Second Threshold Date | 35.00% | 35.00% | |||||||||
RITUXAN | |||||||||||
Co-promotion profit sharing formula | |||||||||||
Until GAZYVA First Non-CLL FDA Approval | 40.00% | 40.00% | |||||||||
After First GA101 Threshold Date | |||||||||||
Until First GAZYVA Threshold Date | 39.00% | 39.00% | |||||||||
After First Threshold Date and until Second Threshold Date | 37.50% | 37.50% | |||||||||
After Second Threshold Date | 35.00% | 35.00% | |||||||||
RITUXAN | Roche Group - Genentech | Outside the U.S | |||||||||||
Revenues from unconsolidated joint business | |||||||||||
Revenue on sales in the rest of world for RITUXAN | $ 69.4 | $ 78.3 | $ 38.7 |
Collaborative and Other Rela111
Collaborative and Other Relationships (Details 1) | 12 Months Ended | |
Dec. 31, 2015 | ||
Sobi rate to Biogen on net sales in the Sobi Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Reimbursement, under the amended agreement, Method | Royalty | |
Rate during the reimbursement period | Base Rate plus 5% | [1] |
Sobi rate to Biogen on net sales in the Sobi Territory [Member] | Maximum | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Base rate following first commercial sale in the territory | 12.00% | [1] |
Sobi rate to Biogen on net sales in the Sobi Territory [Member] | Minimum | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Base rate following first commercial sale in the territory | 10.00% | [1] |
Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Reimbursement, under the amended agreement, Method | Royalty | |
Rate during the reimbursement period | Base Rate less 5% | [1] |
Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Maximum | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Base rate following first commercial sale in the territory | 12.00% | [1] |
Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Minimum | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Base rate following first commercial sale in the territory | 10.00% | [1] |
Biogen rate to sobi on net sales in the Biogen North America Territory [Member] | Sobi Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Rate prior to first commercial sale in the territory | 2.00% | |
Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Reimbursement, under the amended agreement, Method | Royalty | |
Rate during the reimbursement period | Base Rate less 5% | [1] |
Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Maximum | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Base rate following first commercial sale in the territory | 17.00% | [1] |
Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Minimum | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Base rate following first commercial sale in the territory | 15.00% | [1] |
Biogen rate to sobi on net sales in the Biogen direct Territory [Member] | Sobi Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Rate prior to first commercial sale in the territory | 2.00% | |
Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Reimbursement, under the amended agreement, Method | Net Revenue Share | [2],[3] |
Rate during the reimbursement period | Base Rate less 15% | [1],[2],[3] |
Biogen rate to Sobi on net revenue from the Biogen distributor Territory [Member] | Sobi Territory [Member] | ||
Mechanism for reimbursement, under the amended agreement amounts payable | ||
Rate prior to first commercial sale in the territory | 10.00% | [2],[3] |
Base rate following first commercial sale in the territory | 50.00% | [1],[2],[3] |
[1] | A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales. | |
[2] | Net revenue represents Biogen’s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities. | |
[3] | The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor. |
Collaborative and Other Rela112
Collaborative and Other Relationships (Details 2) - AbbVie - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Collaborative arrangements and non-collaborative arrangement transactions | |||
Total expense incurred by collaboration | $ 113.8 | $ 117.8 | $ 133.4 |
Biogen's share of expense reflected within our consolidation statements of income | $ 60.8 | $ 67.4 | $ 71 |
Collaborative and Other Rela113
Collaborative and Other Relationships Collaborative and Other Relationships (Details 3) - Eisai - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Collaborative arrangements and non-collaborative arrangement transactions | |||
Total expense incurred by collaboration | $ 84.1 | $ 57.5 | $ 0 |
Biogen's share of expense reflected within our consolidation statements of income | $ 40.4 | $ 29.1 | $ 0 |
Collaborative and Other Rela114
Collaborative and Other Relationships (Details Textual) $ in Millions, ₩ in Billions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||
Feb. 29, 2012USD ($) | Dec. 31, 2015USD ($) | Sep. 30, 2015USD ($) | Jun. 30, 2015USD ($) | Mar. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Sep. 30, 2014USD ($) | Jun. 30, 2014USD ($) | Mar. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Sep. 30, 2013USD ($) | Dec. 31, 2012USD ($) | Jun. 30, 2012USD ($) | Mar. 31, 2012USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | Dec. 31, 2010USD ($) | Dec. 31, 2015KRW (₩) | Dec. 31, 2014KRW (₩) | Feb. 29, 2012KRW (₩) | Jan. 31, 2007 | |
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Revenue on sales in the rest of world for RITUXAN | $ 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | $ 9,188.5 | $ 8,203.4 | $ 5,542.3 | |||||||||||
Research and development | 2,012.8 | 1,893.4 | 1,444.1 | |||||||||||||||||||
Income (Loss) from Equity Method Investments | (12.5) | (15.1) | (17.2) | |||||||||||||||||||
Other revenues from external customers | 79.5 | 49 | $ 55.6 | $ 52 | $ 49.2 | $ 103.4 | 61.9 | 90.1 | 236.1 | 304.5 | 263.9 | |||||||||||
Biogen Hemophilia | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Stock acquired in acquisition | 100.00% | |||||||||||||||||||||
Milestone Payments Made During Period | 20 | $ 40 | ||||||||||||||||||||
Genentech | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Revenue on sales in the rest of world for RITUXAN | 41.2 | |||||||||||||||||||||
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | 8.5 | |||||||||||||||||||||
Elan | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Reimbursements of research and developments expense from Elan | 11.7 | |||||||||||||||||||||
Reimbursements of selling general and administrative expenses from Elan | 20.6 | |||||||||||||||||||||
Amount reflected in collaboration profit sharing line for collaboration | 85.4 | |||||||||||||||||||||
Acorda | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones | 375 | 375 | ||||||||||||||||||||
Expected additional milestone payments when certain sales threshold is met | 15 | 15 | ||||||||||||||||||||
Foreign sales required to trigger milestone | 100 | |||||||||||||||||||||
Biogen's share of expense reflected within our consolidation statements of income | 30.6 | 29.2 | 24.3 | |||||||||||||||||||
Swedish Orphan Biovitrum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Consideration per product | $ 10 | |||||||||||||||||||||
Percentage of reimbursement expenses | 50.00% | |||||||||||||||||||||
Percentage of development reimbursement expenses | 100.00% | |||||||||||||||||||||
Reimbursement cost achieving period | 6 years | |||||||||||||||||||||
Time period for paying remaining balance due | 90 days | |||||||||||||||||||||
Term for revocation option right | 18 months | |||||||||||||||||||||
AbbVie | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 16 | |||||||||||||||||||||
Biogen's share of expense reflected within our consolidation statements of income | 60.8 | 67.4 | 71 | |||||||||||||||||||
Estimated additional payments upon achievement of development and commercial milestones. | 32 | 32 | ||||||||||||||||||||
Ionis Pharmaceuticals | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 75 | $ 30 | 20 | 20 | ||||||||||||||||||
Term of collaboration agreement | 6 years | |||||||||||||||||||||
Total upfront and milestone payments made to collaborative partner | $ 100 | |||||||||||||||||||||
Prepaid research and discovery services | $ 25 | |||||||||||||||||||||
License Fee | 70 | |||||||||||||||||||||
Expected License Fee And Regulatory Milestone Payments | 130 | 130 | ||||||||||||||||||||
Additional milestone payments for product candidate using a different modality | 90 | |||||||||||||||||||||
Additional Milestone Payment | 10 | 10 | ||||||||||||||||||||
Eisai | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | 21.6 | 117.7 | ||||||||||||||||||||
Biogen's share of expense reflected within our consolidation statements of income | 40.4 | 29.1 | $ 0 | |||||||||||||||||||
Total upfront and milestone payments made to collaborative partner | 100 | |||||||||||||||||||||
Additional Milestone Payment | 1,000 | 1,000 | ||||||||||||||||||||
Milestone Payments Made During Period | $ 35 | |||||||||||||||||||||
Sangamo BioSciences | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Biogen's share of expense reflected within our consolidation statements of income | 13.6 | 28.9 | ||||||||||||||||||||
Total upfront and milestone payments made to collaborative partner | 20 | |||||||||||||||||||||
Additional Milestone Payment | 300 | 300 | ||||||||||||||||||||
AGTC | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | 48.1 | 54.5 | ||||||||||||||||||||
Total upfront and milestone payments made to collaborative partner | 124 | |||||||||||||||||||||
Prepaid research and discovery services | 58.4 | |||||||||||||||||||||
Additional Milestone Payment | 1,100 | 1,100 | ||||||||||||||||||||
Purchase of common stock | 30 | |||||||||||||||||||||
Total licensing and other fees | $ 35.6 | |||||||||||||||||||||
Research and development services | 6.5 | |||||||||||||||||||||
Premium on equity investment | 7.5 | |||||||||||||||||||||
Mitsubishi Tanabe Pharma Corporation | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | 60 | |||||||||||||||||||||
Additional Milestone Payment | $ 484 | 484 | ||||||||||||||||||||
Other research and discovery | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 9.7 | $ 40 | ||||||||||||||||||||
Samsung Biosimilar Agreement | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 46 | |||||||||||||||||||||
Equity Method Investments, Expected Profit Share | 50.00% | |||||||||||||||||||||
RITUXAN | ||||||||||||||||||||||
Collaborative arrangements and non-collaborative arrangement transactions | ||||||||||||||||||||||
Royalties Terms Of Collaboration Agreement | 10% and 12% on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting 11 years | |||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Period of collaboration agreement | 11 years | |||||||||||||||||||||
Percentage of Co promotion Operating Profits first fifty million | 30.00% | 30.00% | 30.00% | |||||||||||||||||||
Percentage of share of Co promotion profits exceeding $50 million | 40.00% | 40.00% | 40.00% | 40.00% | 40.00% | 40.00% | 40.00% | 40.00% | ||||||||||||||
Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World | expire through 2012 | |||||||||||||||||||||
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One | 39.00% | 39.00% | 39.00% | |||||||||||||||||||
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One | 40.00% | 40.00% | 40.00% | |||||||||||||||||||
RITUXAN | Maximum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Percentage of royalties as per collaboration | 12.00% | |||||||||||||||||||||
RITUXAN | Minimum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Percentage of royalties as per collaboration | 10.00% | |||||||||||||||||||||
GAZYVA | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Percentage of future development and commercialization expenses payable related to GAZYVA | 35.00% | |||||||||||||||||||||
Percentage of Co promotion Operating Profits first fifty million | 35.00% | 35.00% | 35.00% | |||||||||||||||||||
Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment | $ 50 | $ 50 | ||||||||||||||||||||
Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one | 150 | |||||||||||||||||||||
Limit of gross sale of GAZYVA to be achieved in any 12 months under option one | 150 | |||||||||||||||||||||
Sales Trigger Gross Sales Threshold | $ 500 | |||||||||||||||||||||
Percentage Of Co Promotion Operating Losses | 35.00% | |||||||||||||||||||||
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One | 39.00% | 39.00% | 39.00% | |||||||||||||||||||
New Anti-CD20 | Maximum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Future percentage of co-promotion operating profits | 38.00% | |||||||||||||||||||||
New Anti-CD20 | Minimum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Future percentage of co-promotion operating profits | 30.00% | |||||||||||||||||||||
ELOCTATE | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Revenue on sales in the rest of world for RITUXAN | $ 319.7 | $ 58.4 | $ 0 | |||||||||||||||||||
ELOCTATE | Swedish Orphan Biovitrum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | 200 | |||||||||||||||||||||
ALPROLIX | Swedish Orphan Biovitrum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 175 | |||||||||||||||||||||
Ocrelizumab | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Reduction in royalty rate | 50.00% | |||||||||||||||||||||
Ocrelizumab | Maximum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Future royalties percentage to be received on sale of ocrelizumab | 24.00% | |||||||||||||||||||||
Ocrelizumab | Minimum | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Future royalties percentage to be received on sale of ocrelizumab | 13.50% | |||||||||||||||||||||
SOD1 | Ionis Pharmaceuticals | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 10 | |||||||||||||||||||||
DMPK | Ionis Pharmaceuticals | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 12 | 2.8 | 14 | 10 | ||||||||||||||||||
Biogen's share of expense reflected within our consolidation statements of income | 9 | 10.9 | 11.2 | |||||||||||||||||||
License Fee | 70 | |||||||||||||||||||||
Expected License Fee And Regulatory Milestone Payments | $ 130 | 130 | ||||||||||||||||||||
Additional Milestone Payment | 4.2 | $ 59 | 4.2 | |||||||||||||||||||
SMNRx | Ionis Pharmaceuticals | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | $ 29 | 42.8 | 57.3 | |||||||||||||||||||
Biogen's share of expense reflected within our consolidation statements of income | 74.9 | 27.7 | 13.6 | |||||||||||||||||||
Estimated additional payments upon achievement of development and commercial milestones. | $ 325 | 325 | ||||||||||||||||||||
Expected License Fee And Regulatory Milestone Payments | 150 | 150 | ||||||||||||||||||||
Additional Milestone Payment | 92 | 100 | 92 | 100 | ||||||||||||||||||
Lead programs | AGTC | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | 5 | |||||||||||||||||||||
Additional Milestone Payment | 472.5 | 472.5 | ||||||||||||||||||||
Discovery programs | AGTC | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Additional Milestone Payment | 592.5 | 592.5 | ||||||||||||||||||||
Samsung Biosimilar Agreement | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Additional Milestone Payment | 75 | 75 | ||||||||||||||||||||
Investments By Third Party In Joint Venture As Per Agreement. | $ 250 | ₩ 280.5 | ||||||||||||||||||||
Joint Venture Owner Ship Percentage By Third Party. | 85.00% | |||||||||||||||||||||
Equity Method Investments | $ 45 | $ 5.7 | $ 8.6 | $ 5.7 | 8.6 | ₩ 6.3 | ₩ 9.1 | ₩ 49.5 | ||||||||||||||
Percentage of equity interest to the portion of total capital stock | 15.00% | 9.00% | 9.00% | 9.00% | 15.00% | |||||||||||||||||
Equity Method Investment Ownership Percentage Maximum | 49.90% | |||||||||||||||||||||
Other revenues from external customers | $ 62.9 | 58.5 | 43.1 | |||||||||||||||||||
Samsung Biosimilar Agreement | Biosimilars | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Additional Milestone Payment | $ 25 | 25 | ||||||||||||||||||||
New Anti-CD20 | Third Party Anti CD-20 | Roche Group - Genentech | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Research and development | 25.7 | |||||||||||||||||||||
Hoechst | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages | 49.7 | |||||||||||||||||||||
Research and development | Eisai | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Amount recorded to reflect fair value of options granted | $ 17.7 | |||||||||||||||||||||
Outside the U.S | AbbVie | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Estimated additional payments upon achievement of development and commercial milestones. | 12 | 12 | ||||||||||||||||||||
Outside the U.S | RITUXAN | Roche Group - Genentech | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Revenue on sales in the rest of world for RITUXAN | $ 69.4 | 78.3 | 38.7 | |||||||||||||||||||
Outside the U.S | Ocrelizumab | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Future royalties percentage to be received on sale of ocrelizumab | 3.00% | |||||||||||||||||||||
U.S | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Revenue on sales in the rest of world for RITUXAN | $ 6,545.8 | 5,566.7 | 3,581 | |||||||||||||||||||
Other revenues from external customers | 142 | 212.6 | 193.5 | |||||||||||||||||||
U.S | Roche Group - Genentech | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | 1,269.8 | $ 1,117.1 | $ 1,087.3 | |||||||||||||||||||
U.S | AbbVie | ||||||||||||||||||||||
Collaborative and Other Relationships (Textual) | ||||||||||||||||||||||
Estimated additional payments upon achievement of development and commercial milestones. | $ 20 | $ 20 |
Litigation (Details)
Litigation (Details) | 3 Months Ended |
Dec. 31, 2011 | |
ITALY | |
Loss Contingencies [Line Items] | |
Reimbursement Limit Stated In Resolution | 24 months |
Commitments and Contingencie116
Commitments and Contingencies (Details) $ in Millions | Dec. 31, 2015USD ($) | |
Minimum rental commitments under non-cancelable leases | ||
Minimum lease payments, 2016 | $ 75.9 | [1] |
Minimum lease payments, 2017 | 75.7 | [1] |
Minimum lease payments, 2018 | 67.9 | [1] |
Minimum lease payments, 2019 | 66.7 | [1] |
Minimum lease payments, 2020 | 63.2 | [1] |
Minimum lease payments, Thereafter | 382.7 | [1] |
Minimum lease payments, Total | 732.1 | [1] |
Less: income from subleases, 2016 | (6) | |
Less: income from subleases, 2017 | (6) | |
Less: income from subleases, 2018 | (6.3) | |
Less: income from subleases, 2019 | (6.3) | |
Less: income from subleases, 2020 | (6.3) | |
Less: income from subleases, Thereafter | (28.9) | |
Less: income from subleases, Total | (59.8) | |
Net minimum lease payments, 2016 | 69.9 | |
Net minimum lease payments, 2017 | 69.7 | |
Net minimum lease payments, 2018 | 61.6 | |
Net minimum lease payments, 2019 | 60.4 | |
Net minimum lease payments, 2020 | 56.9 | |
Net minimum lease payments, Thereafter | 353.8 | |
Net minimum lease payments, Total | $ 672.3 | |
[1] | As a result of our decision to relocate our corporate headquarters to Cambridge, Massachusetts, we vacated part of our Weston, Massachusetts facility in the fourth quarter of 2013. We incurred a charge of $27.2 million in connection with this move. This charge represented our remaining lease obligation for the vacated portion of our Weston, Massachusetts facility, net of sublease income expected to be received. The term of our sublease to the vacated portion of our Weston, Massachusetts facility started in January 2014 and will continue through the remaining term of our lease agreement. |
Commitments and Contingencies C
Commitments and Contingencies Commitments and Contingencies (Details 1) $ in Millions | Dec. 31, 2015USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
Capital leases, future minimum payments due in 2016 | $ 2 |
Capital leases, future minimum payments due in 2017 | 2 |
Capital leases, future minimum payments due in 2018 | 16.7 |
Capital leases, future minimum payments due in 2019 | 0 |
Capital leases, future minimum payments due in 2020 | 0 |
Capital leases, future minimum payments due thereafter | 0 |
Capital leases, future minimum payments due total | 20.7 |
Less: interest on capital lease | (0.9) |
Net present value of the future minimum lease payments | $ 19.8 |
Commitments and Contingencie118
Commitments and Contingencies (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||||||||
Dec. 31, 2015 | Jun. 30, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2010 | Dec. 31, 2006 | Jun. 30, 2013 | Apr. 02, 2013 | Jan. 31, 2007 | |
Business Acquisition [Line Items] | ||||||||||
Cancellable future commitments | $ 559 | $ 559 | ||||||||
Maximum contingent consideration in the form of development and approval milestones | 1,300 | 1,300 | ||||||||
Increase to goodwill | 908.1 | $ 527.3 | ||||||||
Commitments And Contingencies (Textual) | ||||||||||
Lease rent expense which terminates at various dates through 2028 | 68.6 | 62.4 | $ 56.1 | |||||||
Liabilities associated with uncertain tax positions | 45.4 | 45.4 | ||||||||
Accrued expenses | 25 | 25 | ||||||||
Potential future milestone payments commitment, approximately | 2,800 | 2,800 | ||||||||
TYSABRI product | ||||||||||
Commitments And Contingencies (Textual) | ||||||||||
Future contingent payment for annual worldwide net sales up to $2.0 billion | 18.00% | |||||||||
Future contingent payment threshold | $ 2,000 | |||||||||
Future contingent payment for annual worldwide net sales that exceed $2.0 billion | 25.00% | |||||||||
Biogen Hemophilia | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Maximum contingent consideration in the form of development and approval milestones | $ 80 | |||||||||
Milestone payments made during period | $ 20 | $ 40 | ||||||||
Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Amount paid in cash | $ 220 | |||||||||
Cambridge Leases | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Charges recognized to vacate building | $ 27.2 | |||||||||
Solothurn | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cancellable future commitments | 126.4 | 126.4 | ||||||||
TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Maximum contingent consideration in the form of development and approval milestones | $ 15 | |||||||||
Increase to goodwill | 900 | $ 600 | ||||||||
Six billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Amount paid in cash | 850 | |||||||||
Cumulative sales level | 6,000 | 6,000 | ||||||||
Four billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cumulative sales level | 4,000 | 4,000 | ||||||||
Five billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cumulative sales level | 5,000 | 5,000 | ||||||||
Seven billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Increase to goodwill | 300 | |||||||||
Cumulative sales level | 7,000 | 7,000 | ||||||||
One billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cumulative sales level | 1,000 | 1,000 | ||||||||
Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Increase to goodwill | 300 | |||||||||
Cumulative sales level | 20,000 | 20,000 | ||||||||
Three billion | TECFIDERA | Fumapharm AG | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Cumulative sales level | $ 3,000 | $ 3,000 |
Employee Benefit Plans (Details
Employee Benefit Plans (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Savings plan [Member] | |||
Defined Benefit Plan Disclosure [Line Items] | |||
Minimum Qualifying Age For Employee Benefit Plan | 21 years | ||
Employee Benefit Plans (Textual) [Abstract] | |||
Expenses related to savings plan | $ 51.8 | $ 49.3 | $ 39.3 |
Deferred compensation plan [Member] | |||
Employee Benefit Plans (Textual) [Abstract] | |||
Deferred compensation related to Employee Benefit Plan | $ 126.9 | $ 105.2 | |
Swiss plan [Member] | |||
Employee Benefit Plans (Textual) [Abstract] | |||
Percentage of minimum investment return | 1.75% | 1.75% | 1.50% |
Unfunded net pension | $ 42.4 | $ 31.9 | |
Employee Benefit Plan obligations | 63.9 | 43.9 | |
Pension Expense | 12.9 | 9.8 | $ 10.9 |
German plan [Member] | |||
Employee Benefit Plans (Textual) [Abstract] | |||
Employee Benefit Plan obligations | 27.6 | 24.8 | |
Periodic pension cost | $ 4 | $ 3.5 | $ 3.3 |
Segment Information (Details)
Segment Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Revenue by product | |||||||||||
Product, net | $ 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | $ 9,188.5 | $ 8,203.4 | $ 5,542.3 |
U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 6,545.8 | 5,566.7 | 3,581 | ||||||||
Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 2,642.7 | 2,636.7 | 1,961.3 | ||||||||
TECFIDERA | |||||||||||
Revenue by product | |||||||||||
Product, net | 3,638.4 | 2,909.2 | 876.1 | ||||||||
TECFIDERA | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 2,908.2 | 2,426.6 | 864.4 | ||||||||
TECFIDERA | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 730.2 | 482.6 | 11.7 | ||||||||
AVONEX | |||||||||||
Revenue by product | |||||||||||
Product, net | 2,630.2 | 3,013.1 | 3,005.5 | ||||||||
AVONEX | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 1,790.2 | 1,956.7 | 1,902.4 | ||||||||
AVONEX | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 840 | 1,056.4 | 1,103.1 | ||||||||
PLEGRIDY | |||||||||||
Revenue by product | |||||||||||
Product, net | 338.5 | 44.5 | 0 | ||||||||
PLEGRIDY | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 227.1 | 27.8 | 0 | ||||||||
PLEGRIDY | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 111.4 | 16.7 | 0 | ||||||||
TYSABRI | |||||||||||
Revenue by product | |||||||||||
Product, net | 1,886.1 | 1,959.5 | 1,526.5 | ||||||||
TYSABRI | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 1,103.1 | 1,025.1 | 814.2 | ||||||||
TYSABRI | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 783 | 934.4 | 712.3 | ||||||||
FAMPYRA | |||||||||||
Revenue by product | |||||||||||
Product, net | 89.7 | 80.2 | 74 | ||||||||
FAMPYRA | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 0 | 0 | 0 | ||||||||
FAMPYRA | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 89.7 | 80.2 | 74 | ||||||||
ELOCTATE | |||||||||||
Revenue by product | |||||||||||
Product, net | 319.7 | 58.4 | 0 | ||||||||
ELOCTATE | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 308.3 | 58.4 | 0 | ||||||||
ELOCTATE | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 11.4 | 0 | 0 | ||||||||
ALPROLIX | |||||||||||
Revenue by product | |||||||||||
Product, net | 234.5 | 76 | 0 | ||||||||
ALPROLIX | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 208.9 | 72.1 | 0 | ||||||||
ALPROLIX | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | 25.6 | 3.9 | 0 | ||||||||
FUMADERM | |||||||||||
Revenue by product | |||||||||||
Product, net | 51.4 | 62.5 | 60.2 | ||||||||
FUMADERM | U.S | |||||||||||
Revenue by product | |||||||||||
Product, net | 0 | 0 | 0 | ||||||||
FUMADERM | Rest of world | |||||||||||
Revenue by product | |||||||||||
Product, net | $ 51.4 | $ 62.5 | $ 60.2 |
Segment Information (Details 1)
Segment Information (Details 1) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | ||
Geographic information | ||||||||||||
Product, net | $ 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | $ 9,188.5 | $ 8,203.4 | $ 5,542.3 | |
Revenues from unconsolidated joint business | 1,339.2 | 1,195.4 | 1,126 | |||||||||
Other revenues from external customers | 79.5 | $ 49 | $ 55.6 | $ 52 | 49.2 | $ 103.4 | $ 61.9 | $ 90.1 | 236.1 | 304.5 | 263.9 | |
Long-lived assets | 2,187.6 | 1,765.7 | 2,187.6 | 1,765.7 | 1,750.7 | |||||||
U.S | ||||||||||||
Geographic information | ||||||||||||
Product, net | 6,545.8 | 5,566.7 | 3,581 | |||||||||
Revenues from unconsolidated joint business | 1,269.8 | 1,117.1 | 1,087.3 | |||||||||
Other revenues from external customers | 142 | 212.6 | 193.5 | |||||||||
Long-lived assets | 1,296.5 | 1,055.5 | 1,296.5 | 1,055.5 | 984.4 | |||||||
Europe | ||||||||||||
Geographic information | ||||||||||||
Product, net | [1] | 1,497.6 | 1,383.9 | 1,170.2 | ||||||||
Revenues from unconsolidated joint business | [1] | 3.5 | 7.7 | 1.6 | ||||||||
Other revenues from external customers | [1] | 29.6 | 31.6 | 26.1 | ||||||||
Long-lived assets | [1] | 879.4 | 701.9 | 879.4 | 701.9 | 758.3 | ||||||
Germany | ||||||||||||
Geographic information | ||||||||||||
Product, net | 668.1 | 811.8 | 417.7 | |||||||||
Revenues from unconsolidated joint business | 0 | 0 | 0 | |||||||||
Other revenues from external customers | 1.6 | 1.8 | 1.2 | |||||||||
Long-lived assets | 2.3 | 2.5 | 2.3 | 2.5 | 2.5 | |||||||
Asia | ||||||||||||
Geographic information | ||||||||||||
Product, net | 143.7 | 112.8 | 93.2 | |||||||||
Revenues from unconsolidated joint business | 0 | 0 | 3.2 | |||||||||
Other revenues from external customers | 62.9 | 58.5 | 43.1 | |||||||||
Long-lived assets | 7.7 | 2.6 | 7.7 | 2.6 | 2.1 | |||||||
Other | ||||||||||||
Geographic information | ||||||||||||
Product, net | 333.3 | 328.2 | 280.2 | |||||||||
Revenues from unconsolidated joint business | 65.9 | 70.6 | 33.9 | |||||||||
Other revenues from external customers | 0 | 0 | 0 | |||||||||
Long-lived assets | $ 1.7 | $ 3.2 | $ 1.7 | $ 3.2 | $ 3.3 | |||||||
[1] | Represents amounts related to Europe less those attributable to Germany. |
Segment Information (Details Te
Segment Information (Details Textual) $ in Millions | 12 Months Ended | ||
Dec. 31, 2015USD ($)segment | Dec. 31, 2014USD ($) | Dec. 31, 2013USD ($) | |
Revenue from External Customer [Line Items] | |||
Revenues from unconsolidated joint business in percentage | 12.00% | 12.00% | 16.00% |
Long-lived assets related to operations in Denmark | $ 2,187.6 | $ 1,765.7 | $ 1,750.7 |
Segment Information (Textual) [Abstract] | |||
Number of reportable segment | segment | 1 | ||
Distributor One | |||
Revenue from External Customer [Line Items] | |||
Entity wide percentage of revenue from major distributors | 34.00% | 33.00% | 32.00% |
Distributor Two | |||
Revenue from External Customer [Line Items] | |||
Entity wide percentage of revenue from major distributors | 26.00% | 27.00% | 24.00% |
DENMARK | |||
Revenue from External Customer [Line Items] | |||
Long-lived assets related to operations in Denmark | $ 684.9 | $ 676 | $ 731.1 |
Quarterly Financial Data (Un123
Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Selected Quarterly Financial Information [Abstract] | |||||||||||
Product, net | $ 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | $ 9,188.5 | $ 8,203.4 | $ 5,542.3 |
Unconsolidated joint business revenues | 333.9 | 337.2 | 337.5 | 330.6 | 304.5 | 290.7 | 303.3 | 296.9 | 1,339.2 | 1,195.4 | 1,126 |
Other | 79.5 | 49 | 55.6 | 52 | 49.2 | 103.4 | 61.9 | 90.1 | 236.1 | 304.5 | 263.9 |
Total revenues | 2,839.3 | 2,777.9 | 2,591.6 | 2,555 | 2,640.7 | 2,511.4 | 2,421.5 | 2,129.8 | 10,763.8 | 9,703.3 | 6,932.2 |
Gross Profit | 2,507.5 | 2,467.9 | 2,305.5 | 2,242.6 | 2,343.4 | 2,208.8 | 2,129.6 | 1,850.5 | 9,523.4 | 8,532.3 | |
Net income | 828.7 | 1,019.5 | 924.8 | 820.2 | 882.6 | 856.1 | 723.1 | 479.7 | 3,593.2 | 2,941.6 | 1,862.3 |
Net income attributable to Biogen Idec Inc | $ 831.6 | $ 965.6 | $ 927.3 | $ 822.5 | $ 883.5 | $ 856.9 | $ 714.5 | $ 480 | $ 3,547 | $ 2,934.8 | $ 1,862.3 |
Basic earnings per share attributable to Biogen Inc. | $ 3.77 | $ 4.16 | $ 3.94 | $ 3.50 | $ 3.75 | $ 3.63 | $ 3.02 | $ 2.03 | $ 15.38 | $ 12.42 | $ 7.86 |
Diluted earnings per share attributable to Biogen Inc. | $ 3.77 | $ 4.15 | $ 3.93 | $ 3.49 | $ 3.74 | $ 3.62 | $ 3.01 | $ 2.02 | $ 15.34 | $ 12.37 | $ 7.81 |
Basic earnings per share attributable to Biogen Inc. | 220.4 | 232.2 | 235.3 | 235 | 235.5 | 236.2 | 236.7 | 236.8 | 230.7 | 236.4 | 236.9 |
Diluted earnings per share attributable to Biogen Inc. | 220.8 | 232.6 | 235.7 | 235.6 | 236.3 | 237 | 237.4 | 237.8 | 231.2 | 237.2 | 238.3 |
Quarterly Financial Data (Un124
Quarterly Financial Data (Unaudited) (Details Textual) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013 | |
Schedule Of Development Milestone And Collaboration [Line Items] | |||||||||||
Research and development | $ 2,012.8 | $ 1,893.4 | $ 1,444.1 | ||||||||
Net income attributable to noncontrolling interests, net of tax | 46.2 | 6.8 | 0 | ||||||||
Restructuring charges | $ 93.4 | 93.4 | 0 | 0 | |||||||
Product, net | 2,425.9 | $ 2,391.7 | $ 2,198.6 | $ 2,172.3 | $ 2,287 | $ 2,117.3 | $ 2,056.3 | $ 1,742.8 | 9,188.5 | $ 8,203.4 | $ 5,542.3 |
AGTC | |||||||||||
Schedule Of Development Milestone And Collaboration [Line Items] | |||||||||||
Research and development | 48.1 | $ 54.5 | |||||||||
Mitsubishi Tanabe Pharma Corporation | |||||||||||
Schedule Of Development Milestone And Collaboration [Line Items] | |||||||||||
Research and development | $ 60 | ||||||||||
Eisai | |||||||||||
Schedule Of Development Milestone And Collaboration [Line Items] | |||||||||||
Research and development | 21.6 | $ 117.7 | |||||||||
Neurimmune | |||||||||||
Schedule Of Development Milestone And Collaboration [Line Items] | |||||||||||
Net income attributable to noncontrolling interests, net of tax | $ 60 | ||||||||||
ITALY | |||||||||||
Schedule Of Development Milestone And Collaboration [Line Items] | |||||||||||
Product, net | $ 53.5 |